DaVita (DVA) 10-Q 1 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares shares in Millions	6 Months Ended
	Jun. 30, 2017	Jul. 28, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	DVA
Entity Registrant Name	DAVITA INC.
Entity Central Index Key	927,066
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		191.2

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Patient service revenues	$ 2,682,467	$ 2,583,514	$ 5,283,845	$ 5,065,448
Less: Provision for uncollectible accounts	(115,485)	(111,428)	(228,468)	(220,633)
Net patient service operating revenues	2,566,982	2,472,086	5,055,377	4,844,815
Capitated revenues	1,022,078	899,985	1,940,114	1,787,993
Other revenues	288,417	345,580	579,269	665,979
Total net operating revenues	3,877,477	3,717,651	7,574,760	7,298,787
Operating expenses and charges:
Patient care costs and other costs	2,859,911	2,671,025	5,582,731	5,253,358
General and administrative	382,315	386,895	774,095	773,324
Depreciation and amortization	200,038	180,381	390,244	349,736
Provision for uncollectible accounts	(606)	3,566	1,304	6,083
Equity investment (income) loss	(3,614)	505	(7,549)	(882)
Goodwill and asset impairment charges	61,117	176,000	100,483	253,000
Gain on changes in ownership interests, net	0	(29,791)	(6,273)	(29,791)
Gain on settlement, net	0	0	(526,827)	0
Total operating expenses and charges	3,499,161	3,388,581	6,308,208	6,604,828
Operating income	378,316	329,070	1,266,552	693,959
Debt expense	(107,962)	(102,894)	(212,391)	(205,778)
Other income, net	5,253	3,215	9,496	6,191
Consolidated income before income taxes	275,607	229,391	1,063,657	494,372
Income tax expense	113,982	134,888	401,747	261,710
Net income	161,625	94,503	661,910	232,662
Less: Net income attributable to noncontrolling interests	(34,624)	(41,121)	(87,212)	(81,846)
Net income attributable to DaVita Inc.	$ 127,001	$ 53,382	$ 574,698	$ 150,816
Earnings per share:
Basic net income per share attributable to DaVita Inc. (usd per share)	$ 0.66	$ 0.26	$ 3	$ 0.74
Diluted net income per share attributable to DaVita Inc. (usd per share)	$ 0.65	$ 0.26	$ 2.95	$ 0.73
Weighted average shares for earnings per share:
Basic (in shares)	191,088,216	204,497,970	191,728,913	204,432,315
Diluted (in shares)	193,987,983	208,047,172	194,630,936	207,987,530

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 161,625	$ 94,503	$ 661,910	$ 232,662
Unrealized losses on interest rate cap and swap agreements:
Unrealized losses on interest rate cap and swap agreements	(1,815)	(2,616)	(5,002)	(8,085)
Reclassifications of net rate cap and swap agreements realized losses into net income	1,265	448	2,529	913
Unrealized gains on investments:
Unrealized gains on investments	1,057	638	2,614	867
Reclassification of net investment realized gains into net income	(71)	0	(211)	(93)
Unrealized gains on foreign currency translation:
Foreign currency translation adjustments	49,142	(4,844)	62,403	6,337
Other comprehensive income (loss)	49,578	(6,374)	62,333	(61)
Total comprehensive income	211,203	88,129	724,243	232,601
Less: Comprehensive income attributable to the noncontrolling interests	(34,624)	(41,270)	(87,210)	(81,995)
Comprehensive income attributable to DaVita Inc.	$ 176,579	$ 46,859	$ 637,033	$ 150,606

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
ASSETS
Cash and cash equivalents	$ 711,997	$ 913,187
Short-term investments	211,436	310,198
Accounts receivable, less allowance of $240,918 and $252,056	2,053,812	1,917,302
Inventories	199,304	164,858
Other receivables	644,755	453,483
Prepaid and other current assets	202,464	210,604
Income taxes receivable	0	10,596
Total current assets	4,023,768	3,980,228
Property and equipment, net of accumulated depreciation of $3,130,797 and $2,832,160	3,248,030	3,175,367
Intangible assets, net of accumulated amortization of $1,035,664 and $940,731	1,462,894	1,527,767
Equity method and other investments	542,468	502,389
Long-term investments	114,693	103,679
Other long-term assets	60,140	44,510
Goodwill	9,889,791	9,407,317
Total assets	19,341,784	18,741,257
LIABILITIES AND EQUITY
Accounts payable	439,741	522,415
Other liabilities	885,274	856,847
Accrued compensation and benefits	760,284	815,761
Medical payables	390,387	336,381
Current portion of long-term debt	182,323	165,041
Income tax payable	115,316	0
Total current liabilities	2,773,325	2,696,445
Long-term debt	8,910,814	8,947,327
Other long-term liabilities	520,886	465,358
Deferred income taxes	855,159	809,128
Total liabilities	13,060,184	12,918,258
Commitments and contingencies:
Noncontrolling interests subject to put provisions	1,009,704	973,258
Equity:
Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)
Common stock ($0.001 par value, 450,000,000 shares authorized; 194,774,810 and 194,554,491 shares issued and 191,200,237 and 194,554,491 shares outstanding, respectively)	195	195
Additional paid-in capital	1,058,090	1,027,182
Treasury Stock, Value	(231,674)	0
Retained earnings	4,285,011	3,710,313
Accumulated other comprehensive loss	(27,308)	(89,643)
Total DaVita Inc. shareholders’ equity	5,084,314	4,648,047
Noncontrolling interests not subject to put provisions	187,582	201,694
Shareholders’ equity	5,271,896	4,849,741
Total liabilities and shareholder’s equity	$ 19,341,784	$ 18,741,257

CONSOLIDATED BALANCE SHEETS (u5

CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 240,918	$ 252,056
Property and equipment, accumulated depreciation	3,130,797	2,832,160
Intangible assets, accumulated amortization	$ 1,035,664	$ 940,731
Preferred stock, par value (usd per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	450,000,000	450,000,000
Common stock, shares issued (in shares)	194,774,810	194,554,491
Common stock, shares outstanding (in shares)	191,200,237	194,554,491
Treasury Stock, Common, Shares	3,574,573	0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income	$ 661,910	$ 232,662
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	390,244	349,736
Goodwill and asset impairment charges	100,483	253,000
Stock-based compensation expense	17,504	23,717
Deferred income taxes	40,938	19,952
Equity investment income, net	9,367	14,275
Gain (Loss) on Disposition of Business	(6,273)	(29,791)
Other non-cash charges	28,615	23,120
Changes in operating assets and liabilities, other than from acquisitions and divestitures:
Accounts receivable	(113,208)	(104,005)
Inventories	(31,067)	(9,213)
Other receivables and other current assets	(112,469)	(107,610)
Other long-term assets	(12,124)	(431)
Accounts payable	(55,897)	22,809
Accrued compensation and benefits	(63,727)	41,098
Other current liabilities	13,991	112,825
Income taxes	123,637	135,026
Other long-term liabilities	19,520	(31,531)
Net cash provided by (used in) operating activities	1,011,444	945,639
Cash flows from investing activities:
Additions of property and equipment	(398,940)	(358,627)
Acquisitions	(619,839)	(473,314)
Proceeds from asset and business sales	70,236	17,393
Purchase of investments available for sale	(6,812)	(7,873)
Purchase of investments held-to-maturity	(220,632)	(518,965)
Proceeds from sale of investments available for sale	5,049	5,337
Proceeds from investments held-to-maturity	320,484	545,685
Purchase of equity investments	(1,194)	(8,785)
Proceeds from Sale of Equity Method Investments	0	40,920
Net cash used in investing activities	(851,648)	(758,229)
Cash flows from financing activities:
Borrowings	25,529,555	26,134,952
Payments on long-term debt and other financing costs	(25,593,587)	(26,196,373)
Purchase of treasury stock	(231,674)	(274,926)
Distributions to noncontrolling interests	(116,075)	(94,153)
Stock award exercises and other share issuances, net	8,163	9,465
Contributions from noncontrolling interests	39,872	13,117
Purchase of noncontrolling interests	(1,432)	(6,240)
Other items	0	10,604
Net cash (used in) provided by financing activities	(365,178)	(403,554)
Effect of exchange rate changes on cash and cash equivalents	4,192	444
Net (decrease) increase in cash	(201,190)	(215,700)
Cash and cash equivalents at beginning of period	913,187	1,499,116
Cash and cash equivalents at end of period	$ 711,997	$ 1,283,416

CONSOLIDATED STATEMENTS OF EQUI

CONSOLIDATED STATEMENTS OF EQUITY (unaudited) - USD ($) $ in Thousands	Total	Total	TotalRestricted Stock Units	TotalStock Appreciation Rights	Non- controlling Interests subject to put provisions	Common stock	Common stockRestricted Stock Units	Common stockStock Appreciation Rights	Additional paid-in capital	Additional paid-in capitalRestricted Stock Units	Additional paid-in capitalStock Appreciation Rights	Retained earnings	Treasury stock	Treasury stockRestricted Stock Units	Treasury stockStock Appreciation Rights	Accumulated other comprehensive(loss)	Non-controlling interests not subject to put provisions
Beginning balance at Dec. 31, 2015		$ 4,870,780			$ 864,066	$ 217			$ 1,118,326			$ 4,356,835	$ (544,772)			$ (59,826)	$ 213,392
Beginning Balance (in shares) at Dec. 31, 2015						217,120,000							(7,366,000)
Comprehensive income:
Other comprehensive income	$ (61)
Beginning balance at Dec. 31, 2015		4,870,780			864,066	$ 217			1,118,326			4,356,835	$ (544,772)			(59,826)	213,392
Beginning Balance (in shares) at Dec. 31, 2015						217,120,000							(7,366,000)
Comprehensive income:
Net income		879,874			99,834							879,874					53,374
Other comprehensive income		(29,817)														(29,817)	190
Stock purchase shares issued		23,903				$ 1			23,902
Stock purchase shares issued (in shares)						438,000							0
Stock unit shares issued/settled			$ 0	$ 0			$ 0	$ 0		$ (19,815)	$ (36,685)			$ 19,815	$ 36,685
Stock unit shares issued/settled (in shares)							4,000	218,000						276,000	513,000
Stock-settled stock-based compensation expense		37,970							37,970
Excess tax benefits from stock awards exercised		13,251							13,251
Changes in noncontrolling interest from:
Distributions					(111,092)												(81,309)
Contributions					33,517												14,073
Acquisitions and divestitures		3,423			28,874				3,423								2,585
Partial purchases		(13,105)			(6,660)				(13,105)								(1,747)
Fair value		(65,855)			65,855				(65,855)
Reclassifications and expirations of puts					(1,136)												1,136
Purchase of treasury stock		(1,072,377)											$ (1,072,377)
Purchase of treasury stock (in shares)													(16,649,000)
Retirement of treasury stock		0				$ (23)			(34,230)			(1,526,396)	$ 1,560,649
Retirement of treasury stock (in shares)						(23,226,000)							23,226,000
Ending balance at Dec. 31, 2016	$ 4,849,741	4,648,047			973,258	$ 195			1,027,182			3,710,313	$ 0			(89,643)	201,694
Ending Balance (in shares) at Dec. 31, 2016	194,554,491					194,554,000							0
Comprehensive income:
Other comprehensive income	$ (6,374)
Net income		574,698			56,721							574,698					30,491
Other comprehensive income	62,333	62,335														62,335	(2)
Stock unit shares issued/settled			$ 0	$ 0			$ 0	$ 0		$ 0	$ 0			$ 0	$ 0
Stock unit shares issued/settled (in shares)							105,000	116,000						0	0
Stock-settled stock-based compensation expense		17,468							17,468
Changes in noncontrolling interest from:
Distributions		0			(72,636)												(43,439)
Contributions		0			31,368												8,504
Acquisitions and divestitures		(709)			34,365				(709)								(7,457)
Partial purchases		195			(1,544)				195								(83)
Fair value		13,954			(13,954)				13,954
Reclassifications and expirations of puts					2,126												(2,126)
Purchase of treasury stock	$ (231,674)	(231,674)											$ (231,674)
Purchase of treasury stock (in shares)	(3,575,000)												3,575,000
Ending balance at Jun. 30, 2017	$ 5,271,896	5,084,314			1,009,704	$ 195			1,058,090			4,285,011	$ (231,674)			(27,308)	187,582
Ending Balance (in shares) at Jun. 30, 2017	191,200,237					194,775,000							(3,575,000)
Comprehensive income:
Other comprehensive income	$ 49,578
Ending balance at Jun. 30, 2017	$ 5,271,896	$ 5,084,314			$ 1,009,704	$ 195			$ 1,058,090			$ 4,285,011	$ (231,674)			$ (27,308)	$ 187,582
Ending Balance (in shares) at Jun. 30, 2017	191,200,237					194,775,000							(3,575,000)

Condensed consolidated interim

Condensed consolidated interim financial statements	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Condensed consolidated interim financial statements	Condensed consolidated interim financial statements The condensed consolidated interim financial statements included in this report are prepared by the Company without audit. In the opinion of management, all adjustments necessary for a fair presentation of the results of operations are reflected in these condensed consolidated interim financial statements. All significant intercompany accounts and transactions have been eliminated. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. The most significant estimates and assumptions underlying these financial statements and accompanying notes generally involve revenue recognition and accounts receivable, contingencies, impairments of goodwill and other long-lived assets, fair value estimates, accounting for income taxes, variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, long-term incentive program compensation and medical liability claims. The results of operations for the six months ended June 30, 2017 are not necessarily indicative of the operating results for the full year. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 . Prior year balances and amounts have been reclassified to conform to the current year presentation. The Company has evaluated subsequent events through the date these condensed consolidated financial statements were issued and has included all necessary adjustments and disclosures.

Earnings per share

Earnings per share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Earnings per share	Earnings per share Basic net income per share is calculated by dividing net income attributable to the Company, adjusted for any change in noncontrolling interests redemption rights in excess of fair value, by the weighted average number of common shares and vested stock units outstanding, net of shares held in escrow from the DaVita HealthCare Partners merger that under certain circumstances may be returned to the Company. Diluted net income per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units (under the treasury stock method) as well as contingently returnable shares held in escrow. The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share are as follows: Three months ended Six months ended 2017 2016 2017 2016 Basic: Net income attributable to DaVita Inc. $ 127,001 $ 53,382 $ 574,698 $ 150,816 Weighted average shares outstanding during the period 193,282 206,692 193,923 206,626 Contingently returnable shares held in escrow from the DaVita (2,194 ) (2,194 ) (2,194 ) (2,194 ) Weighted average shares for basic earnings per share calculation 191,088 204,498 191,729 204,432 Basic net income per share attributable to DaVita Inc. $ 0.66 $ 0.26 $ 3.00 $ 0.74 Diluted: Net income attributable to DaVita Inc. $ 127,001 $ 53,382 $ 574,698 $ 150,816 Weighted average shares outstanding during the period 193,282 206,692 193,923 206,626 Assumed incremental shares from stock plans 706 1,355 708 1,362 Weighted average shares for diluted earnings per share calculation 193,988 208,047 194,631 207,988 Diluted net income per share attributable to DaVita Inc. $ 0.65 $ 0.26 $ 2.95 $ 0.73 Anti-dilutive potential common shares excluded from calculation (1) 3,780 1,811 3,603 2,042 (1) Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Accounts receivable

Accounts receivable	6 Months Ended
	Jun. 30, 2017
Receivables [Abstract]
Accounts receivable	Accounts receivable Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the ultimate collectability of accounts receivable, the Company analyzes its historical cash collection experience and trends for each of its government payors and commercial payors to estimate the adequacy of the allowance for doubtful accounts and the amount of the provision for uncollectible accounts. Management regularly updates its analysis based upon the most recent information available to determine its current provision for uncollectible accounts and the adequacy of its allowance for doubtful accounts. For receivables associated with dialysis patient services covered by Medicare, the Company receives 80% of the payment directly from Medicare as established under the government’s bundled payment system and determines an appropriate allowance for doubtful accounts and provision for uncollectible accounts on the remaining balance due depending upon the Company’s estimate of the amounts ultimately collectible from other secondary coverage sources or from the patients. For receivables associated with services to patients covered by commercial payors that are either based upon contractual terms or for non-contracted health plan coverage, the Company provides an allowance for doubtful accounts by recording a provision for uncollectible accounts based upon its historical collection experience, potential inefficiencies in its billing processes and for which collectability is determined to be unlikely. For receivables associated with the Company’s capitated health plans, the balances remain on the balance sheet for as long as the respective plan years are open, which varies by health plan but is generally two years in length, with collections occurring on a periodic basis throughout the duration of the corresponding plan year. Approximately 1% of the Company’s net accounts receivable are associated with patient pay. The Company’s policy is to reserve 100% of the outstanding accounts receivable balances for dialysis services when those amounts due have been outstanding for more than three months and to reserve 100% of the outstanding accounts receivable balances for services of DaVita Medical Group (DMG, formerly known as HealthCare Partners or HCP) when those amounts due have been outstanding for more than twelve months and when the amount is not subject to a payment plan. During the six months ended June 30, 2017 , the Company’s allowance for doubtful accounts decreased by $11,138 . This was primarily due to an increase in write-offs of aged balances and timing of adjustments related to the U.S. dialysis and related lab business. There were no unusual transactions impacting the allowance for doubtful accounts.

Investments in debt and equity

Investments in debt and equity securities	6 Months Ended
	Jun. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Investments in debt and equity securities	Investments in debt and equity securities The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company’s intentions and strategy concerning those investments. Equity securities that have readily determinable fair values, and certain other financial instruments that have readily determinable fair values or redemption values, are classified as available-for-sale and recorded at fair value. The Company’s investments in these securities and certain other financial instruments consist of the following: June 30, 2017 December 31, 2016 Held to Available Total Held to Available Total Certificates of deposit, commercial paper and $ 210,236 $ — $ 210,236 $ 256,827 $ — $ 256,827 Investments in mutual funds and common stock — 53,209 53,209 50,000 47,404 97,404 Cash surrender value of life insurance policies — 62,684 62,684 — 59,646 59,646 $ 210,236 $ 115,893 $ 326,129 $ 306,827 $ 107,050 $ 413,877 Short-term investments $ 210,236 $ 1,200 $ 211,436 $ 306,827 $ 3,371 $ 310,198 Long-term investments — 114,693 114,693 — 103,679 103,679 $ 210,236 $ 115,893 $ 326,129 $ 306,827 $ 107,050 $ 413,877 The cost of the certificates of deposit, commercial paper and money market funds at June 30, 2017 and December 31, 2016 approximates their fair value. As of June 30, 2017 and December 31, 2016 , the available-for-sale investments included $6,783 and $3,701 of gross pre-tax unrealized gains, respectively. During the six months ended June 30, 2017 , the Company recorded gross pre-tax unrealized gains of $3,428 , or $2,616 after tax, in other comprehensive income associated with changes in the fair value of these investments. During the six months ended June 30, 2017 , the Company sold investments in mutual funds and debt securities for net proceeds of $5,049 and recognized a pre-tax gain of $346 , or $211 after-tax, which was previously recorded in other comprehensive income. During the six months ended June 30, 2016 , the Company sold investments in mutual funds for net proceeds of $1,347 and recognized a pre-tax gain of $152 , or $93 after-tax, which was previously recorded in other comprehensive income. The investments in mutual funds classified as available-for-sale are held within a trust to fund existing obligations associated with several of the Company’s non-qualified deferred compensation plans. Investments in life insurance policies are carried at their cash surrender value, are held within trusts to fund existing obligations associated with certain of the Company’s non-qualified deferred compensation plans, and are principally classified as long-term to correspond with the long-term classification of the related plan liabilities. Certain DMG legal entities are required to maintain minimum cash balances in order to comply with regulatory requirements in conjunction with medical claim reserves. As of June 30, 2017 , this minimum cash balance was approximately $56,717 .

Equity investments

Equity investments	6 Months Ended
	Jun. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Equity investments	Equity method and other investments Equity investments that do not have readily determinable fair values are carried on the cost or equity method, as applicable. The Company maintains equity method investments in nonconsolidated investees in both its DaVita Kidney Care (Kidney Care) and DMG lines of business, as well as minor cost method investments in private securities of certain other healthcare businesses. The Company classifies its non-marketable cost- and equity method investments as equity method and other investments on its balance sheet. Equity method and other investments in nonconsolidated businesses were $542,468 and $502,389 at June 30, 2017 and December 31, 2016, respectively. The increase in these equity investments was primarily due to foreign exchange valuation changes, which caused an increase in our investment in the APAC JV (described below). During the six months ended June 30, 2017 and 2016, the Company recognized equity investment income of $7,549 and $882 , respectively, from equity method investments in nonconsolidated businesses. Effective as of August 1, 2016, the Company deconsolidated its Asia Pacific dialysis business held by DaVita Care Pte. Ltd. (the “APAC JV”), adjusted its retained investment in the APAC JV to estimated fair value at that time, and has accounted for this retained investment on the equity method since August 1, 2016. The Company holds a 60% voting interest and an 86.7% current economic interest in DaVita Care Pte. Ltd., an entity which was previously a wholly-owned subsidiary of the Company. Based on the governance structure and voting rights established for the APAC JV, certain key decisions affecting the joint venture’s operations are no longer at the unilateral discretion of the Company, but rather are shared with other noncontrolling investors. These other noncontrolling investors collectively hold a 40% voting interest and a 13.3% current economic interest in the APAC JV. The economic interests of these other noncontrolling investors are expected to increase to match their voting interests in the APAC JV as they make additional subscribed capital contributions through August 1, 2019. Each of these other noncontrolling investors also holds reserved approval rights over certain key decisions affecting the joint venture’s operations. As a result, the Company has no longer consolidated the APAC JV since its formation on August 1, 2016.

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill Changes in goodwill by reportable segments were as follows: U.S. dialysis and related lab services DMG Other-ancillary services and strategic initiatives Consolidated total Balance at January 1, 2016 $ 5,629,183 $ 3,398,264 $ 267,032 $ 9,294,479 Acquisitions 75,295 248,901 123,632 447,828 Divestitures (12,891 ) (2,223 ) (29,645 ) (44,759 ) Goodwill impairment charges — (253,000 ) (28,415 ) (281,415 ) Foreign currency and other adjustments — — (8,816 ) (8,816 ) Balance at December 31, 2016 $ 5,691,587 $ 3,391,942 $ 323,788 $ 9,407,317 Acquisitions 427,299 31,796 113,669 572,764 Divestitures (32,260 ) (29 ) (54 ) (32,343 ) Goodwill impairment charges — (50,619 ) (34,696 ) (85,315 ) Foreign currency and other adjustments — — 27,368 27,368 Balance at June 30, 2017 $ 6,086,626 $ 3,373,090 $ 430,075 $ 9,889,791 Balance at June 30, 2017: Goodwill $ 6,086,626 $ 3,865,478 $ 499,095 $ 10,451,199 Accumulated impairment charges — (492,388 ) (69,020 ) (561,408 ) $ 6,086,626 $ 3,373,090 $ 430,075 $ 9,889,791 The Company elected to early adopt ASU No. 2017-04 , Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment effective January 1, 2017. The amendments in this ASU simplify the test for goodwill impairment by eliminating the second step in the assessment. All goodwill impairment tests performed during 2017 have been performed under this new guidance. Each of the Company’s operating segments described in Note 18 to these condensed consolidated financial statements represents an individual reporting unit for goodwill impairment testing purposes, except that each sovereign jurisdiction within the Company’s international operating segments is considered a separate reporting unit. Within the U.S. dialysis and related lab services operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit. The Company has applied a similar aggregation to the DMG operations in each region, to the vascular access service centers in its vascular access reporting unit, to the physician practices in its physician services and direct primary care reporting units, and to the dialysis centers within each international reporting unit. For the Company’s other operating segments, discrete business components below the operating segment level constitute individual reporting units. Based on continuing developments at the Company’s DMG and vascular access reporting units during the second quarter of 2017, the Company performed impairment assessments for certain at-risk reporting units. As a result of the assessments performed during the three months ended June 30, 2017, the Company recognized goodwill impairment charges of $49,946 at its DMG Florida reporting unit and $673 at its DMG New Mexico reporting unit. These charges resulted primarily from changes in expectations concerning government reimbursement, including the effect of Medicare Advantage final benchmark payment rates for 2018 announced on April 3, 2017 and the Company’s expected ability to mitigate them, as well as medical cost and utilization trends. During the three months ended June 30, 2017, the Company also recognized an incremental goodwill impairment charge of $10,498 at its vascular access reporting unit. This additional charge resulted primarily from continuing changes in the Company’s outlook as the Company’s partners and operators have continued to evaluate and make decisions concerning changes in operations, including termination of their management services agreements and center closures as a result of the Centers for Medicare and Medicaid Services (CMS) 2017 Physician Fee Schedule Final Rule and the Ambulatory Surgical Center Payment Final Rule released November 2, 2016, which introduced significant changes in reimbursement structure for this business unit. As of June 30, 2017, there was no goodwill remaining at the Company's vascular access reporting unit. For the three and six months ended June 30, 2017, the Company has recognized total goodwill impairment charges of $61,117 and $85,315 , respectively. During the three months ended June 30, 2016, the Company recognized goodwill impairment charges of $97,000 at its DMG Florida reporting unit and $79,000 at its DMG Nevada reporting unit. These charges resulted primarily from changes in expectations concerning government reimbursement and the Company’s expected ability to mitigate them, as well as medical cost trends and other market conditions. For the three and six months ended June 30, 2016, the Company recognized total goodwill impairment charges of $176,000 and $253,000 , respectively. Further reductions in reimbursement rates, increases in medical cost or utilization trends, or other significant adverse changes in expected future cash flows or valuation assumptions could result in goodwill impairment charges in the future for the following reporting units, which remain at risk of goodwill impairment: Goodwill balance Carrying (1) Sensitivities Operating (2) Discount (3) Reporting unit DMG Nevada $ 275,914 17.0 % (2.4 )% (3.8 )% DMG Florida $ 397,127 — % (1.6 )% (2.8 )% DMG New Mexico $ 70,253 — % (1.6 )% (2.4 )% DMG Washington $ 247,552 9.3 % (1.7 )% (3.6 )% (1) Excess of estimated fair value of the reporting unit over its carrying amount as of the latest assessment date. (2) Potential impact on estimated fair value of a sustained, long-term reduction of 3% in operating income as of the latest assessment date. (3) Potential impact on estimated fair value of an increase in discount rates of 100 basis points as of the latest assessment date. Except as described above, none of the Company’s various other reporting units was considered at risk of goodwill impairment as of June 30, 2017 . Since the dates of their last annual goodwill impairment tests, there have been certain developments, events, changes in operating performance and other changes in key circumstances that have affected these other businesses. However, except as further described above, these changes did not cause management to believe it is more likely than not that the fair value of any of its reporting units would be less than their respective carrying amounts.

Medical payables

Medical payables	6 Months Ended
	Jun. 30, 2017
Health Care Organizations [Abstract]
Medical payables	Medical payables The following table includes estimates for the cost of professional medical services provided by non-employed physicians and other providers, as well as inpatient and other ancillary costs, other than California's non-global risk contracts. The Company does not include inpatient and other ancillary costs for non-global risk contracts held in California, as state regulation does not allow medical group entities to assume risk for inpatient services. Healthcare costs payable are included in medical payables in the condensed consolidated balance sheet. The following table shows the components of changes in health care costs payable for the six months ended June 30, 2017 : Six months ended June 30, 2017 Healthcare costs payable, beginning of the period $ 214,275 Add: Components of incurred health care costs Current year 991,818 Prior years (6,838 ) Total incurred health care costs 984,980 Less: Claims paid Current year 727,814 Prior years 186,623 Total claims paid 914,437 Healthcare costs payable, end of the period $ 284,818 The Company’s prior year estimates of healthcare costs payable resulted in medical claims being settled for different amounts than originally estimated. When significant increases (decreases) in prior-year health care cost estimates occur that the Company believes significantly impact its current year operating results, the Company discloses that amount as unfavorable (favorable) development of prior-year’s health care cost estimates. Actual claim payments for prior year services have not been materially different from the Company’s year-end estimates.

Income taxes

Income taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income taxes	Income taxes As of June 30, 2017 , the Company’s total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold was $25,926 , all of which would impact the Company’s effective tax rate if recognized. This balance represents an increase of $1,860 from the December 31, 2016 balance of $24,066 . The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. At June 30, 2017 and December 31, 2016 , the Company had approximately $3,891 and $2,595 , respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefits.

Long-term debt

Long-term debt	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Long-term debt	Long-term debt Long-term debt was comprised of the following: June 30, 2017 December 31, 2016 Senior secured credit facilities: Term Loan A $ 825,000 $ 862,500 Term Loan B 3,395,000 3,412,500 Senior notes 4,500,000 4,500,000 Acquisition obligations and other notes payable 139,371 117,547 Capital lease obligations 305,643 299,682 Total debt principal outstanding 9,165,014 9,192,229 Discount and deferred financing costs (71,877 ) (79,861 ) 9,093,137 9,112,368 Less current portion (182,323 ) (165,041 ) $ 8,910,814 $ 8,947,327 Scheduled maturities of long-term debt at June 30, 2017 were as follows: 2017 (remainder of the year) 96,454 2018 172,318 2019 746,464 2020 71,432 2021 3,303,146 2022 1,280,031 Thereafter 3,495,169 During the first six months of 2017 , the Company made mandatory principal payments under its senior secured credit facilities totaling $37,500 on Term Loan A and $17,500 on Term Loan B. As of June 30, 2017, the Company maintains several active and forward interest rate cap agreements that have the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on specific portions of the Company's floating rate debt, as described below. The cap agreements are designated as cash flow hedges and, as a result, changes in the fair values of these cap agreements are reported in other comprehensive income. The amortization of the original cap premium is recognized as a component of debt expense on a straight-line basis over the term of the cap agreements. The cap agreements do not contain credit-risk contingent features. As of June 30, 2017 , the Company maintains several interest rate cap agreements that were entered into in November 2014 with notional amounts totaling $3,500,000 . These cap agreements became effective September 30, 2016 and have the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 3.50% on an equivalent amount of the Company’s debt. The cap agreements expire on June 30, 2018 . As of June 30, 2017 , the total fair value of these cap agreements was an asset of approximately $1 . During the six months ended June 30, 2017 , the Company recognized debt expense of $4,139 from these caps. During the six months ended June 30, 2017 , the Company recorded a loss of $115 in other comprehensive income due to a decrease in unrealized fair value of these cap agreements. As of June 30, 2017 , the Company also maintains several forward interest rate cap agreements that were entered into in October 2015 with notional amounts totaling $3,500,000 . These forward cap agreements will become effective June 29, 2018 and will have the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 3.50% on an equivalent amount of its debt. These cap agreements expire on June 30, 2020 . As of June 30, 2017 , the total fair value of these cap agreements was an asset of approximately $1,742 . During the six months ended June 30, 2017 , the Company recorded a loss of $8,071 in other comprehensive income due to a decrease in the unrealized fair value of these forward cap agreements. The following table summarizes the Company’s derivative instruments as of June 30, 2017 and December 31, 2016 : June 30, 2017 December 31, 2016 Derivatives designated as hedging instruments Balance sheet location Fair value Balance sheet location Fair value Interest rate cap agreements Other long-term assets $ 1,743 Other long-term assets $ 9,929 The following table summarizes the effects of the Company’s interest rate cap and swap agreements for the three and six months ended June 30, 2017 and 2016 : Amount of losses Location of losses reclassified from accumulated OCI into income Amount of losses Three months ended Six months ended Three months ended Six months ended Derivatives designated as cash flow hedges 2017 2016 2017 2016 2017 2016 2017 2016 Interest rate swap $ — $ (168 ) $ — $ (860 ) Debt expense $ — $ 123 $ — $ 274 Interest rate cap (2,969 ) (4,115 ) (8,186 ) (12,374 ) Debt expense 2,070 610 4,139 1,220 Tax benefit 1,154 1,667 3,184 5,149 Tax expense (805 ) (285 ) (1,610 ) (581 ) Total $ (1,815 ) $ (2,616 ) $ (5,002 ) $ (8,085 ) $ 1,265 $ 448 $ 2,529 $ 913 As of June 30, 2017 , the interest rate on the Company’s Term Loan B debt bears interest at LIBOR plus an interest rate margin of 2.75% . Term Loan B is subject to interest rate caps if LIBOR should rise above 3.50% . Term Loan A bears interest at LIBOR plus an interest rate margin of 2.00% . The capped portion of Term Loan A is $105,000 if LIBOR should rise above 3.50% . In addition, the uncapped portion of Term Loan A, which is subject to the variability of LIBOR, is $720,000 . Interest rates on the Company’s senior notes are fixed by their terms. The Company’s weighted average effective interest rate on the senior secured credit facilities at end of the quarter was 4.20% , based on the current margins in effect of 2.00% for Term Loan A and 2.75% for Term Loan B, as of June 30, 2017 . The Company’s overall weighted average effective interest rate during the quarter ended June 30, 2017 was 4.69% and as of June 30, 2017 was 4.76% . As of June 30, 2017 , the Company’s interest rates are fixed on approximately 53.3% of its total debt. As of June 30, 2017 , the Company had undrawn revolving credit facilities totaling $1,000,000 , of which approximately $94,623 was committed for outstanding letters of credit. The remaining amount is unencumbered. In addition, the Company has approximately $1,286 of committed letters of credit outstanding related to DMG, which is backed by a certificate of deposit.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors. The Company operates in a highly regulated industry and is a party to various lawsuits, claims, governmental investigations and audits (including investigations resulting from its obligation to self-report suspected violations of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of June 30, 2017 and December 31, 2016, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were approximately $62,000 and $69,000 , respectively. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which may be exacerbated by various factors, including that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding. The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject. Inquiries by the Federal Government and Certain Related Civil Proceedings Swoben Private Civil Suit : In April 2013, HealthCare Partners (HCP), now known as the Company’s DMG subsidiary, was one of several defendants served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), an HMO. On July 13, 2009, pursuant to the qui tam provisions of the federal False Claims Act (FCA) and the California False Claims Act, James M. Swoben, as relator, filed his initial qui tam action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In 2009 and 2010, the relator twice amended his complaint and added additional defendants, and in November 2011, he filed his Third Amended Complaint under seal alleging violations of the federal FCA and the California False Claims Act, and added additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage (MA) program, referred to as HCC and RAF scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The U.S. Department of Justice (DOJ) reviewed these allegations and in January 2013 declined to intervene in the case. HCP and the other defendants filed motions to dismiss the Third Amended Complaint, and the court dismissed with prejudice the claims and judgment was entered in September 2013. Upon the plaintiff’s appeal, a panel of the Ninth Circuit overturned the trial court’s ruling and vacated the dismissal of the case. The Company, with certain defendants, petitioned the Ninth Circuit for a rehearing, but in December 2016, the Ninth Circuit rejected the petition and determined the relator should be given an opportunity to amend the complaint, and remanded the case back to district court. In March 2017, the relator filed his Fourth Amended Complaint alleging that HCP and certain health insurance companies employed one-way retrospective reviews that were designed only to identify additional diagnoses that would be submitted to CMS for risk adjustment purposes, and thereby drive higher risk scores that would increase the capitated payments made by the federal government under the MA program. In March 2017, the DOJ partially intervened as to certain defendant HMOs, but elected not to intervene with respect to HCP. The Company disputes the allegations and intends to defend accordingly. 2015 U.S. Office of Inspector General (OIG) Medicare Advantage Civil Investigation : In March 2015, JSA HealthCare Corporation (JSA), a subsidiary of DMG, received a subpoena from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS). The Company has been advised by an attorney with the Civil Division of the DOJ in Washington, D.C. that the subpoena relates to an ongoing civil investigation concerning MA service providers’ risk adjustment practices and data, including identification and verification of patient diagnoses and factors used in making the diagnoses. The subpoena requests documents and information for the period from January 1, 2008 through December 31, 2013, for certain MA plans for which JSA provided services. It also requests information regarding JSA’s communications about patient diagnoses as they relate to certain MA plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted. The Company is producing the requested information and is cooperating with the government’s investigation. In addition to the subpoena described above, in June 2015, the Company received a subpoena from the OIG. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to the Company’s and its subsidiaries’ (including DMG’s and its subsidiary JSA’s) provision of services to MA plans and related patient diagnosis coding and risk adjustment submissions and payments. The Company believes that the request is part of a broader industry investigation into MA patient diagnosis coding and risk adjustment practices and potential overpayments by the government. The information requested includes information relating to patient diagnosis coding practices for a number of conditions, including potentially improper historical DMG coding for a particular condition. With respect to that condition, the guidance related to that coding issue was discontinued following the Company’s November 1, 2012 acquisition of DMG, and the Company notified CMS in April 2015 of the coding practice and potential overpayments. In that regard, the Company has identified certain additional coding practices which may have been problematic and is in discussions with the DOJ about the scope and nature of a review of claims relating to those practices. The Company is cooperating with the government and is producing the requested information. In addition, the Company is continuing to review other DMG coding practices to determine whether there were any improper coding issues. In connection with the DMG merger, the Company has certain indemnification rights against the sellers and an escrow was established as security for the indemnification. The Company has submitted an indemnification claim against the sellers secured by the escrow for any and all liabilities incurred relating to these matters and intends to pursue recovery from the escrow. However, the Company can make no assurances that the indemnification and escrow will cover the full amount of the Company’s potential losses related to these matters. 2016 U.S. Attorney Prescription Drug Investigation : In early February 2016, the Company announced that its pharmacy services’ wholly-owned subsidiary, DaVita Rx, received a CID from the U.S. Attorney’s Office for the Northern District of Texas. The government is conducting an FCA investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as into the Company’s relationship with pharmaceutical manufacturers. The CID covers the period from January 1, 2006 through the present. In the spring of 2015, the Company initiated an internal compliance review of DaVita Rx during which it identified potential billing and operational issues, including potential write-offs and discounts of patient co-payment obligations, and credits to payors for returns of prescription drugs related to DaVita Rx. The Company notified the government in September 2015 that it was conducting this review of DaVita Rx and began providing regular updates of its review. Upon completion of its review, the Company filed a self-disclosure with the OIG in February 2016 and has been working to address and update the practices it identified in the self-disclosure, some of which overlap with information requested by the U.S. Attorney’s Office. The OIG informed the Company in February 2016 that its submission was not accepted. They indicated that the OIG is not expressing an opinion regarding the conduct disclosed or the Company’s legal positions. The Company is cooperating with the government. Solari Post-Acquisition Matter : In 2016, HCP Nevada disclosed to the OIG for the HHS that proper procedures for clinical and eligibility determinations may not have been followed by Las Vegas Solari Hospice (Solari), which was acquired in March 2013 and sold in September 2016 by HCP Nevada. In June 2016, the Company was notified by the OIG that the disclosure submission had been accepted into the OIG’s Self Disclosure Protocol. HCP Nevada had previously made a disclosure and repayment of overpayments to National Government Services (NGS), the Medicare Administrative Contractor for HCP Nevada, for claims submitted by Solari to the federal government prior to DMG’s acquisition of Solari and claims made to the government post-acquisition for which the sellers had certain responsibilities pursuant to a management services agreement. The Company is cooperating with the government in this matter. 2017 U.S. Attorney American Kidney Fund Investigation : On January 4, 2017, the Company was served with an administrative subpoena for records by the United States Attorney’s Office, District of Massachusetts, relating to an investigation into possible federal health care offenses. The subpoena covers the period from January 1, 2007 through the present, and seeks documents relevant to charitable patient assistance organizations, particularly the American Kidney Fund, including documents related to efforts to provide patients with information concerning the availability of charitable assistance. The Company is cooperating with the government and is producing the requested information. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. In addition to the inquiries and proceedings specifically identified above, the Company is frequently subject to other inquiries by state or federal government agencies and/or private civil qui tam complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, possible criminal penalties, any of which could have a material adverse effect on the Company. Shareholder Claims Peace Officers’ Annuity and Benefit Fund of Georgia Securities Class Action Civil Suit : On February 1, 2017, the Peace Officers’ Annuity and Benefit Fund of Georgia filed a putative federal securities class action complaint in the U.S. District Court for the District of Colorado against the Company and certain executives. The complaint covers the time period of August 2015 to October 2016 and alleges, generally, that the Company and its executives violated federal securities laws concerning the Company’s financial results and revenue derived from patients who received charitable premium assistance from an industry-funded non-profit organization. The complaint further alleges that the process by which patients obtained commercial insurance and received charitable premium assistance was improper and “created a false impression of DaVita’s business and operational status and future growth prospects.” The Company disputes these allegations and intends to defend this action accordingly. Blackburn Shareholder Derivative Civil Suit : On February 10, 2017, Charles Blackburn filed a derivative shareholder lawsuit in the U.S. District Court for the District of Delaware against the Company, as nominal defendant, the Board of Directors and certain executives. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. The Company disputes these allegations and intends to defend this action accordingly. Gabilondo Shareholder Derivative Civil Suit : On May 30, 2017, Antonio Gabilondo filed a derivative shareholder lawsuit in the U.S. District Court for the District of Delaware against the Company, as nominal defendant, the Board of Directors and certain executives. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. The Company disputes these allegations and intends to defend this action accordingly. City of Warren Police and Fire Retirement System Shareholder Derivative Civil Suit : On June 9, 2017, the City of Warren Police and Fire Retirement System filed a derivative shareholder lawsuit in the U.S. District Court for the District of Delaware against the Company, as nominal defendant, the Board of Directors, and certain executives. The complaint covers the time period of 2015 to the present and alleges, generally, a breach of fiduciary duty, corporate waste, unjust enrichment, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. The Company disputes these allegations and intends to defend this action accordingly. Other Proceedings In addition to the foregoing, from time to time the Company is subject to other lawsuits, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters. In that regard, the Company had a pending lawsuit in the U.S. Court of Federal Claims against the federal government which was originally filed in May 2011. The lawsuit related to the U.S. Department of Veterans Affairs (VA) underpayment of dialysis services the Company provided from 2005 through 2011 to veterans pursuant to VA regulations. In the first quarter of 2017, the Company received a payment of $538,000 related to the settlement with the VA. The Company's consolidated entities recognized a net gain of $527,000 on this settlement. The Company's nonconsolidated and managed entities recognized a gain of $9,000 , of which the Company's equity investment share was $3,000 . The net effect was a net increase of $530,000 to the Company's operating income. * * * Other than as described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 10, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, or otherwise harm the Company’s business, financial results or reputation. Resolved Matters 2015 U.S. Attorney Transportation Investigation : In February 2015, the Company announced that it received six administrative subpoenas from the OIG for medical records from six different dialysis centers in southern California operated by the Company. Specifically, each subpoena sought the medical records of a single patient of each respective dialysis center. In February 2016, the Company received four additional subpoenas for four additional dialysis centers in southern California. The subpoenas were similarly limited in scope to the subpoenas received in 2015. On February 8, 2017, the Company was served with a qui tam complaint in the U.S. District Court for the Central District of California. The Company was advised by an attorney with the United States Attorney’s Office for the Central District of California that the qui tam was related to the investigation concerning the medical necessity of patient transportation, which was the basis for the subpoenas. The relator alleged that an ambulance company submitted false claims for patient transportation. Although the Company does not provide transportation nor does it bill for the transport of its dialysis patients, the relator alleged that two of its purported clinical staff caused the submission of a small number of those claims through improper certifications of medical necessity. The DOJ has declined to intervene. In April 2017, the court granted the Company's motion to dismiss and dismissed the complaint without prejudice for failing to state a claim upon which relief can be granted. In May 2017, the relator filed a First Amended Complaint and the Company filed an additional motion to dismiss. In June 2017, the court granted the Company’s motion and dismissed the complaint without prejudice. Plaintiff was given until July 24, 2017 to file an amended complaint. Instead, the plaintiff decided not to proceed against the Company and filed a notice of dismissal on July 25, 2017. 2015 U.S. Department of Justice Vascular Access Investigation and Related Qui Tam Litigation : In November 2015, the Company announced that RMS Lifeline, Inc., a wholly-owned subsidiary of the Company that operates under the name Lifeline Vascular Access (Lifeline), received a Civil Investigative Demand (CID) from the DOJ. The CID relates to two vascular access centers in Florida that are part of Lifeline’s vascular access business. The CID covers the period from January 1, 2008 through the present. The Company acquired these two centers in December 2012. Based on the language of the CID, the DOJ appeared to be looking at whether angiograms performed at the two centers were medically unnecessary and therefore whether related claims filed with federal healthcare programs possibly violated the FCA. Lifeline does not perform dialysis services but instead provides vascular access management services for dialysis patients. The Company cooperated with the government and produced the requested information. The DOJ investigation was initiated pursuant to a complaint brought under the qui tam provisions of the FCA (the Complaint). The Complaint was originally filed under seal in August 2014 in the U.S. District Court, Middle District of Florida, United States ex. rel James Spafford v. DaVita HealthCare Partners, Inc., et al., Case Number 6:14-cv-1251-Orl-41DAB, naming several doctors along with the Company as defendants. In December 2015, a First Amended Complaint was filed under seal. In May 2016, the First Amended Complaint was unsealed. The First Amended Complaint alleged violations of the FCA due to the submission of claims to the government for allegedly medically unnecessary angiograms and angiography procedures at the two vascular access centers as well as employment-related claims. The Complaint covers alleged conduct dating from July 2008, prior to the Company’s acquisition of the centers, to the present. The DOJ declined to intervene. In January 2017, the Company finalized and executed a settlement agreement with the relator and the government for an immaterial amount, and in April 2017, the court dismissed the case with prejudice. Vainer Private Civil Suit : As previously disclosed, the Company received a subpoena for documents from the OIG relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters, covering the period from January 2003 to December 2008. The Company subsequently learned that the allegations underlying this inquiry were made as part of a civil complaint filed by relators, Daniel Barbir and Dr. Alon Vainer, pursuant to the qui tam provisions of the federal FCA. The relators also alleged that the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents from 2003 through 2010 fraudulently created unnecessary waste, which was billed to and paid for by the government. In June 2015, the Company finalized the terms of the settlement with plaintiffs, including a settlement amount of $450,000 and attorney fees and other costs of $45,000 which was paid in 2015. 2011 U.S. Attorney Medicaid Investigation : In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request related to payments for infusion drugs covered by Medicaid composite payments for dialysis. The Company cooperated with the government and produced the requested documents. In April 2014, the Company reached an agreement in principle with the government. In March 2016, the Company finalized and executed settlement agreements with the State of New York and the DOJ, including a settlement payment of an immaterial amount.

Noncontrolling interests subjec

Noncontrolling interests subject to put provisions and other commitments	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Noncontrolling interests subject to put provisions and other commitments	Noncontrolling interests subject to put provisions and other commitments The Company has potential obligations to purchase the noncontrolling interests held by third parties in several of its majority-owned and other nonconsolidated entities. These obligations are in the form of put provisions and are exercisable at the third-party owners’ discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners’ equity interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the equity interests put to the Company, which is intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of the noncontrolling interests subject to put provisions is a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company’s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may be settled could vary significantly depending upon market conditions including potential purchasers’ access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners’ equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value are immaterial. The Company has other potential commitments to provide operating capital to a number of dialysis centers that are wholly-owned by third parties or businesses in which the Company maintains a noncontrolling equity interest as well as to physician-owned vascular access clinics or medical practices that the Company operates under management and administrative services agreements of approximately $5,892 . Certain consolidated joint ventures are originally contractually scheduled to dissolve after terms ranging from 10 to 50 years. While noncontrolling interests in these limited life entities qualify as mandatorily redeemable financial instruments, they are subject to a classification and measurement scope exception from the accounting guidance generally applicable to other mandatorily redeemable financial instruments. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.

Long-term incentive compensatio

Long-term incentive compensation	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Long-term incentive compensation	Long-term incentive compensation Long-term incentive program (LTIP) compensation includes both stock-based awards (principally stock-settled stock appreciation rights, restricted stock units, and performance stock units) as well as long-term performance-based cash awards. Long-term incentive compensation expense, which was primarily general and administrative in nature, was attributed to the Company’s U.S. dialysis and related lab services business, DMG business, corporate administrative support, and the other ancillary services and strategic initiatives. The Company’s stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. During the six months ended June 30, 2017 , the Company granted 1,426 stock-settled stock appreciation rights with an aggregate grant-date fair value of $20,865 and a weighted-average expected life of approximately 4.2 years, 387 stock units with an aggregate grant-date fair value of $25,517 and a weighted-average expected life of approximately 3.4 years, and 15 cash-settled stock appreciation rights with an aggregate grant-date fair value of $204 and a weighted-average expected life of approximately 4.3 years. For the six months ended June 30, 2017 and 2016 , the Company recognized $30,946 and $50,647 , respectively, in total LTIP expense, of which $17,504 and $23,717 , respectively, represented stock-based compensation expense for stock appreciation rights, restricted stock units, and discounted employee stock plan purchases, which are primarily included in general and administrative expense. The estimated tax benefits recorded for stock-based compensation for the six months ended June 30, 2017 and 2016 was $5,912 and $8,160 , respectively. As of June 30, 2017 , the Company had $149,543 of total estimated but unrecognized compensation expense for outstanding LTIP awards, including $84,475 related to stock-based compensation arrangements under the Company’s equity compensation and employee stock purchase plans. The Company expects to recognize the performance-based cash component of these LTIP costs over a weighted average remaining period of 1.2 years and the stock-based component of these LTIP costs over a weighted average remaining period of 1.5 years. For the six months ended June 30, 2017 and 2016 , the Company received $5,693 and $23,658 , respectively, in actual tax benefits upon the exercise of stock awards.

Share Repurchases Share Repurch

Share Repurchases Share Repurchases (Notes)	6 Months Ended
	Jun. 30, 2017
Equity, Class of Treasury Stock [Line Items]
Treasury Stock [Text Block]	Share repurchases During the six months ended June 30, 2017, the Company repurchased a total of 3,575 shares of its common stock for $231,674 or an average price of $64.81 per share. On July 13, 2016, the Company’s Board of Directors approved a share repurchase authorization in the amount of $1,240,748 . This share repurchase authorization was in addition to the $259,252 remaining at that time under the Company’s Board of Directors’ prior share repurchase authorization announced in April 2015. As of June 30, 2017 , there was $445,430 available under the current Board authorizations for additional share repurchases. Although these share repurchase authorizations do not have expiration dates, the Company remains subject to share repurchase limitations under the terms of its senior secured credit facilities and the indentures governing its senior notes.

Comprehensive income

Comprehensive income	6 Months Ended
	Jun. 30, 2017
Statement of Comprehensive Income [Abstract]
Comprehensive income	Comprehensive income For the three months ended June 30, 2017 For the six months ended June 30, 2017 Interest Investment Foreign Accumulated Interest Investment Foreign Accumulated Beginning balance $ (13,952 ) $ 3,594 $ (66,528 ) $ (76,886 ) $ (12,029 ) $ 2,175 $ (79,789 ) $ (89,643 ) Unrealized (losses) (2,969 ) 1,446 49,142 47,619 (8,186 ) 3,428 62,403 57,645 Related income tax 1,154 (389 ) — 765 3,184 (812 ) — 2,372 (1,815 ) 1,057 49,142 48,384 (5,002 ) 2,616 62,403 60,017 Reclassification 2,070 (117 ) — 1,953 4,139 (346 ) — 3,793 Related income tax (expense) benefit (805 ) 46 — (759 ) (1,610 ) 135 — (1,475 ) 1,265 (71 ) — 1,194 2,529 (211 ) — 2,318 Ending balance $ (14,502 ) $ 4,580 $ (17,386 ) $ (27,308 ) $ (14,502 ) $ 4,580 $ (17,386 ) $ (27,308 ) For the three months ended June 30, 2016 For the six months ended June 30, 2016 Interest Investment Foreign Accumulated Interest Investment Foreign Accumulated Beginning balance $ (15,929 ) $ 1,497 $ (39,081 ) $ (53,513 ) $ (10,925 ) $ 1,361 $ (50,262 ) $ (59,826 ) Unrealized (losses) (4,283 ) 782 (4,844 ) (8,345 ) (13,234 ) 1,124 6,337 (5,773 ) Related income tax 1,667 (293 ) — 1,374 5,149 (406 ) — 4,743 (2,616 ) 489 (4,844 ) (6,971 ) (8,085 ) 718 6,337 (1,030 ) Reclassification 733 — — 733 1,494 (152 ) — 1,342 Related income tax (expense) benefit (285 ) — — (285 ) (581 ) 59 — (522 ) 448 — — 448 913 (93 ) — 820 Ending balance $ (18,097 ) $ 1,986 $ (43,925 ) $ (60,036 ) $ (18,097 ) $ 1,986 $ (43,925 ) $ (60,036 ) The reclassification of net cap and swap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income. See Note 9 to these condensed consolidated financial statements for further details. The reclassification of net investment realized gains into income are recorded in other income in the corresponding consolidated statements of income. See Note 4 to these condensed consolidated financial statements for further details.

Acquisitions and divestitures

Acquisitions and divestitures	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Acquisitions and divestitures	Acquisitions and divestitures Acquisition of Renal Ventures On May 1, 2017 , the Company completed its acquisition of 100% of the equity of Colorado-based Renal Ventures Management, LLC (Renal Ventures) for approximately $361,563 in net cash, subject to certain post-closing adjustments. Renal Ventures operated 36 operating dialysis centers, one uncertified dialysis center and one home program that provided services to approximately 2,600 patients in six states. As a part of this transaction, the Company was required to divest three Renal Ventures outpatient dialysis centers, and three outpatient dialysis centers and one uncertified dialysis center of the Company for approximately $21,219 in net cash. The Company also incurred approximately $4,600 in transaction and integration costs during the six months ended June 30, 2017 associated with the acquisition that are included in general and administrative expenses. The initial purchase price allocation for the Renal Ventures acquisition is recorded at estimated fair values based upon the best information available to management and will be finalized when certain information arranged to be obtained has been received. In particular, certain working capital items, income tax amounts and the fair value of intangibles and fixed assets are pending final audit, issuance of final tax returns and valuation reports. The following table summarizes the assets acquired and liabilities assumed in the transactions and recognized at the acquisition date at estimated fair values: Current assets $ 24,529 Property and equipment 36,295 Amortizable intangible and other long-term assets 11,547 Goodwill 296,582 Current liabilities (6,912 ) Long-term liabilities (478 ) $ 361,563 The amortizable intangible assets acquired relate to non-compete agreements having a weighted-average useful life of five years. The total estimated amount of goodwill deductible for tax purposes associated with this acquisition was approximately $296,582 . Other routine acquisitions During the six months ended June 30, 2017 , the Company acquired dialysis and other businesses consisting of 20 dialysis centers located in the U.S., 55 dialysis centers located outside the U.S., and five other medical businesses for a total of $258,276 in net cash, $3,823 in deferred purchase price obligations, and $8,787 in earn-outs and liabilities assumed. The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company’s condensed consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions. The initial purchase price allocations for these transactions have been recorded at estimated fair values based on the best information available to management and will be finalized when certain information arranged to be obtained has been received. In particular, certain income tax amounts are pending final evaluation and quantification of pre-acquisition tax contingencies and filing of final tax returns. In addition, valuation of medical claims liabilities, certain working capital items, and the fair value of fixed assets and intangibles are pending final audits and related valuation reports. The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values: Current assets $ 7,439 Property and equipment 13,278 Amortizable intangible and other long-term assets 14,180 Non-amortizable intangibles 4,833 Goodwill 276,182 Current liabilities (6,467 ) Long-term liabilities (2,484 ) Noncontrolling interests (36,075 ) $ 270,886 Amortizable intangible assets acquired during the first six months of 2017 had weighted-average estimated useful lives of approximately five years. The majority of the intangible assets acquired during the first six months of 2017 relate to non-compete agreements having a weighted-average useful life and amortization period of five years. The total estimated amount of goodwill deductible for tax purposes associated with these acquisitions was approximately $207,080 . Pro forma financial information The following summary, prepared on a pro forma basis, combines the results of operations as if the acquisitions through June 30, 2017 had been consummated as of the beginning of 2017 and 2016, after including the impact of certain adjustments such as amortization of intangibles and income tax effects. Three months ended Six months ended 2017 2016 2017 2016 (unaudited) Pro forma net revenues $ 3,900,750 $ 3,820,558 $ 7,678,519 $ 7,576,206 Pro forma net income attributable to DaVita Inc. 128,654 58,996 579,906 160,709 Pro forma basic net income per share attributable to DaVita Inc. 0.67 0.29 3.02 0.79 Pro forma diluted net income per share attributable to DaVita Inc. 0.66 0.28 2.98 0.77 Contingent earn-out obligations The Company has several contingent earn-out obligations associated with acquisitions that could result in the Company paying the former owners of acquired companies a total of up to $16,684 if certain EBITDA, operating income performance targets or quality margins are met primarily over the next one to six years. Contingent earn-out obligations are remeasured at fair value at each reporting date until the contingencies are resolved with changes in the liability due to the re-measurement recorded in earnings. See Note 17 to these condensed consolidated financial statements for further details. As of June 30, 2017 , the Company has estimated the fair value of these contingent earn-out obligations to be $11,674 , of which a total of $4,666 is included in other liabilities and the remaining $7,008 is included in other long-term liabilities in the Company’s consolidated balance sheet. The following is a reconciliation of changes in the contingent earn-out obligations for the six months ended June 30, 2017 : Beginning balance, January 1, 2017 $ 9,977 Contingent earn-out obligations associated with acquisitions 3,849 Remeasurement of fair value for contingent earn-out obligations 415 Payments on contingent earn-out obligations (2,567 ) $ 11,674

Variable interest entities

Variable interest entities	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable interest entities	Variable interest entities The Company relies on the operating activities of certain legal entities that it does not directly own or control, but over which it has indirect influence and of which it is considered the primary beneficiary. These entities are subject to the consolidation guidance applicable to variable interest entities (VIEs). Under U.S. generally accepted accounting principles (GAAP), VIEs typically include entities for which (i) the entity’s equity is not sufficient to finance its activities without additional subordinated financial support; (ii) the equity holders as a group lack the power to direct the activities that most significantly influence the entity’s economic performance, the obligation to absorb the entity’s expected losses, or the right to receive the entity’s expected returns; or (iii) the voting rights of some investors are not proportional to their obligations to absorb the entity’s losses. The Company has determined that substantially all of the legal entities it is associated with that qualify as VIEs must be included in its consolidated financial statements. The Company manages these entities and provides operating and capital funding as necessary for these entities to accomplish their operational and strategic objectives. A number of these entities are subject to nominee ownership transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. In other cases, the Company’s management agreements with these entities include both financial terms and protective and participating rights to the entities’ operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for the entities to the Company. In some cases, such entities are subject to broad exclusivity or noncompetition restrictions that benefit the Company. Further, in some cases, the Company has contractual arrangements with the nominee owners that effectively indemnify these parties from the economic losses from, or entitle the Company to the economic benefits of, these entities. The analyses upon which these consolidation determinations rest are complex, involve uncertainties, and require significant judgment on various matters, some of which could be subject to different interpretations. At June 30, 2017 , these condensed consolidated financial statements include total assets of VIEs of $765,663 and total liabilities and noncontrolling interests of VIEs to third parties of $402,425 . The Company also sponsors certain deferred compensation plans whose trusts qualify as VIEs and the Company consolidates each of these plans as their primary beneficiary. The assets of these plans are recorded in short-term or long-term investments with matching offsetting liabilities recorded in accrued compensation and benefits and other long-term liabilities. See Note 4 to these condensed consolidated financial statements for disclosures on the assets of these consolidated non-qualified deferred compensation plans.

Fair value of financial instrum

Fair value of financial instruments	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair value of financial instruments	Fair value of financial instruments The Company measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equity that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the Financial Accounting Standards Board (FASB). The following table summarizes the Company’s assets, liabilities and temporary equity that are measured at fair value on a recurring basis as of June 30, 2017 : Total Quoted prices in Significant other Significant Assets Investments in mutual funds and common stock $ 53,209 $ 53,209 $ — $ — Cash surrender value of life insurance policies $ 62,684 $ — $ 62,684 $ — Interest rate cap agreements $ 1,743 $ — $ 1,743 $ — Funds on deposit with third parties $ 75,671 $ 75,671 $ — $ — Liabilities Contingent earn-out obligations $ 11,674 $ — $ — $ 11,674 Temporary equity Noncontrolling interests subject to put provisions $ 1,009,704 $ — $ — $ 1,009,704 Investments in mutual funds and common stock represent available-for-sale investments that are recorded at estimated fair value based upon quoted redemption prices reported by each mutual fund. See Note 4 to these condensed consolidated financial statements for further discussion. Investments in life insurance policies are carried at their cash surrender value which approximates their fair value. See Note 4 to these condensed consolidated financial statements for further discussion. Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 9 to these condensed consolidated financial statements for further discussion. Funds on deposit with third parties represent funds held with various third parties as required by regulation or contract and invested by those parties in various investments, which are measured at estimated fair value based primarily on quoted market prices. Contingent earn-out obligations are measured at estimated fair value based primarily on unobservable inputs including projected EBITDA, estimated probability of achieving gross margins or quality margins of certain medical procedures and the estimated probability of earn-out payments being made using an option pricing technique and a simulation model for expected EBITDA and operating income. In addition, a probability adjusted model was used to estimate the fair value amounts of the quality margins. The estimated fair value of these contingent earn-out obligations are remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value. See Note 11 to these condensed consolidated financial statements for a discussion of the Company’s methodology for estimating the fair value of noncontrolling interests subject to put obligations. Other financial instruments consist primarily of cash, accounts receivable, accounts payable, other accrued liabilities and debt. The balances of the non-debt financial instruments are presented in the condensed consolidated financial statements at June 30, 2017 at their approximate fair values due to the short-term nature of their settlements. The carrying balance of the Company’s senior secured credit facilities totaled $4,148,123 as of June 30, 2017 , and the fair value was approximately $4,240,812 based upon quoted market prices, a level 2 input. The carrying balance of the Company’s senior notes was $4,500,000 as of June 30, 2017 and their fair value was approximately $4,565,875 , based upon quoted market prices, a level 2 input.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment reporting	Segment reporting The Company operates two major divisions, Kidney Care and DMG. The Kidney Care division is comprised of the Company’s U.S. dialysis and related lab services business, its ancillary services and strategic initiatives, including its international operations, and the Company’s corporate administrative support. The Company’s U.S. dialysis and related lab services business is its largest line of business, and is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as ESRD. The Company’s DMG division is a patient- and physician-focused integrated healthcare delivery and management company with over two decades of experience providing coordinated outcomes-based medical care in a cost-effective manner. The Company’s ancillary services and strategic initiatives consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care and the Company’s international dialysis and integrated health operations. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker in making decisions about allocating resources to and assessing the financial performance of the Company’s various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer. The Company’s separate operating segments include its U.S. dialysis and related lab services business, its DMG operations in each region, each of its ancillary services and strategic initiatives, and its consolidated international kidney care and other healthcare operations in the European and Middle Eastern, Latin America, and Asia Pacific markets, and under the Saudi Ministry of Health charter. The U.S. dialysis and related lab services business and the DMG business each qualify as separately reportable segments, and all of the other ancillary services and strategic initiatives operating segments, including the international operating segments, have been combined and disclosed in the other segments category. The Company’s operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the financial performance of the operating segments. For internal management reporting, segment operations include direct segment operating expenses but exclude corporate administrative support costs, which consist primarily of indirect labor, benefits and long-term incentive based compensation of certain departments which provide support to various operating lines of business. These corporate administrative support costs are reduced by internal management fees received from the Company’s ancillary lines of businesses. The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes: Three months ended June 30, Six months ended June 30, 2017 2016 2017 2016 Segment net revenues: U.S. dialysis and related lab services Patient service revenues: External sources $ 2,403,222 $ 2,352,574 $ 4,752,123 $ 4,666,236 Intersegment revenues 26,436 14,470 50,196 28,779 Total dialysis and related lab services revenues 2,429,658 2,367,044 4,802,319 4,695,015 Less: Provision for uncollectible accounts (109,335 ) (106,515 ) (216,105 ) (211,266 ) Net dialysis and related lab services patient service revenues 2,320,323 2,260,529 4,586,214 4,483,749 Other revenues (1) 4,891 4,250 10,194 8,223 Total net dialysis and related lab services revenues 2,325,214 2,264,779 4,596,408 4,491,972 DMG DMG revenues: Capitated revenues 987,420 874,119 1,877,105 1,740,138 Net patient service revenues 189,529 169,167 368,501 281,601 Other revenues (2) 19,070 16,235 37,339 26,569 Intersegment capitated and other revenues 47 44 105 115 Total net DMG revenues 1,196,066 1,059,565 2,283,050 2,048,423 Other—Ancillary services and strategic initiatives Net patient service revenues 83,566 56,860 150,858 108,244 Capitated revenues 34,658 25,866 63,009 47,855 Other external sources 264,456 325,095 531,736 631,187 Intersegment revenues 10,913 14,720 26,216 26,546 Total ancillary services and strategic initiatives revenues 393,593 422,541 771,819 813,832 Total net segment revenues 3,914,873 3,746,885 7,651,277 7,354,227 Elimination of intersegment revenues (37,396 ) (29,234 ) (76,517 ) (55,440 ) Consolidated net revenues $ 3,877,477 $ 3,717,651 $ 7,574,760 $ 7,298,787 Segment operating margin (loss): U.S. dialysis and related lab services (3) $ 450,472 $ 449,190 $ 1,395,212 $ 889,245 DMG (12,880 ) (102,059 ) (572 ) (159,204 ) Other—Ancillary services and strategic initiatives (48,245 ) (12,644 ) (106,466 ) (23,745 ) Total segment operating margin 389,347 334,487 1,288,174 706,296 Reconciliation of segment operating margin to consolidated income Corporate administrative support (11,031 ) (5,417 ) (21,622 ) (12,337 ) Consolidated operating income 378,316 329,070 1,266,552 693,959 Debt expense (107,962 ) (102,894 ) (212,391 ) (205,778 ) Other income, net 5,253 3,215 9,496 6,191 Consolidated income before income taxes $ 275,607 $ 229,391 $ 1,063,657 $ 494,372 (1) Includes management fees for providing management and administrative services to dialysis centers that are wholly-owned by third parties and legal entities in which the Company owns a noncontrolling equity investment. (2) Includes medical consulting service fees and management fees for providing management and administrative services to unconsolidated joint ventures and revenue related to the maintenance of existing physician networks. (3) U.S. dialysis and related lab services operating income includes the net gain on the settlement with the VA. Depreciation and amortization expense by reportable segment is as follows Three months ended June 30, Six months ended June 30, 2017 2016 2017 2016 U.S. dialysis and related lab services $ 130,002 $ 119,350 $ 255,030 $ 235,887 DMG 60,011 54,211 117,334 100,473 Ancillary services and strategic initiatives 10,025 6,820 17,880 13,376 $ 200,038 $ 180,381 $ 390,244 $ 349,736 Subsequent to the issuance of the Company’s fiscal year 2016 consolidated financial statements and their inclusion in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 24, 2017 (the “2016 10-K”), the Company determined that it had misstated its disclosure of segment assets at December 31, 2016 in Note 25 to those consolidated financial statements. This misstatement resulted in an overstatement of “U.S. dialysis and related lab services” segment assets of $338,963 and a corresponding understatement of “Other - ancillary services and strategic initiatives” segment assets of the same amount. The Company performed an assessment of the materiality of this misstatement and concluded that this misstatement as originally disclosed was not materially misleading in its 2016 consolidated financial statements taken as a whole. The Company therefore has not amended its financial statements filed on its 2016 10-K to correct this misstatement, but has provided the corrected disclosure here. Summary of assets by reportable segment is as follows: June 30, 2017 December 31, 2016 Segment assets U.S. dialysis and related lab services (including equity investments of $83,102 and $66,924, respectively) $ 11,500,974 $ 11,099,137 DMG (including equity investments of $13,169 and $10,350, 6,282,819 6,213,091 Other—Ancillary services and strategic initiatives (including equity investments of $446,197 and $425,115, respectively) 1,557,991 1,429,029 Consolidated assets $ 19,341,784 $ 18,741,257 Expenditures for property and equipment by reportable segment is as follows: Three months ended Six months ended 2017 2016 2017 2016 U.S. dialysis and related lab services $ 152,233 $ 150,932 $ 325,761 $ 284,380 DMG 20,883 18,098 48,671 38,243 Ancillary services and strategic initiatives 11,289 16,410 24,508 36,004 $ 184,405 $ 185,440 $ 398,940 $ 358,627

Changes in DaVita Inc.'s Owners

Changes in DaVita Inc.'s Ownership Interest in Consolidated Subsidiaries	6 Months Ended
	Jun. 30, 2017
Noncontrolling Interest [Abstract]
Changes in DaVita Inc.'s ownership interest in consolidated subsidiaries	Changes in DaVita Inc.’s ownership interest in consolidated subsidiaries The effects of changes in DaVita Inc.’s ownership interest on the Company’s equity are as follows: Three months ended June 30, Six months ended June 30, 2017 2016 2017 2016 Net income attributable to DaVita Inc. $ 127,001 $ 53,382 $ 574,698 $ 150,816 Changes in paid-in capital for: Sales of noncontrolling interests — (885 ) — — Purchases of noncontrolling interests 618 (1,193 ) 195 (4,530 ) Net transfers to noncontrolling interests 618 (2,078 ) 195 (4,530 ) Net income attributable to DaVita Inc., net of $ 127,619 $ 51,304 $ 574,893 $ 146,286

New Accounting Standards

New Accounting Standards	6 Months Ended
	Jun. 30, 2017
Accounting Changes and Error Corrections [Abstract]
New accounting standards	New accounting standards In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers , which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. In July 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date . This guidance approves a one-year deferral of the effective date of ASU 2014-09. The ASU now permits the Company to adopt this standard effective January 1, 2018. Early application is permitted as of January 1, 2017. In March, April, and May 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) , each of which amends the guidance in ASU 2014-09. When they become effective, these ASUs will replace most existing revenue recognition guidance in GAAP. The Company has assembled an internal revenue task force that meets regularly to discuss and evaluate the overall impact this guidance will have on various revenue streams in the condensed consolidated financial statements and related disclosures. Based on the Company's current assessment, which is still ongoing, the Company does not expect this guidance to have a material effect on its net income, and is continuing to evaluate the impact it will have on its disclosures. The Company expects to adopt these ASU’s effective January 1, 2018 retrospectively with the cumulative effect of initially applying it recognized at the date of initial application (the cumulative effect method). In January 2016, the FASB issued ASU No. 2016-01, Financial Statements - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments in this ASU revise accounting related to (i) the classification and measurement of investments in equity securities and (ii) the presentation of certain fair value changes for financial liabilities at fair value. The amendments in this ASU are effective for the Company beginning on January 1, 2018 and are to be applied through a cumulative effect adjustment to the statement of financial position. Early adoption is permitted under certain circumstances. The adoption of this ASU is not expected to have a material impact on the Company’s condensed consolidated financial statements when adopted on January 1, 2018. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . The amendments in this ASU revise the accounting related to lessee accounting. Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for substantially all leases with lease terms in excess of twelve months. The new lease guidance also simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. The amendments in this ASU are effective for the Company beginning on January 1, 2019 and are to be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. The Company has assembled an internal lease task force that meets regularly to discuss and evaluate the overall impact of this guidance on its condensed consolidated financial statements and related disclosures, as well as the expected timing of adoption. The Company believes that the new standard will have a material impact on its condensed consolidated balance sheet but will not have a material impact on its results of operations or liquidity. The Company expects to adopt this ASU on January 1, 2019, and continues to evaluate the effect that the implementation of this ASU will have on its condensed consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The amendments in this ASU eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this ASU were effective for the Company beginning on January 1, 2017 and was applied prospectively. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . The changes required by this ASU involve several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows, and an election on estimating forfeitures. The amendments in this ASU were effective for the Company beginning January 1, 2017. The method of adoption differs for each of the topics covered by the ASU. The primary effect of this ASU for the Company is the presentation of excess tax benefits or deficiencies as a component of income tax expense within the Company's condensed consolidated statement of income rather than within additional paid-in capital on its condensed consolidated balance sheet. In addition, these excess tax benefits or deficiencies are presented as an operating activity on the condensed consolidated statement of cash flows rather than as a financing activity. The Company elected to apply the presentation requirements for cash flows related to excess tax benefits prospectively. Additionally, the Company has elected to continue to estimate forfeitures expected to occur in determining the amount of compensation cost to be recognized each period. The new standard may cause volatility in the Company’s effective tax rates and diluted earnings per share due to the tax effects related to share-based payments being recorded within the Company’s condensed consolidated statement of income, including a potential increase in the Company’s provision for income taxes if a significant number of outstanding stock awards are exercised at recent levels of the Company’s stock price. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . The amendments in this ASU clarify how certain cash receipts and cash payments should be classified on the statement of cash flows. The new standard is effective for the Company beginning January 1, 2018 and should be applied retrospectively to all periods presented. The Company has not yet determined the effect that adoption of this ASU will have on its condensed consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory . The amendments in this ASU allow entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The current guidance does not allow recognition until the asset has been sold to an outside party. The amendments in this ASU are effective for the Company beginning on January 1, 2018 and are to be applied on a modified retrospective basis. The Company has not yet determined the effect that adoption of this ASU will have on its condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . The amendments in this ASU simplify the test for goodwill impairment by eliminating the second step in testing for goodwill impairment. The amendments in this new ASU are effective for the Company January 1, 2020 and are to be applied on a prospective basis. Early adoption was permitted on or after January 1, 2017 and the Company early adopted this ASU as of January 1, 2017.

Condensed Consolidating Financi

Condensed Consolidating Financial Statements	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed consolidating financial statements	Condensed consolidating financial statements The following information is presented in accordance with Rule 3-10 of Regulation S-X. The operating and investing activities of the separate legal entities included in the Company’s condensed consolidated financial statements are fully interdependent and integrated. Revenues and operating expenses of the separate legal entities include intercompany charges for management and other administrative services. The Company’s senior notes are guaranteed by a substantial majority of its domestic subsidiaries as measured by revenue, income and assets. The subsidiary guarantors have guaranteed the senior notes on a joint and several basis. However, a subsidiary guarantor will be released from its obligations under its guarantee of the senior notes and the indentures governing the senior notes if, in general, there is a sale or other disposition of all or substantially all of the assets of such subsidiary guarantor, including by merger or consolidation, or a sale or other disposition of all of the equity interests in such subsidiary guarantor held by the Company and its restricted subsidiaries, as defined in the indentures; such subsidiary guarantor is designated by the Company as an unrestricted subsidiary, as defined in the indentures, or otherwise ceases to be a restricted subsidiary of the Company, in each case in accordance with the indentures; or such subsidiary guarantor no longer guarantees any other indebtedness, as defined in the indentures, of the Company or any of its restricted subsidiaries, except for guarantees that are contemporaneously released. The senior notes are not guaranteed by certain of the Company’s domestic subsidiaries, any of the Company’s foreign subsidiaries, or any entities that do not constitute subsidiaries within the meaning of the indentures, such as corporations in which the Company holds capital stock with less than a majority of the voting power, joint ventures and partnerships in which the Company holds less than a majority of the equity or voting interests, non-owned entities and third parties. Condensed Consolidating Statements of Income Guarantor subsidiaries Non- Guarantor subsidiaries Consolidating adjustments Consolidated total For The Three Months Ended June 30, 2017 DaVita Inc. Patient services revenues $ — $ 1,681,249 $ 1,055,797 $ (54,579 ) $ 2,682,467 Less: Provision for uncollectible accounts — (74,413 ) (41,072 ) — (115,485 ) Net patient service revenues — 1,606,836 1,014,725 (54,579 ) 2,566,982 Capitated revenues — 467,852 555,947 (1,721 ) 1,022,078 Other revenues 193,585 501,861 34,257 (441,286 ) 288,417 Total net revenues 193,585 2,576,549 1,604,929 (497,586 ) 3,877,477 Operating expenses and charges 138,104 2,396,723 1,461,920 (497,586 ) 3,499,161 Operating income 55,481 179,826 143,009 — 378,316 Debt expense (106,159 ) (92,346 ) (14,943 ) 105,486 (107,962 ) Other income, net 102,299 2,191 6,249 (105,486 ) 5,253 Income tax expense 22,969 70,927 20,086 — 113,982 Equity earnings in subsidiaries 98,349 79,605 — (177,954 ) — Net income 127,001 98,349 114,229 (177,954 ) 161,625 Less: Net income attributable to noncontrolling interests — — — (34,624 ) (34,624 ) Net income attributable to DaVita Inc. $ 127,001 $ 98,349 $ 114,229 $ (212,578 ) $ 127,001 Guarantor Non- Consolidating Consolidated For The Three Months Ended June 30, 2016 DaVita Inc. Patient service revenues $ — $ 1,664,361 $ 959,946 $ (40,793 ) $ 2,583,514 Less: Provision for uncollectible accounts — (74,498 ) (36,930 ) — (111,428 ) Net patient service revenues — 1,589,863 923,016 (40,793 ) 2,472,086 Capitated revenues — 463,732 436,337 (84 ) 899,985 Other revenues 196,910 521,065 31,749 (404,144 ) 345,580 Total net revenues 196,910 2,574,660 1,391,102 (445,021 ) 3,717,651 Operating expenses 134,072 2,510,119 1,189,411 (445,021 ) 3,388,581 Operating income 62,838 64,541 201,691 — 329,070 Debt expense (102,101 ) (91,259 ) (12,998 ) 103,464 (102,894 ) Other income 98,654 5,421 2,604 (103,464 ) 3,215 Income tax expense 41,942 89,203 3,743 — 134,888 Equity earnings in subsidiaries 35,933 146,433 — (182,366 ) — Net income 53,382 35,933 187,554 (182,366 ) 94,503 Less: Net income attributable to noncontrolling interests — — — (41,121 ) (41,121 ) Net income attributable to DaVita Inc. $ 53,382 $ 35,933 $ 187,554 $ (223,487 ) $ 53,382 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2017 DaVita Inc. Patient services revenues $ — $ 3,234,605 $ 2,154,549 $ (105,309 ) $ 5,283,845 Less: Provision for uncollectible accounts — (136,694 ) (91,774 ) — (228,468 ) Net patient service revenues — 3,097,911 2,062,775 (105,309 ) 5,055,377 Capitated revenues — 931,479 1,010,901 (2,266 ) 1,940,114 Other revenues 414,971 979,536 69,894 (885,132 ) 579,269 Total net revenues 414,971 5,008,926 3,143,570 (992,707 ) 7,574,760 Operating expenses and charges 270,014 4,276,878 2,754,023 (992,707 ) 6,308,208 Operating income 144,957 732,048 389,547 — 1,266,552 Debt expense (208,823 ) (183,747 ) (28,659 ) 208,838 (212,391 ) Other income, net 202,636 5,728 9,970 (208,838 ) 9,496 Income tax expense 57,062 292,348 52,337 — 401,747 Equity earnings in subsidiaries 492,990 231,309 — (724,299 ) — Net income 574,698 492,990 318,521 (724,299 ) 661,910 Less: Net income attributable to noncontrolling interests — — — (87,212 ) (87,212 ) Net income attributable to DaVita Inc. $ 574,698 $ 492,990 $ 318,521 $ (811,511 ) $ 574,698 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2016 DaVita Inc. Patient services revenues $ — $ 3,317,673 $ 1,827,984 $ (80,209 ) $ 5,065,448 Less: Provision for uncollectible accounts — (133,311 ) (87,322 ) — (220,633 ) Net patient service revenues — 3,184,362 1,740,662 (80,209 ) 4,844,815 Capitated revenues — 931,694 856,510 (211 ) 1,787,993 Other revenues 383,885 1,005,420 59,269 (782,595 ) 665,979 Total net revenues 383,885 5,121,476 2,656,441 (863,015 ) 7,298,787 Operating expenses and charges 256,345 4,887,749 2,323,749 (863,015 ) 6,604,828 Operating income 127,540 233,727 332,692 — 693,959 Debt expense (203,202 ) (183,432 ) (24,512 ) 205,368 (205,778 ) Other income, net 197,214 9,757 4,588 (205,368 ) 6,191 Income tax expense 77,088 162,457 22,165 — 261,710 Equity earnings in subsidiaries 106,352 208,757 — (315,109 ) — Net income 150,816 106,352 290,603 (315,109 ) 232,662 Less: Net income attributable to noncontrolling interests — — — (81,846 ) (81,846 ) Net income attributable to DaVita Inc. $ 150,816 $ 106,352 $ 290,603 $ (396,955 ) $ 150,816 Condensed Consolidating Statements of Comprehensive Income Guarantor Non- Consolidating Consolidated For The Three Months Ended June 30, 2017 DaVita Inc. Net income $ 127,001 $ 98,349 $ 114,229 $ (177,954 ) $ 161,625 Other comprehensive income 436 — 49,142 — 49,578 Total comprehensive income 127,437 98,349 163,371 (177,954 ) 211,203 Less: Comprehensive income attributable to — — — (34,624 ) (34,624 ) Comprehensive income attributable to DaVita Inc. $ 127,437 $ 98,349 $ 163,371 $ (212,578 ) $ 176,579 Guarantor Non- Consolidating Consolidated For The Three Months Ended June 30, 2016 DaVita Inc. Net income $ 53,382 $ 35,933 $ 187,554 $ (182,366 ) $ 94,503 Other comprehensive loss (1,530 ) — (4,844 ) — (6,374 ) Total comprehensive income 51,852 35,933 182,710 (182,366 ) 88,129 Less: Comprehensive income attributable to the — — — (41,270 ) (41,270 ) Comprehensive income attributable to DaVita Inc. $ 51,852 $ 35,933 $ 182,710 $ (223,636 ) $ 46,859 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2017 DaVita Inc. Net income $ 574,698 $ 492,990 $ 318,521 $ (724,299 ) $ 661,910 Other comprehensive (loss) income (70 ) — 62,403 — 62,333 Total comprehensive income 574,628 492,990 380,924 (724,299 ) 724,243 Less: Comprehensive income attributable to — — — (87,210 ) (87,210 ) Comprehensive income attributable to DaVita Inc. $ 574,628 $ 492,990 $ 380,924 $ (811,509 ) $ 637,033 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2016 DaVita Inc. Net income $ 150,816 $ 106,352 $ 290,603 $ (315,109 ) $ 232,662 Other comprehensive (loss) income (6,398 ) — 6,337 — (61 ) Total comprehensive income 144,418 106,352 296,940 (315,109 ) 232,601 Less: Comprehensive income attributable to the — — — (81,995 ) (81,995 ) Comprehensive income attributable to DaVita Inc. $ 144,418 $ 106,352 $ 296,940 $ (397,104 ) $ 150,606 Condensed Consolidating Balance Sheets Guarantor Non- Consolidating Consolidated As of June 30, 2017 DaVita Inc. Cash and cash equivalents $ 374,973 $ 40,508 $ 296,516 $ — $ 711,997 Accounts receivable, net — 1,278,053 775,759 — 2,053,812 Other current assets 254,108 891,208 112,643 — 1,257,959 Total current assets 629,081 2,209,769 1,184,918 — 4,023,768 Property and equipment, net 345,667 1,669,583 1,232,780 — 3,248,030 Intangible assets, net 355 1,405,712 56,827 — 1,462,894 Investments in subsidiaries 10,368,953 2,375,421 — (12,744,374 ) — Intercompany receivables 3,266,741 — 1,035,735 (4,302,476 ) — Other long-term assets and investments 45,228 92,891 579,182 — 717,301 Goodwill — 7,850,917 2,038,874 — 9,889,791 Total assets $ 14,656,025 $ 15,604,293 $ 6,128,316 $ (17,046,850 ) $ 19,341,784 Current liabilities $ 399,436 $ 1,807,277 $ 566,612 $ — $ 2,773,325 Intercompany payables — 2,181,952 2,120,524 (4,302,476 ) — Long-term debt and other long-term liabilities 8,578,628 1,246,111 462,120 — 10,286,859 Noncontrolling interests subject to put provisions 593,647 — — 416,057 1,009,704 Total DaVita Inc. shareholder's equity 5,084,314 10,368,953 2,375,421 (12,744,374 ) 5,084,314 Noncontrolling interests not subject to put provisions — — 603,639 (416,057 ) 187,582 Total equity 5,084,314 10,368,953 2,979,060 (13,160,431 ) 5,271,896 Total liabilities and equity $ 14,656,025 $ 15,604,293 $ 6,128,316 $ (17,046,850 ) $ 19,341,784 Guarantor Non- Consolidating Consolidated As of December 31, 2016 DaVita Inc. Cash and cash equivalents $ 549,921 $ 59,192 $ 304,074 $ — $ 913,187 Accounts receivable, net — 1,215,232 702,070 — 1,917,302 Other current assets 277,911 736,727 135,101 — 1,149,739 Total current assets 827,832 2,011,151 1,141,245 — 3,980,228 Property and equipment, net 337,200 1,689,798 1,148,369 — 3,175,367 Intangible assets, net 487 1,491,057 36,223 — 1,527,767 Investments in subsidiaries 9,717,728 2,002,660 — (11,720,388 ) — Intercompany receivables 3,250,692 — 866,955 (4,117,647 ) — Other long-term assets and investments 39,994 86,710 523,874 — 650,578 Goodwill — 7,838,984 1,568,333 — 9,407,317 Total assets $ 14,173,933 $ 15,120,360 $ 5,284,999 $ (15,838,035 ) $ 18,741,257 Current liabilities $ 303,840 $ 1,865,193 $ 527,412 $ — $ 2,696,445 Intercompany payables — 2,322,124 1,795,523 (4,117,647 ) — Long-term debt and other long-term liabilities 8,614,445 1,215,315 392,053 — 10,221,813 Noncontrolling interests subject to put provisions 607,601 — — 365,657 973,258 Total DaVita Inc. shareholder's equity 4,648,047 9,717,728 2,002,660 (11,720,388 ) 4,648,047 Noncontrolling interests not subject to put provisions — — 567,351 (365,657 ) 201,694 Total equity 4,648,047 9,717,728 2,570,011 (12,086,045 ) 4,849,741 Total liabilities and equity $ 14,173,933 $ 15,120,360 $ 5,284,999 $ (15,838,035 ) $ 18,741,257 Condensed Consolidating Statements of Cash Flows Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2017 DaVita Inc. Cash flows from operating activities: Net income $ 574,698 $ 492,990 $ 318,521 $ (724,299 ) $ 661,910 Changes in operating assets and liabilities and non-cash items included in net income (431,980 ) 52,218 4,997 724,299 349,534 Net cash provided by operating activities 142,718 545,208 323,518 — 1,011,444 Cash flows from investing activities: Additions of property and equipment, net (50,966 ) (182,494 ) (165,480 ) — (398,940 ) Acquisitions — (538,450 ) (81,389 ) — (619,839 ) Proceeds from asset and business sales — 70,127 109 — 70,236 Proceeds (purchases) from investment sales and other items, net 49,036 (2,974 ) 50,833 — 96,895 Net cash used in investing activities (1,930 ) (653,791 ) (195,927 ) — (851,648 ) Cash flows from financing activities: Long-term debt and related financing costs, net (54,992 ) (6,893 ) (2,147 ) — (64,032 ) Intercompany (payments) borrowing (37,233 ) 98,224 (60,991 ) — — Other items (223,511 ) (1,432 ) (76,203 ) — (301,146 ) Net cash (used in) provided by financing activities (315,736 ) 89,899 (139,341 ) — (365,178 ) Effect of exchange rate changes on cash — — 4,192 — 4,192 Net decrease in cash and cash equivalents (174,948 ) (18,684 ) (7,558 ) — (201,190 ) Cash and cash equivalents at beginning of period 549,921 59,192 304,074 — 913,187 Cash and cash equivalents at end of period $ 374,973 $ 40,508 $ 296,516 $ — $ 711,997 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2016 DaVita Inc. Cash flows from operating activities: Net income $ 150,816 $ 106,352 $ 290,603 $ (315,109 ) $ 232,662 Changes in operating assets and liabilities and non-cash (1,505 ) 219,697 179,676 315,109 712,977 Net cash provided by operating activities 149,311 326,049 470,279 — 945,639 Cash flows from investing activities: Additions of property and equipment, net (42,266 ) (171,164 ) (145,197 ) — (358,627 ) Acquisitions — (462,592 ) (10,722 ) — (473,314 ) Proceeds from asset and business sales — 17,393 — — 17,393 Proceeds (purchases) from investment sales and other 21,230 (10,869 ) 45,958 — 56,319 Net cash used in investing activities (21,036 ) (627,232 ) (109,961 ) — (758,229 ) Cash flows from financing activities: Long-term debt and related financing costs, net (42,493 ) (13,917 ) (4,823 ) — (61,233 ) Intercompany borrowing (payments) 11,208 247,765 (258,973 ) — — Other items (255,032 ) (6,253 ) (81,036 ) — (342,321 ) Net cash (used in) provided by financing activities (286,317 ) 227,595 (344,832 ) — (403,554 ) Effect of exchange rate changes on cash — — 444 — 444 Net (decrease) increase in cash and cash equivalents (158,042 ) (73,588 ) 15,930 — (215,700 ) Cash and cash equivalents at beginning of period 1,186,636 109,357 203,123 — 1,499,116 Cash and cash equivalents at end of period $ 1,028,594 $ 35,769 $ 219,053 $ — $ 1,283,416

Supplemental Data

Supplemental Data	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental data	Supplemental data The following information is presented as supplemental data as required by the indentures governing the Company’s senior notes. Condensed Consolidating Statements of Income Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) For The Six Months Ended June 30, 2017 Patient service operating revenues $ 5,283,845 $ 273,017 $ — $ 5,010,828 Less: Provision for uncollectible accounts (228,468 ) (7,351 ) — (221,117 ) Net patient service operating revenues 5,055,377 265,666 — 4,789,711 Capitated revenues 1,940,114 785,139 — 1,154,975 Other revenues 579,269 19,596 — 559,673 Total net operating revenues 7,574,760 1,070,401 — 6,504,359 Operating expenses 6,308,208 1,032,529 (232 ) 5,275,911 Operating income 1,266,552 37,872 232 1,228,448 Debt expense, including refinancing charges (212,391 ) (3,323 ) — (209,068 ) Other income 9,496 151 — 9,345 Income tax expense 401,747 32,700 93 368,954 Net income 661,910 2,000 139 659,771 Less: Net income attributable to noncontrolling interests (87,212 ) — — (87,212 ) Net income attributable to DaVita Inc. $ 574,698 $ 2,000 $ 139 $ 572,559 (1) After elimination of the unrestricted subsidiaries and the physician groups. Condensed Consolidating Statements of Comprehensive Income Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) For The Six Months Ended June 30, 2017 Net income $ 661,910 $ 2,000 $ 139 $ 659,771 Other comprehensive income 62,333 — — 62,333 Total comprehensive income 724,243 2,000 139 722,104 Less: Comprehensive income attributable to the noncontrolling (87,210 ) — — (87,210 ) Comprehensive income attributable to DaVita Inc. $ 637,033 $ 2,000 $ 139 $ 634,894 (1) After elimination of the unrestricted subsidiaries and the physician groups. Condensed Consolidating Balance Sheets Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) As of June 30, 2017 Cash and cash equivalents $ 711,997 $ 107,232 $ — $ 604,765 Accounts receivable, net 2,053,812 213,804 — 1,840,008 Other current assets 1,257,959 13,679 — 1,244,280 Total current assets 4,023,768 334,715 — 3,689,053 Property and equipment, net 3,248,030 3,368 — 3,244,662 Amortizable intangibles, net 1,462,894 4,553 — 1,458,341 Other long-term assets 717,301 82,477 2,946 631,878 Goodwill 9,889,791 29,865 — 9,859,926 Total assets $ 19,341,784 $ 454,978 $ 2,946 $ 18,883,860 Current liabilities $ 2,773,325 $ 178,259 $ — $ 2,595,066 Payables to parent — 114,038 2,946 (116,984 ) Long-term debt and other long-term liabilities 10,286,859 55,870 — 10,230,989 Noncontrolling interests subject to put provisions 1,009,704 — — 1,009,704 Total DaVita Inc. shareholders’ equity 5,084,314 106,811 — 4,977,503 Noncontrolling interests not subject to put provisions 187,582 — — 187,582 Shareholders’ equity 5,271,896 106,811 — 5,165,085 Total liabilities and shareholder’s equity $ 19,341,784 $ 454,978 $ 2,946 $ 18,883,860 (1) After elimination of the unrestricted subsidiaries and the physician groups. Condensed Consolidating Statements of Cash Flows Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) For The Six Months Ended June 30, 2017 Cash flows from operating activities: Net income $ 661,910 $ 2,000 $ 139 $ 659,771 Changes in operating and intercompany assets and liabilities 349,534 (37,812 ) (139 ) 387,485 Net cash provided by (used in) operating activities 1,011,444 (35,812 ) — 1,047,256 Cash flows from investing activities: Additions of property and equipment (398,940 ) (5,603 ) — (393,337 ) Acquisitions and divestitures, net (619,839 ) — — (619,839 ) Proceeds from discontinued operations 70,236 — — 70,236 Investments and other items 96,895 (1,386 ) — 98,281 Net cash used in investing activities (851,648 ) (6,989 ) — (844,659 ) Cash flows from financing activities: Long-term debt (64,032 ) — — (64,032 ) Intercompany — 45,342 — (45,342 ) Other items (301,146 ) — — (301,146 ) Net cash (used in) provided by financing activities (365,178 ) 45,342 — (410,520 ) Effect of exchange rate changes on cash 4,192 — — 4,192 Net (decrease) increase in cash (201,190 ) 2,541 — (203,731 ) Cash and cash equivalents at beginning of period 913,187 104,691 — 808,496 Cash and cash equivalents at end of period $ 711,997 $ 107,232 $ — $ 604,765 (1) After elimination of the unrestricted subsidiaries and the physician groups.

Condensed consolidated interi30

Condensed consolidated interim financial statements (Policies)	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Condensed consolidated interim financial statements	The condensed consolidated interim financial statements included in this report are prepared by the Company without audit. In the opinion of management, all adjustments necessary for a fair presentation of the results of operations are reflected in these condensed consolidated interim financial statements. All significant intercompany accounts and transactions have been eliminated. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. The most significant estimates and assumptions underlying these financial statements and accompanying notes generally involve revenue recognition and accounts receivable, contingencies, impairments of goodwill and other long-lived assets, fair value estimates, accounting for income taxes, variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, long-term incentive program compensation and medical liability claims. The results of operations for the six months ended June 30, 2017 are not necessarily indicative of the operating results for the full year. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 . Prior year balances and amounts have been reclassified to conform to the current year presentation. The Company has evaluated subsequent events through the date these condensed consolidated financial statements were issued and has included all necessary adjustments and disclosures.
Earnings per share	Basic net income per share is calculated by dividing net income attributable to the Company, adjusted for any change in noncontrolling interests redemption rights in excess of fair value, by the weighted average number of common shares and vested stock units outstanding, net of shares held in escrow from the DaVita HealthCare Partners merger that under certain circumstances may be returned to the Company. Diluted net income per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units (under the treasury stock method) as well as contingently returnable shares held in escrow.
Accounts receivable	Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the ultimate collectability of accounts receivable, the Company analyzes its historical cash collection experience and trends for each of its government payors and commercial payors to estimate the adequacy of the allowance for doubtful accounts and the amount of the provision for uncollectible accounts. Management regularly updates its analysis based upon the most recent information available to determine its current provision for uncollectible accounts and the adequacy of its allowance for doubtful accounts. For receivables associated with dialysis patient services covered by Medicare, the Company receives 80% of the payment directly from Medicare as established under the government’s bundled payment system and determines an appropriate allowance for doubtful accounts and provision for uncollectible accounts on the remaining balance due depending upon the Company’s estimate of the amounts ultimately collectible from other secondary coverage sources or from the patients. For receivables associated with services to patients covered by commercial payors that are either based upon contractual terms or for non-contracted health plan coverage, the Company provides an allowance for doubtful accounts by recording a provision for uncollectible accounts based upon its historical collection experience, potential inefficiencies in its billing processes and for which collectability is determined to be unlikely. For receivables associated with the Company’s capitated health plans, the balances remain on the balance sheet for as long as the respective plan years are open, which varies by health plan but is generally two years in length, with collections occurring on a periodic basis throughout the duration of the corresponding plan year. Approximately 1% of the Company’s net accounts receivable are associated with patient pay. The Company’s policy is to reserve 100% of the outstanding accounts receivable balances for dialysis services when those amounts due have been outstanding for more than three months and to reserve 100% of the outstanding accounts receivable balances for services of DaVita Medical Group (DMG, formerly known as HealthCare Partners or HCP) when those amounts due have been outstanding for more than twelve months and when the amount is not subject to a payment plan.
Investments in debt and equity securities	The investments in mutual funds classified as available-for-sale are held within a trust to fund existing obligations associated with several of the Company’s non-qualified deferred compensation plans. The Company classifies certain debt securities as held-to-maturity and records them at amortized cost based on the Company’s intentions and strategy concerning those investments. Equity securities that have readily determinable fair values, and certain other financial instruments that have readily determinable fair values or redemption values, are classified as available-for-sale and recorded at fair value.
Income taxes	The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense.
Long-term debt	the Company maintains several active and forward interest rate cap agreements that have the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on specific portions of the Company's floating rate debt, as described below. The cap agreements are designated as cash flow hedges and, as a result, changes in the fair values of these cap agreements are reported in other comprehensive income. The amortization of the original cap premium is recognized as a component of debt expense on a straight-line basis over the term of the cap agreements. The cap agreements do not contain credit-risk contingent features.
Long-term incentive compensation	The Company’s stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures.
Comprehensive income	The reclassification of net cap and swap realized losses into income are recorded as debt expense in the corresponding consolidated statements of income. See Note 9 to these condensed consolidated financial statements for further details. The reclassification of net investment realized gains into income are recorded in other income in the corresponding consolidated statements of income. See Note 4 to these condensed consolidated financial statements for further details.
Variable interest entities	The Company relies on the operating activities of certain legal entities that it does not directly own or control, but over which it has indirect influence and of which it is considered the primary beneficiary. These entities are subject to the consolidation guidance applicable to variable interest entities (VIEs). Under U.S. generally accepted accounting principles (GAAP), VIEs typically include entities for which (i) the entity’s equity is not sufficient to finance its activities without additional subordinated financial support; (ii) the equity holders as a group lack the power to direct the activities that most significantly influence the entity’s economic performance, the obligation to absorb the entity’s expected losses, or the right to receive the entity’s expected returns; or (iii) the voting rights of some investors are not proportional to their obligations to absorb the entity’s losses. The Company also sponsors certain deferred compensation plans whose trusts qualify as VIEs and the Company consolidates each of these plans as their primary beneficiary. The assets of these plans are recorded in short-term or long-term investments with matching offsetting liabilities recorded in accrued compensation and benefits and other long-term liabilities. The analyses upon which these consolidation determinations rest are complex, involve uncertainties, and require significant judgment on various matters, some of which could be subject to different interpretations.
Fair value of financial instruments	Investments in mutual funds and common stock represent available-for-sale investments that are recorded at estimated fair value based upon quoted redemption prices reported by each mutual fund. See Note 4 to these condensed consolidated financial statements for further discussion. Investments in life insurance policies are carried at their cash surrender value which approximates their fair value. See Note 4 to these condensed consolidated financial statements for further discussion. Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 9 to these condensed consolidated financial statements for further discussion. Funds on deposit with third parties represent funds held with various third parties as required by regulation or contract and invested by those parties in various investments, which are measured at estimated fair value based primarily on quoted market prices. Contingent earn-out obligations are measured at estimated fair value based primarily on unobservable inputs including projected EBITDA, estimated probability of achieving gross margins or quality margins of certain medical procedures and the estimated probability of earn-out payments being made using an option pricing technique and a simulation model for expected EBITDA and operating income. In addition, a probability adjusted model was used to estimate the fair value amounts of the quality margins. The estimated fair value of these contingent earn-out obligations are remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value.
New accounting standards	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers , which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. In July 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date . This guidance approves a one-year deferral of the effective date of ASU 2014-09. The ASU now permits the Company to adopt this standard effective January 1, 2018. Early application is permitted as of January 1, 2017. In March, April, and May 2016, the FASB issued ASU 2016-08, ASU 2016-10, ASU 2016-11, and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) , each of which amends the guidance in ASU 2014-09. When they become effective, these ASUs will replace most existing revenue recognition guidance in GAAP. The Company has assembled an internal revenue task force that meets regularly to discuss and evaluate the overall impact this guidance will have on various revenue streams in the condensed consolidated financial statements and related disclosures. Based on the Company's current assessment, which is still ongoing, the Company does not expect this guidance to have a material effect on its net income, and is continuing to evaluate the impact it will have on its disclosures. The Company expects to adopt these ASU’s effective January 1, 2018 retrospectively with the cumulative effect of initially applying it recognized at the date of initial application (the cumulative effect method). In January 2016, the FASB issued ASU No. 2016-01, Financial Statements - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments in this ASU revise accounting related to (i) the classification and measurement of investments in equity securities and (ii) the presentation of certain fair value changes for financial liabilities at fair value. The amendments in this ASU are effective for the Company beginning on January 1, 2018 and are to be applied through a cumulative effect adjustment to the statement of financial position. Early adoption is permitted under certain circumstances. The adoption of this ASU is not expected to have a material impact on the Company’s condensed consolidated financial statements when adopted on January 1, 2018. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . The amendments in this ASU revise the accounting related to lessee accounting. Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for substantially all leases with lease terms in excess of twelve months. The new lease guidance also simplifies the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. The amendments in this ASU are effective for the Company beginning on January 1, 2019 and are to be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. The Company has assembled an internal lease task force that meets regularly to discuss and evaluate the overall impact of this guidance on its condensed consolidated financial statements and related disclosures, as well as the expected timing of adoption. The Company believes that the new standard will have a material impact on its condensed consolidated balance sheet but will not have a material impact on its results of operations or liquidity. The Company expects to adopt this ASU on January 1, 2019, and continues to evaluate the effect that the implementation of this ASU will have on its condensed consolidated financial statements and related disclosures. In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The amendments in this ASU eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an investor must adjust the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The amendments in this ASU were effective for the Company beginning on January 1, 2017 and was applied prospectively. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . The changes required by this ASU involve several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows, and an election on estimating forfeitures. The amendments in this ASU were effective for the Company beginning January 1, 2017. The method of adoption differs for each of the topics covered by the ASU. The primary effect of this ASU for the Company is the presentation of excess tax benefits or deficiencies as a component of income tax expense within the Company's condensed consolidated statement of income rather than within additional paid-in capital on its condensed consolidated balance sheet. In addition, these excess tax benefits or deficiencies are presented as an operating activity on the condensed consolidated statement of cash flows rather than as a financing activity. The Company elected to apply the presentation requirements for cash flows related to excess tax benefits prospectively. Additionally, the Company has elected to continue to estimate forfeitures expected to occur in determining the amount of compensation cost to be recognized each period. The new standard may cause volatility in the Company’s effective tax rates and diluted earnings per share due to the tax effects related to share-based payments being recorded within the Company’s condensed consolidated statement of income, including a potential increase in the Company’s provision for income taxes if a significant number of outstanding stock awards are exercised at recent levels of the Company’s stock price. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . The amendments in this ASU clarify how certain cash receipts and cash payments should be classified on the statement of cash flows. The new standard is effective for the Company beginning January 1, 2018 and should be applied retrospectively to all periods presented. The Company has not yet determined the effect that adoption of this ASU will have on its condensed consolidated financial statements. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory . The amendments in this ASU allow entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The current guidance does not allow recognition until the asset has been sold to an outside party. The amendments in this ASU are effective for the Company beginning on January 1, 2018 and are to be applied on a modified retrospective basis. The Company has not yet determined the effect that adoption of this ASU will have on its condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . The amendments in this ASU simplify the test for goodwill impairment by eliminating the second step in testing for goodwill impairment. The amendments in this new ASU are effective for the Company January 1, 2020 and are to be applied on a prospective basis. Early adoption was permitted on or after January 1, 2017 and the Company early adopted this ASU as of January 1, 2017.
Put Obligation Fair Value Estimate of Noncontrolling Interest
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Noncontrolling interests subject to put provisions and other commitments	The Company has potential obligations to purchase the noncontrolling interests held by third parties in several of its majority-owned and other nonconsolidated entities. These obligations are in the form of put provisions and are exercisable at the third-party owners’ discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners’ equity interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the equity interests put to the Company, which is intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of the noncontrolling interests subject to put provisions is a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company’s current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may be settled could vary significantly depending upon market conditions including potential purchasers’ access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners’ equity interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value are immaterial.

Earnings per share (Tables)

Earnings per share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Earnings Per Share	The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share are as follows: Three months ended Six months ended 2017 2016 2017 2016 Basic: Net income attributable to DaVita Inc. $ 127,001 $ 53,382 $ 574,698 $ 150,816 Weighted average shares outstanding during the period 193,282 206,692 193,923 206,626 Contingently returnable shares held in escrow from the DaVita (2,194 ) (2,194 ) (2,194 ) (2,194 ) Weighted average shares for basic earnings per share calculation 191,088 204,498 191,729 204,432 Basic net income per share attributable to DaVita Inc. $ 0.66 $ 0.26 $ 3.00 $ 0.74 Diluted: Net income attributable to DaVita Inc. $ 127,001 $ 53,382 $ 574,698 $ 150,816 Weighted average shares outstanding during the period 193,282 206,692 193,923 206,626 Assumed incremental shares from stock plans 706 1,355 708 1,362 Weighted average shares for diluted earnings per share calculation 193,988 208,047 194,631 207,988 Diluted net income per share attributable to DaVita Inc. $ 0.65 $ 0.26 $ 2.95 $ 0.73 Anti-dilutive potential common shares excluded from calculation (1) 3,780 1,811 3,603 2,042 (1) Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Investments in debt and equit32

Investments in debt and equity securities (Tables)	6 Months Ended
	Jun. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Investments	The Company’s investments in these securities and certain other financial instruments consist of the following: June 30, 2017 December 31, 2016 Held to Available Total Held to Available Total Certificates of deposit, commercial paper and $ 210,236 $ — $ 210,236 $ 256,827 $ — $ 256,827 Investments in mutual funds and common stock — 53,209 53,209 50,000 47,404 97,404 Cash surrender value of life insurance policies — 62,684 62,684 — 59,646 59,646 $ 210,236 $ 115,893 $ 326,129 $ 306,827 $ 107,050 $ 413,877 Short-term investments $ 210,236 $ 1,200 $ 211,436 $ 306,827 $ 3,371 $ 310,198 Long-term investments — 114,693 114,693 — 103,679 103,679 $ 210,236 $ 115,893 $ 326,129 $ 306,827 $ 107,050 $ 413,877

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Goodwill by Reportable Segments	Changes in goodwill by reportable segments were as follows: U.S. dialysis and related lab services DMG Other-ancillary services and strategic initiatives Consolidated total Balance at January 1, 2016 $ 5,629,183 $ 3,398,264 $ 267,032 $ 9,294,479 Acquisitions 75,295 248,901 123,632 447,828 Divestitures (12,891 ) (2,223 ) (29,645 ) (44,759 ) Goodwill impairment charges — (253,000 ) (28,415 ) (281,415 ) Foreign currency and other adjustments — — (8,816 ) (8,816 ) Balance at December 31, 2016 $ 5,691,587 $ 3,391,942 $ 323,788 $ 9,407,317 Acquisitions 427,299 31,796 113,669 572,764 Divestitures (32,260 ) (29 ) (54 ) (32,343 ) Goodwill impairment charges — (50,619 ) (34,696 ) (85,315 ) Foreign currency and other adjustments — — 27,368 27,368 Balance at June 30, 2017 $ 6,086,626 $ 3,373,090 $ 430,075 $ 9,889,791 Balance at June 30, 2017: Goodwill $ 6,086,626 $ 3,865,478 $ 499,095 $ 10,451,199 Accumulated impairment charges — (492,388 ) (69,020 ) (561,408 ) $ 6,086,626 $ 3,373,090 $ 430,075 $ 9,889,791
Schedule of Reporting Units Goodwill Balances	Goodwill balance Carrying (1) Sensitivities Operating (2) Discount (3) Reporting unit DMG Nevada $ 275,914 17.0 % (2.4 )% (3.8 )% DMG Florida $ 397,127 — % (1.6 )% (2.8 )% DMG New Mexico $ 70,253 — % (1.6 )% (2.4 )% DMG Washington $ 247,552 9.3 % (1.7 )% (3.6 )% (1) Excess of estimated fair value of the reporting unit over its carrying amount as of the latest assessment date. (2) Potential impact on estimated fair value of a sustained, long-term reduction of 3% in operating income as of the latest assessment date. (3) Potential impact on estimated fair value of an increase in discount rates of 100 basis points as of the latest assessment date.

Medical payables (Tables)

Medical payables (Tables)	6 Months Ended
	Jun. 30, 2017
Health Care Organizations [Abstract]
Components of Changes in Health Care Costs Payable	The following table shows the components of changes in health care costs payable for the six months ended June 30, 2017 : Six months ended June 30, 2017 Healthcare costs payable, beginning of the period $ 214,275 Add: Components of incurred health care costs Current year 991,818 Prior years (6,838 ) Total incurred health care costs 984,980 Less: Claims paid Current year 727,814 Prior years 186,623 Total claims paid 914,437 Healthcare costs payable, end of the period $ 284,818

Long-term debt (Tables)

Long-term debt (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Long-term Debt	Long-term debt was comprised of the following: June 30, 2017 December 31, 2016 Senior secured credit facilities: Term Loan A $ 825,000 $ 862,500 Term Loan B 3,395,000 3,412,500 Senior notes 4,500,000 4,500,000 Acquisition obligations and other notes payable 139,371 117,547 Capital lease obligations 305,643 299,682 Total debt principal outstanding 9,165,014 9,192,229 Discount and deferred financing costs (71,877 ) (79,861 ) 9,093,137 9,112,368 Less current portion (182,323 ) (165,041 ) $ 8,910,814 $ 8,947,327
Scheduled Maturities of Long-term Debt	Scheduled maturities of long-term debt at June 30, 2017 were as follows: 2017 (remainder of the year) 96,454 2018 172,318 2019 746,464 2020 71,432 2021 3,303,146 2022 1,280,031 Thereafter 3,495,169
Derivative Instruments	The following table summarizes the Company’s derivative instruments as of June 30, 2017 and December 31, 2016 : June 30, 2017 December 31, 2016 Derivatives designated as hedging instruments Balance sheet location Fair value Balance sheet location Fair value Interest rate cap agreements Other long-term assets $ 1,743 Other long-term assets $ 9,929
Effects of Interest Rate Swap and Cap Agreements	The following table summarizes the effects of the Company’s interest rate cap and swap agreements for the three and six months ended June 30, 2017 and 2016 : Amount of losses Location of losses reclassified from accumulated OCI into income Amount of losses Three months ended Six months ended Three months ended Six months ended Derivatives designated as cash flow hedges 2017 2016 2017 2016 2017 2016 2017 2016 Interest rate swap $ — $ (168 ) $ — $ (860 ) Debt expense $ — $ 123 $ — $ 274 Interest rate cap (2,969 ) (4,115 ) (8,186 ) (12,374 ) Debt expense 2,070 610 4,139 1,220 Tax benefit 1,154 1,667 3,184 5,149 Tax expense (805 ) (285 ) (1,610 ) (581 ) Total $ (1,815 ) $ (2,616 ) $ (5,002 ) $ (8,085 ) $ 1,265 $ 448 $ 2,529 $ 913

Comprehensive income (Tables)

Comprehensive income (Tables)	6 Months Ended
	Jun. 30, 2017
Statement of Comprehensive Income [Abstract]
Comprehensive income	For the three months ended June 30, 2017 For the six months ended June 30, 2017 Interest Investment Foreign Accumulated Interest Investment Foreign Accumulated Beginning balance $ (13,952 ) $ 3,594 $ (66,528 ) $ (76,886 ) $ (12,029 ) $ 2,175 $ (79,789 ) $ (89,643 ) Unrealized (losses) (2,969 ) 1,446 49,142 47,619 (8,186 ) 3,428 62,403 57,645 Related income tax 1,154 (389 ) — 765 3,184 (812 ) — 2,372 (1,815 ) 1,057 49,142 48,384 (5,002 ) 2,616 62,403 60,017 Reclassification 2,070 (117 ) — 1,953 4,139 (346 ) — 3,793 Related income tax (expense) benefit (805 ) 46 — (759 ) (1,610 ) 135 — (1,475 ) 1,265 (71 ) — 1,194 2,529 (211 ) — 2,318 Ending balance $ (14,502 ) $ 4,580 $ (17,386 ) $ (27,308 ) $ (14,502 ) $ 4,580 $ (17,386 ) $ (27,308 ) For the three months ended June 30, 2016 For the six months ended June 30, 2016 Interest Investment Foreign Accumulated Interest Investment Foreign Accumulated Beginning balance $ (15,929 ) $ 1,497 $ (39,081 ) $ (53,513 ) $ (10,925 ) $ 1,361 $ (50,262 ) $ (59,826 ) Unrealized (losses) (4,283 ) 782 (4,844 ) (8,345 ) (13,234 ) 1,124 6,337 (5,773 ) Related income tax 1,667 (293 ) — 1,374 5,149 (406 ) — 4,743 (2,616 ) 489 (4,844 ) (6,971 ) (8,085 ) 718 6,337 (1,030 ) Reclassification 733 — — 733 1,494 (152 ) — 1,342 Related income tax (expense) benefit (285 ) — — (285 ) (581 ) 59 — (522 ) 448 — — 448 913 (93 ) — 820 Ending balance $ (18,097 ) $ 1,986 $ (43,925 ) $ (60,036 ) $ (18,097 ) $ 1,986 $ (43,925 ) $ (60,036 )

Acquisitions and divestitures (

Acquisitions and divestitures (Tables)	6 Months Ended
	Jun. 30, 2017
Business Acquisition [Line Items]
Reconciliation of Changes in Contingent Earn-Out Obligations	The following is a reconciliation of changes in the contingent earn-out obligations for the six months ended June 30, 2017 : Beginning balance, January 1, 2017 $ 9,977 Contingent earn-out obligations associated with acquisitions 3,849 Remeasurement of fair value for contingent earn-out obligations 415 Payments on contingent earn-out obligations (2,567 ) $ 11,674
Dialysis and other businesses
Business Acquisition [Line Items]
Aggregate Purchase Cost Allocations for Acquisitions	The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values: Current assets $ 7,439 Property and equipment 13,278 Amortizable intangible and other long-term assets 14,180 Non-amortizable intangibles 4,833 Goodwill 276,182 Current liabilities (6,467 ) Long-term liabilities (2,484 ) Noncontrolling interests (36,075 ) $ 270,886
Renal Ventures
Business Acquisition [Line Items]
Aggregate Purchase Cost Allocations for Acquisitions	The following table summarizes the assets acquired and liabilities assumed in the transactions and recognized at the acquisition date at estimated fair values: Current assets $ 24,529 Property and equipment 36,295 Amortizable intangible and other long-term assets 11,547 Goodwill 296,582 Current liabilities (6,912 ) Long-term liabilities (478 ) $ 361,563

Acquisitions and divestitures B

Acquisitions and divestitures Business Acquisition, Pro Forma Information, Nonrecurring Adjustments (Tables)	6 Months Ended
	Jun. 30, 2017
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table Text Block]	The following summary, prepared on a pro forma basis, combines the results of operations as if the acquisitions through June 30, 2017 had been consummated as of the beginning of 2017 and 2016, after including the impact of certain adjustments such as amortization of intangibles and income tax effects. Three months ended Six months ended 2017 2016 2017 2016 (unaudited) Pro forma net revenues $ 3,900,750 $ 3,820,558 $ 7,678,519 $ 7,576,206 Pro forma net income attributable to DaVita Inc. 128,654 58,996 579,906 160,709 Pro forma basic net income per share attributable to DaVita Inc. 0.67 0.29 3.02 0.79 Pro forma diluted net income per share attributable to DaVita Inc. 0.66 0.28 2.98 0.77

Fair value of financial instr39

Fair value of financial instruments (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Assets, Liabilities and Temporary Equity Measured at Fair Value on a Recurring Basis	The following table summarizes the Company’s assets, liabilities and temporary equity that are measured at fair value on a recurring basis as of June 30, 2017 : Total Quoted prices in Significant other Significant Assets Investments in mutual funds and common stock $ 53,209 $ 53,209 $ — $ — Cash surrender value of life insurance policies $ 62,684 $ — $ 62,684 $ — Interest rate cap agreements $ 1,743 $ — $ 1,743 $ — Funds on deposit with third parties $ 75,671 $ 75,671 $ — $ — Liabilities Contingent earn-out obligations $ 11,674 $ — $ — $ 11,674 Temporary equity Noncontrolling interests subject to put provisions $ 1,009,704 $ — $ — $ 1,009,704

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income Before Income Taxes	The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes: Three months ended June 30, Six months ended June 30, 2017 2016 2017 2016 Segment net revenues: U.S. dialysis and related lab services Patient service revenues: External sources $ 2,403,222 $ 2,352,574 $ 4,752,123 $ 4,666,236 Intersegment revenues 26,436 14,470 50,196 28,779 Total dialysis and related lab services revenues 2,429,658 2,367,044 4,802,319 4,695,015 Less: Provision for uncollectible accounts (109,335 ) (106,515 ) (216,105 ) (211,266 ) Net dialysis and related lab services patient service revenues 2,320,323 2,260,529 4,586,214 4,483,749 Other revenues (1) 4,891 4,250 10,194 8,223 Total net dialysis and related lab services revenues 2,325,214 2,264,779 4,596,408 4,491,972 DMG DMG revenues: Capitated revenues 987,420 874,119 1,877,105 1,740,138 Net patient service revenues 189,529 169,167 368,501 281,601 Other revenues (2) 19,070 16,235 37,339 26,569 Intersegment capitated and other revenues 47 44 105 115 Total net DMG revenues 1,196,066 1,059,565 2,283,050 2,048,423 Other—Ancillary services and strategic initiatives Net patient service revenues 83,566 56,860 150,858 108,244 Capitated revenues 34,658 25,866 63,009 47,855 Other external sources 264,456 325,095 531,736 631,187 Intersegment revenues 10,913 14,720 26,216 26,546 Total ancillary services and strategic initiatives revenues 393,593 422,541 771,819 813,832 Total net segment revenues 3,914,873 3,746,885 7,651,277 7,354,227 Elimination of intersegment revenues (37,396 ) (29,234 ) (76,517 ) (55,440 ) Consolidated net revenues $ 3,877,477 $ 3,717,651 $ 7,574,760 $ 7,298,787 Segment operating margin (loss): U.S. dialysis and related lab services (3) $ 450,472 $ 449,190 $ 1,395,212 $ 889,245 DMG (12,880 ) (102,059 ) (572 ) (159,204 ) Other—Ancillary services and strategic initiatives (48,245 ) (12,644 ) (106,466 ) (23,745 ) Total segment operating margin 389,347 334,487 1,288,174 706,296 Reconciliation of segment operating margin to consolidated income Corporate administrative support (11,031 ) (5,417 ) (21,622 ) (12,337 ) Consolidated operating income 378,316 329,070 1,266,552 693,959 Debt expense (107,962 ) (102,894 ) (212,391 ) (205,778 ) Other income, net 5,253 3,215 9,496 6,191 Consolidated income before income taxes $ 275,607 $ 229,391 $ 1,063,657 $ 494,372 (1) Includes management fees for providing management and administrative services to dialysis centers that are wholly-owned by third parties and legal entities in which the Company owns a noncontrolling equity investment. (2) Includes medical consulting service fees and management fees for providing management and administrative services to unconsolidated joint ventures and revenue related to the maintenance of existing physician networks. (3) U.S. dialysis and related lab services operating income includes the net gain on the settlement with the VA.
Summary of Depreciation and Amortization Expense by Reportable Segment	Three months ended June 30, Six months ended June 30, 2017 2016 2017 2016 U.S. dialysis and related lab services $ 130,002 $ 119,350 $ 255,030 $ 235,887 DMG 60,011 54,211 117,334 100,473 Ancillary services and strategic initiatives 10,025 6,820 17,880 13,376 $ 200,038 $ 180,381 $ 390,244 $ 349,736
Summary of Assets by Reportable Segment	Subsequent to the issuance of the Company’s fiscal year 2016 consolidated financial statements and their inclusion in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 24, 2017 (the “2016 10-K”), the Company determined that it had misstated its disclosure of segment assets at December 31, 2016 in Note 25 to those consolidated financial statements. This misstatement resulted in an overstatement of “U.S. dialysis and related lab services” segment assets of $338,963 and a corresponding understatement of “Other - ancillary services and strategic initiatives” segment assets of the same amount. The Company performed an assessment of the materiality of this misstatement and concluded that this misstatement as originally disclosed was not materially misleading in its 2016 consolidated financial statements taken as a whole. The Company therefore has not amended its financial statements filed on its 2016 10-K to correct this misstatement, but has provided the corrected disclosure here. Summary of assets by reportable segment is as follows: June 30, 2017 December 31, 2016 Segment assets U.S. dialysis and related lab services (including equity investments of $83,102 and $66,924, respectively) $ 11,500,974 $ 11,099,137 DMG (including equity investments of $13,169 and $10,350, 6,282,819 6,213,091 Other—Ancillary services and strategic initiatives (including equity investments of $446,197 and $425,115, respectively) 1,557,991 1,429,029 Consolidated assets $ 19,341,784 $ 18,741,257
Summary of Expenditures for Property and Equipment by Reportable Segment	Expenditures for property and equipment by reportable segment is as follows: Three months ended Six months ended 2017 2016 2017 2016 U.S. dialysis and related lab services $ 152,233 $ 150,932 $ 325,761 $ 284,380 DMG 20,883 18,098 48,671 38,243 Ancillary services and strategic initiatives 11,289 16,410 24,508 36,004 $ 184,405 $ 185,440 $ 398,940 $ 358,627

Changes in DaVita Inc.'s Owne41

Changes in DaVita Inc.'s Ownership Interest in Consolidated Subsidiaries (Tables)	6 Months Ended
	Jun. 30, 2017
Noncontrolling Interest [Abstract]
Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity	The effects of changes in DaVita Inc.’s ownership interest on the Company’s equity are as follows: Three months ended June 30, Six months ended June 30, 2017 2016 2017 2016 Net income attributable to DaVita Inc. $ 127,001 $ 53,382 $ 574,698 $ 150,816 Changes in paid-in capital for: Sales of noncontrolling interests — (885 ) — — Purchases of noncontrolling interests 618 (1,193 ) 195 (4,530 ) Net transfers to noncontrolling interests 618 (2,078 ) 195 (4,530 ) Net income attributable to DaVita Inc., net of $ 127,619 $ 51,304 $ 574,893 $ 146,286

Condensed Consolidating Finan42

Condensed Consolidating Financial Statements (Tables)	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Statements of Income	Condensed Consolidating Statements of Income Guarantor subsidiaries Non- Guarantor subsidiaries Consolidating adjustments Consolidated total For The Three Months Ended June 30, 2017 DaVita Inc. Patient services revenues $ — $ 1,681,249 $ 1,055,797 $ (54,579 ) $ 2,682,467 Less: Provision for uncollectible accounts — (74,413 ) (41,072 ) — (115,485 ) Net patient service revenues — 1,606,836 1,014,725 (54,579 ) 2,566,982 Capitated revenues — 467,852 555,947 (1,721 ) 1,022,078 Other revenues 193,585 501,861 34,257 (441,286 ) 288,417 Total net revenues 193,585 2,576,549 1,604,929 (497,586 ) 3,877,477 Operating expenses and charges 138,104 2,396,723 1,461,920 (497,586 ) 3,499,161 Operating income 55,481 179,826 143,009 — 378,316 Debt expense (106,159 ) (92,346 ) (14,943 ) 105,486 (107,962 ) Other income, net 102,299 2,191 6,249 (105,486 ) 5,253 Income tax expense 22,969 70,927 20,086 — 113,982 Equity earnings in subsidiaries 98,349 79,605 — (177,954 ) — Net income 127,001 98,349 114,229 (177,954 ) 161,625 Less: Net income attributable to noncontrolling interests — — — (34,624 ) (34,624 ) Net income attributable to DaVita Inc. $ 127,001 $ 98,349 $ 114,229 $ (212,578 ) $ 127,001 Guarantor Non- Consolidating Consolidated For The Three Months Ended June 30, 2016 DaVita Inc. Patient service revenues $ — $ 1,664,361 $ 959,946 $ (40,793 ) $ 2,583,514 Less: Provision for uncollectible accounts — (74,498 ) (36,930 ) — (111,428 ) Net patient service revenues — 1,589,863 923,016 (40,793 ) 2,472,086 Capitated revenues — 463,732 436,337 (84 ) 899,985 Other revenues 196,910 521,065 31,749 (404,144 ) 345,580 Total net revenues 196,910 2,574,660 1,391,102 (445,021 ) 3,717,651 Operating expenses 134,072 2,510,119 1,189,411 (445,021 ) 3,388,581 Operating income 62,838 64,541 201,691 — 329,070 Debt expense (102,101 ) (91,259 ) (12,998 ) 103,464 (102,894 ) Other income 98,654 5,421 2,604 (103,464 ) 3,215 Income tax expense 41,942 89,203 3,743 — 134,888 Equity earnings in subsidiaries 35,933 146,433 — (182,366 ) — Net income 53,382 35,933 187,554 (182,366 ) 94,503 Less: Net income attributable to noncontrolling interests — — — (41,121 ) (41,121 ) Net income attributable to DaVita Inc. $ 53,382 $ 35,933 $ 187,554 $ (223,487 ) $ 53,382 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2017 DaVita Inc. Patient services revenues $ — $ 3,234,605 $ 2,154,549 $ (105,309 ) $ 5,283,845 Less: Provision for uncollectible accounts — (136,694 ) (91,774 ) — (228,468 ) Net patient service revenues — 3,097,911 2,062,775 (105,309 ) 5,055,377 Capitated revenues — 931,479 1,010,901 (2,266 ) 1,940,114 Other revenues 414,971 979,536 69,894 (885,132 ) 579,269 Total net revenues 414,971 5,008,926 3,143,570 (992,707 ) 7,574,760 Operating expenses and charges 270,014 4,276,878 2,754,023 (992,707 ) 6,308,208 Operating income 144,957 732,048 389,547 — 1,266,552 Debt expense (208,823 ) (183,747 ) (28,659 ) 208,838 (212,391 ) Other income, net 202,636 5,728 9,970 (208,838 ) 9,496 Income tax expense 57,062 292,348 52,337 — 401,747 Equity earnings in subsidiaries 492,990 231,309 — (724,299 ) — Net income 574,698 492,990 318,521 (724,299 ) 661,910 Less: Net income attributable to noncontrolling interests — — — (87,212 ) (87,212 ) Net income attributable to DaVita Inc. $ 574,698 $ 492,990 $ 318,521 $ (811,511 ) $ 574,698 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2016 DaVita Inc. Patient services revenues $ — $ 3,317,673 $ 1,827,984 $ (80,209 ) $ 5,065,448 Less: Provision for uncollectible accounts — (133,311 ) (87,322 ) — (220,633 ) Net patient service revenues — 3,184,362 1,740,662 (80,209 ) 4,844,815 Capitated revenues — 931,694 856,510 (211 ) 1,787,993 Other revenues 383,885 1,005,420 59,269 (782,595 ) 665,979 Total net revenues 383,885 5,121,476 2,656,441 (863,015 ) 7,298,787 Operating expenses and charges 256,345 4,887,749 2,323,749 (863,015 ) 6,604,828 Operating income 127,540 233,727 332,692 — 693,959 Debt expense (203,202 ) (183,432 ) (24,512 ) 205,368 (205,778 ) Other income, net 197,214 9,757 4,588 (205,368 ) 6,191 Income tax expense 77,088 162,457 22,165 — 261,710 Equity earnings in subsidiaries 106,352 208,757 — (315,109 ) — Net income 150,816 106,352 290,603 (315,109 ) 232,662 Less: Net income attributable to noncontrolling interests — — — (81,846 ) (81,846 ) Net income attributable to DaVita Inc. $ 150,816 $ 106,352 $ 290,603 $ (396,955 ) $ 150,816 Condensed Consolidating Statements of Income Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) For The Six Months Ended June 30, 2017 Patient service operating revenues $ 5,283,845 $ 273,017 $ — $ 5,010,828 Less: Provision for uncollectible accounts (228,468 ) (7,351 ) — (221,117 ) Net patient service operating revenues 5,055,377 265,666 — 4,789,711 Capitated revenues 1,940,114 785,139 — 1,154,975 Other revenues 579,269 19,596 — 559,673 Total net operating revenues 7,574,760 1,070,401 — 6,504,359 Operating expenses 6,308,208 1,032,529 (232 ) 5,275,911 Operating income 1,266,552 37,872 232 1,228,448 Debt expense, including refinancing charges (212,391 ) (3,323 ) — (209,068 ) Other income 9,496 151 — 9,345 Income tax expense 401,747 32,700 93 368,954 Net income 661,910 2,000 139 659,771 Less: Net income attributable to noncontrolling interests (87,212 ) — — (87,212 ) Net income attributable to DaVita Inc. $ 574,698 $ 2,000 $ 139 $ 572,559 (1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Comprehensive Income	Condensed Consolidating Statements of Comprehensive Income Guarantor Non- Consolidating Consolidated For The Three Months Ended June 30, 2017 DaVita Inc. Net income $ 127,001 $ 98,349 $ 114,229 $ (177,954 ) $ 161,625 Other comprehensive income 436 — 49,142 — 49,578 Total comprehensive income 127,437 98,349 163,371 (177,954 ) 211,203 Less: Comprehensive income attributable to — — — (34,624 ) (34,624 ) Comprehensive income attributable to DaVita Inc. $ 127,437 $ 98,349 $ 163,371 $ (212,578 ) $ 176,579 Guarantor Non- Consolidating Consolidated For The Three Months Ended June 30, 2016 DaVita Inc. Net income $ 53,382 $ 35,933 $ 187,554 $ (182,366 ) $ 94,503 Other comprehensive loss (1,530 ) — (4,844 ) — (6,374 ) Total comprehensive income 51,852 35,933 182,710 (182,366 ) 88,129 Less: Comprehensive income attributable to the — — — (41,270 ) (41,270 ) Comprehensive income attributable to DaVita Inc. $ 51,852 $ 35,933 $ 182,710 $ (223,636 ) $ 46,859 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2017 DaVita Inc. Net income $ 574,698 $ 492,990 $ 318,521 $ (724,299 ) $ 661,910 Other comprehensive (loss) income (70 ) — 62,403 — 62,333 Total comprehensive income 574,628 492,990 380,924 (724,299 ) 724,243 Less: Comprehensive income attributable to — — — (87,210 ) (87,210 ) Comprehensive income attributable to DaVita Inc. $ 574,628 $ 492,990 $ 380,924 $ (811,509 ) $ 637,033 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2016 DaVita Inc. Net income $ 150,816 $ 106,352 $ 290,603 $ (315,109 ) $ 232,662 Other comprehensive (loss) income (6,398 ) — 6,337 — (61 ) Total comprehensive income 144,418 106,352 296,940 (315,109 ) 232,601 Less: Comprehensive income attributable to the — — — (81,995 ) (81,995 ) Comprehensive income attributable to DaVita Inc. $ 144,418 $ 106,352 $ 296,940 $ (397,104 ) $ 150,606 Condensed Consolidating Statements of Comprehensive Income Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) For The Six Months Ended June 30, 2017 Net income $ 661,910 $ 2,000 $ 139 $ 659,771 Other comprehensive income 62,333 — — 62,333 Total comprehensive income 724,243 2,000 139 722,104 Less: Comprehensive income attributable to the noncontrolling (87,210 ) — — (87,210 ) Comprehensive income attributable to DaVita Inc. $ 637,033 $ 2,000 $ 139 $ 634,894 (1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Balance Sheets	Condensed Consolidating Balance Sheets Guarantor Non- Consolidating Consolidated As of June 30, 2017 DaVita Inc. Cash and cash equivalents $ 374,973 $ 40,508 $ 296,516 $ — $ 711,997 Accounts receivable, net — 1,278,053 775,759 — 2,053,812 Other current assets 254,108 891,208 112,643 — 1,257,959 Total current assets 629,081 2,209,769 1,184,918 — 4,023,768 Property and equipment, net 345,667 1,669,583 1,232,780 — 3,248,030 Intangible assets, net 355 1,405,712 56,827 — 1,462,894 Investments in subsidiaries 10,368,953 2,375,421 — (12,744,374 ) — Intercompany receivables 3,266,741 — 1,035,735 (4,302,476 ) — Other long-term assets and investments 45,228 92,891 579,182 — 717,301 Goodwill — 7,850,917 2,038,874 — 9,889,791 Total assets $ 14,656,025 $ 15,604,293 $ 6,128,316 $ (17,046,850 ) $ 19,341,784 Current liabilities $ 399,436 $ 1,807,277 $ 566,612 $ — $ 2,773,325 Intercompany payables — 2,181,952 2,120,524 (4,302,476 ) — Long-term debt and other long-term liabilities 8,578,628 1,246,111 462,120 — 10,286,859 Noncontrolling interests subject to put provisions 593,647 — — 416,057 1,009,704 Total DaVita Inc. shareholder's equity 5,084,314 10,368,953 2,375,421 (12,744,374 ) 5,084,314 Noncontrolling interests not subject to put provisions — — 603,639 (416,057 ) 187,582 Total equity 5,084,314 10,368,953 2,979,060 (13,160,431 ) 5,271,896 Total liabilities and equity $ 14,656,025 $ 15,604,293 $ 6,128,316 $ (17,046,850 ) $ 19,341,784 Guarantor Non- Consolidating Consolidated As of December 31, 2016 DaVita Inc. Cash and cash equivalents $ 549,921 $ 59,192 $ 304,074 $ — $ 913,187 Accounts receivable, net — 1,215,232 702,070 — 1,917,302 Other current assets 277,911 736,727 135,101 — 1,149,739 Total current assets 827,832 2,011,151 1,141,245 — 3,980,228 Property and equipment, net 337,200 1,689,798 1,148,369 — 3,175,367 Intangible assets, net 487 1,491,057 36,223 — 1,527,767 Investments in subsidiaries 9,717,728 2,002,660 — (11,720,388 ) — Intercompany receivables 3,250,692 — 866,955 (4,117,647 ) — Other long-term assets and investments 39,994 86,710 523,874 — 650,578 Goodwill — 7,838,984 1,568,333 — 9,407,317 Total assets $ 14,173,933 $ 15,120,360 $ 5,284,999 $ (15,838,035 ) $ 18,741,257 Current liabilities $ 303,840 $ 1,865,193 $ 527,412 $ — $ 2,696,445 Intercompany payables — 2,322,124 1,795,523 (4,117,647 ) — Long-term debt and other long-term liabilities 8,614,445 1,215,315 392,053 — 10,221,813 Noncontrolling interests subject to put provisions 607,601 — — 365,657 973,258 Total DaVita Inc. shareholder's equity 4,648,047 9,717,728 2,002,660 (11,720,388 ) 4,648,047 Noncontrolling interests not subject to put provisions — — 567,351 (365,657 ) 201,694 Total equity 4,648,047 9,717,728 2,570,011 (12,086,045 ) 4,849,741 Total liabilities and equity $ 14,173,933 $ 15,120,360 $ 5,284,999 $ (15,838,035 ) $ 18,741,257 Condensed Consolidating Balance Sheets Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) As of June 30, 2017 Cash and cash equivalents $ 711,997 $ 107,232 $ — $ 604,765 Accounts receivable, net 2,053,812 213,804 — 1,840,008 Other current assets 1,257,959 13,679 — 1,244,280 Total current assets 4,023,768 334,715 — 3,689,053 Property and equipment, net 3,248,030 3,368 — 3,244,662 Amortizable intangibles, net 1,462,894 4,553 — 1,458,341 Other long-term assets 717,301 82,477 2,946 631,878 Goodwill 9,889,791 29,865 — 9,859,926 Total assets $ 19,341,784 $ 454,978 $ 2,946 $ 18,883,860 Current liabilities $ 2,773,325 $ 178,259 $ — $ 2,595,066 Payables to parent — 114,038 2,946 (116,984 ) Long-term debt and other long-term liabilities 10,286,859 55,870 — 10,230,989 Noncontrolling interests subject to put provisions 1,009,704 — — 1,009,704 Total DaVita Inc. shareholders’ equity 5,084,314 106,811 — 4,977,503 Noncontrolling interests not subject to put provisions 187,582 — — 187,582 Shareholders’ equity 5,271,896 106,811 — 5,165,085 Total liabilities and shareholder’s equity $ 19,341,784 $ 454,978 $ 2,946 $ 18,883,860 (1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Cash Flows	Condensed Consolidating Statements of Cash Flows Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2017 DaVita Inc. Cash flows from operating activities: Net income $ 574,698 $ 492,990 $ 318,521 $ (724,299 ) $ 661,910 Changes in operating assets and liabilities and non-cash items included in net income (431,980 ) 52,218 4,997 724,299 349,534 Net cash provided by operating activities 142,718 545,208 323,518 — 1,011,444 Cash flows from investing activities: Additions of property and equipment, net (50,966 ) (182,494 ) (165,480 ) — (398,940 ) Acquisitions — (538,450 ) (81,389 ) — (619,839 ) Proceeds from asset and business sales — 70,127 109 — 70,236 Proceeds (purchases) from investment sales and other items, net 49,036 (2,974 ) 50,833 — 96,895 Net cash used in investing activities (1,930 ) (653,791 ) (195,927 ) — (851,648 ) Cash flows from financing activities: Long-term debt and related financing costs, net (54,992 ) (6,893 ) (2,147 ) — (64,032 ) Intercompany (payments) borrowing (37,233 ) 98,224 (60,991 ) — — Other items (223,511 ) (1,432 ) (76,203 ) — (301,146 ) Net cash (used in) provided by financing activities (315,736 ) 89,899 (139,341 ) — (365,178 ) Effect of exchange rate changes on cash — — 4,192 — 4,192 Net decrease in cash and cash equivalents (174,948 ) (18,684 ) (7,558 ) — (201,190 ) Cash and cash equivalents at beginning of period 549,921 59,192 304,074 — 913,187 Cash and cash equivalents at end of period $ 374,973 $ 40,508 $ 296,516 $ — $ 711,997 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2016 DaVita Inc. Cash flows from operating activities: Net income $ 150,816 $ 106,352 $ 290,603 $ (315,109 ) $ 232,662 Changes in operating assets and liabilities and non-cash (1,505 ) 219,697 179,676 315,109 712,977 Net cash provided by operating activities 149,311 326,049 470,279 — 945,639 Cash flows from investing activities: Additions of property and equipment, net (42,266 ) (171,164 ) (145,197 ) — (358,627 ) Acquisitions — (462,592 ) (10,722 ) — (473,314 ) Proceeds from asset and business sales — 17,393 — — 17,393 Proceeds (purchases) from investment sales and other 21,230 (10,869 ) 45,958 — 56,319 Net cash used in investing activities (21,036 ) (627,232 ) (109,961 ) — (758,229 ) Cash flows from financing activities: Long-term debt and related financing costs, net (42,493 ) (13,917 ) (4,823 ) — (61,233 ) Intercompany borrowing (payments) 11,208 247,765 (258,973 ) — — Other items (255,032 ) (6,253 ) (81,036 ) — (342,321 ) Net cash (used in) provided by financing activities (286,317 ) 227,595 (344,832 ) — (403,554 ) Effect of exchange rate changes on cash — — 444 — 444 Net (decrease) increase in cash and cash equivalents (158,042 ) (73,588 ) 15,930 — (215,700 ) Cash and cash equivalents at beginning of period 1,186,636 109,357 203,123 — 1,499,116 Cash and cash equivalents at end of period $ 1,028,594 $ 35,769 $ 219,053 $ — $ 1,283,416 Condensed Consolidating Statements of Cash Flows Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) For The Six Months Ended June 30, 2017 Cash flows from operating activities: Net income $ 661,910 $ 2,000 $ 139 $ 659,771 Changes in operating and intercompany assets and liabilities 349,534 (37,812 ) (139 ) 387,485 Net cash provided by (used in) operating activities 1,011,444 (35,812 ) — 1,047,256 Cash flows from investing activities: Additions of property and equipment (398,940 ) (5,603 ) — (393,337 ) Acquisitions and divestitures, net (619,839 ) — — (619,839 ) Proceeds from discontinued operations 70,236 — — 70,236 Investments and other items 96,895 (1,386 ) — 98,281 Net cash used in investing activities (851,648 ) (6,989 ) — (844,659 ) Cash flows from financing activities: Long-term debt (64,032 ) — — (64,032 ) Intercompany — 45,342 — (45,342 ) Other items (301,146 ) — — (301,146 ) Net cash (used in) provided by financing activities (365,178 ) 45,342 — (410,520 ) Effect of exchange rate changes on cash 4,192 — — 4,192 Net (decrease) increase in cash (201,190 ) 2,541 — (203,731 ) Cash and cash equivalents at beginning of period 913,187 104,691 — 808,496 Cash and cash equivalents at end of period $ 711,997 $ 107,232 $ — $ 604,765 (1) After elimination of the unrestricted subsidiaries and the physician groups.

Supplemental Data (Tables)

Supplemental Data (Tables)	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Statements of Income	Condensed Consolidating Statements of Income Guarantor subsidiaries Non- Guarantor subsidiaries Consolidating adjustments Consolidated total For The Three Months Ended June 30, 2017 DaVita Inc. Patient services revenues $ — $ 1,681,249 $ 1,055,797 $ (54,579 ) $ 2,682,467 Less: Provision for uncollectible accounts — (74,413 ) (41,072 ) — (115,485 ) Net patient service revenues — 1,606,836 1,014,725 (54,579 ) 2,566,982 Capitated revenues — 467,852 555,947 (1,721 ) 1,022,078 Other revenues 193,585 501,861 34,257 (441,286 ) 288,417 Total net revenues 193,585 2,576,549 1,604,929 (497,586 ) 3,877,477 Operating expenses and charges 138,104 2,396,723 1,461,920 (497,586 ) 3,499,161 Operating income 55,481 179,826 143,009 — 378,316 Debt expense (106,159 ) (92,346 ) (14,943 ) 105,486 (107,962 ) Other income, net 102,299 2,191 6,249 (105,486 ) 5,253 Income tax expense 22,969 70,927 20,086 — 113,982 Equity earnings in subsidiaries 98,349 79,605 — (177,954 ) — Net income 127,001 98,349 114,229 (177,954 ) 161,625 Less: Net income attributable to noncontrolling interests — — — (34,624 ) (34,624 ) Net income attributable to DaVita Inc. $ 127,001 $ 98,349 $ 114,229 $ (212,578 ) $ 127,001 Guarantor Non- Consolidating Consolidated For The Three Months Ended June 30, 2016 DaVita Inc. Patient service revenues $ — $ 1,664,361 $ 959,946 $ (40,793 ) $ 2,583,514 Less: Provision for uncollectible accounts — (74,498 ) (36,930 ) — (111,428 ) Net patient service revenues — 1,589,863 923,016 (40,793 ) 2,472,086 Capitated revenues — 463,732 436,337 (84 ) 899,985 Other revenues 196,910 521,065 31,749 (404,144 ) 345,580 Total net revenues 196,910 2,574,660 1,391,102 (445,021 ) 3,717,651 Operating expenses 134,072 2,510,119 1,189,411 (445,021 ) 3,388,581 Operating income 62,838 64,541 201,691 — 329,070 Debt expense (102,101 ) (91,259 ) (12,998 ) 103,464 (102,894 ) Other income 98,654 5,421 2,604 (103,464 ) 3,215 Income tax expense 41,942 89,203 3,743 — 134,888 Equity earnings in subsidiaries 35,933 146,433 — (182,366 ) — Net income 53,382 35,933 187,554 (182,366 ) 94,503 Less: Net income attributable to noncontrolling interests — — — (41,121 ) (41,121 ) Net income attributable to DaVita Inc. $ 53,382 $ 35,933 $ 187,554 $ (223,487 ) $ 53,382 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2017 DaVita Inc. Patient services revenues $ — $ 3,234,605 $ 2,154,549 $ (105,309 ) $ 5,283,845 Less: Provision for uncollectible accounts — (136,694 ) (91,774 ) — (228,468 ) Net patient service revenues — 3,097,911 2,062,775 (105,309 ) 5,055,377 Capitated revenues — 931,479 1,010,901 (2,266 ) 1,940,114 Other revenues 414,971 979,536 69,894 (885,132 ) 579,269 Total net revenues 414,971 5,008,926 3,143,570 (992,707 ) 7,574,760 Operating expenses and charges 270,014 4,276,878 2,754,023 (992,707 ) 6,308,208 Operating income 144,957 732,048 389,547 — 1,266,552 Debt expense (208,823 ) (183,747 ) (28,659 ) 208,838 (212,391 ) Other income, net 202,636 5,728 9,970 (208,838 ) 9,496 Income tax expense 57,062 292,348 52,337 — 401,747 Equity earnings in subsidiaries 492,990 231,309 — (724,299 ) — Net income 574,698 492,990 318,521 (724,299 ) 661,910 Less: Net income attributable to noncontrolling interests — — — (87,212 ) (87,212 ) Net income attributable to DaVita Inc. $ 574,698 $ 492,990 $ 318,521 $ (811,511 ) $ 574,698 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2016 DaVita Inc. Patient services revenues $ — $ 3,317,673 $ 1,827,984 $ (80,209 ) $ 5,065,448 Less: Provision for uncollectible accounts — (133,311 ) (87,322 ) — (220,633 ) Net patient service revenues — 3,184,362 1,740,662 (80,209 ) 4,844,815 Capitated revenues — 931,694 856,510 (211 ) 1,787,993 Other revenues 383,885 1,005,420 59,269 (782,595 ) 665,979 Total net revenues 383,885 5,121,476 2,656,441 (863,015 ) 7,298,787 Operating expenses and charges 256,345 4,887,749 2,323,749 (863,015 ) 6,604,828 Operating income 127,540 233,727 332,692 — 693,959 Debt expense (203,202 ) (183,432 ) (24,512 ) 205,368 (205,778 ) Other income, net 197,214 9,757 4,588 (205,368 ) 6,191 Income tax expense 77,088 162,457 22,165 — 261,710 Equity earnings in subsidiaries 106,352 208,757 — (315,109 ) — Net income 150,816 106,352 290,603 (315,109 ) 232,662 Less: Net income attributable to noncontrolling interests — — — (81,846 ) (81,846 ) Net income attributable to DaVita Inc. $ 150,816 $ 106,352 $ 290,603 $ (396,955 ) $ 150,816 Condensed Consolidating Statements of Income Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) For The Six Months Ended June 30, 2017 Patient service operating revenues $ 5,283,845 $ 273,017 $ — $ 5,010,828 Less: Provision for uncollectible accounts (228,468 ) (7,351 ) — (221,117 ) Net patient service operating revenues 5,055,377 265,666 — 4,789,711 Capitated revenues 1,940,114 785,139 — 1,154,975 Other revenues 579,269 19,596 — 559,673 Total net operating revenues 7,574,760 1,070,401 — 6,504,359 Operating expenses 6,308,208 1,032,529 (232 ) 5,275,911 Operating income 1,266,552 37,872 232 1,228,448 Debt expense, including refinancing charges (212,391 ) (3,323 ) — (209,068 ) Other income 9,496 151 — 9,345 Income tax expense 401,747 32,700 93 368,954 Net income 661,910 2,000 139 659,771 Less: Net income attributable to noncontrolling interests (87,212 ) — — (87,212 ) Net income attributable to DaVita Inc. $ 574,698 $ 2,000 $ 139 $ 572,559 (1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Comprehensive Income	Condensed Consolidating Statements of Comprehensive Income Guarantor Non- Consolidating Consolidated For The Three Months Ended June 30, 2017 DaVita Inc. Net income $ 127,001 $ 98,349 $ 114,229 $ (177,954 ) $ 161,625 Other comprehensive income 436 — 49,142 — 49,578 Total comprehensive income 127,437 98,349 163,371 (177,954 ) 211,203 Less: Comprehensive income attributable to — — — (34,624 ) (34,624 ) Comprehensive income attributable to DaVita Inc. $ 127,437 $ 98,349 $ 163,371 $ (212,578 ) $ 176,579 Guarantor Non- Consolidating Consolidated For The Three Months Ended June 30, 2016 DaVita Inc. Net income $ 53,382 $ 35,933 $ 187,554 $ (182,366 ) $ 94,503 Other comprehensive loss (1,530 ) — (4,844 ) — (6,374 ) Total comprehensive income 51,852 35,933 182,710 (182,366 ) 88,129 Less: Comprehensive income attributable to the — — — (41,270 ) (41,270 ) Comprehensive income attributable to DaVita Inc. $ 51,852 $ 35,933 $ 182,710 $ (223,636 ) $ 46,859 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2017 DaVita Inc. Net income $ 574,698 $ 492,990 $ 318,521 $ (724,299 ) $ 661,910 Other comprehensive (loss) income (70 ) — 62,403 — 62,333 Total comprehensive income 574,628 492,990 380,924 (724,299 ) 724,243 Less: Comprehensive income attributable to — — — (87,210 ) (87,210 ) Comprehensive income attributable to DaVita Inc. $ 574,628 $ 492,990 $ 380,924 $ (811,509 ) $ 637,033 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2016 DaVita Inc. Net income $ 150,816 $ 106,352 $ 290,603 $ (315,109 ) $ 232,662 Other comprehensive (loss) income (6,398 ) — 6,337 — (61 ) Total comprehensive income 144,418 106,352 296,940 (315,109 ) 232,601 Less: Comprehensive income attributable to the — — — (81,995 ) (81,995 ) Comprehensive income attributable to DaVita Inc. $ 144,418 $ 106,352 $ 296,940 $ (397,104 ) $ 150,606 Condensed Consolidating Statements of Comprehensive Income Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) For The Six Months Ended June 30, 2017 Net income $ 661,910 $ 2,000 $ 139 $ 659,771 Other comprehensive income 62,333 — — 62,333 Total comprehensive income 724,243 2,000 139 722,104 Less: Comprehensive income attributable to the noncontrolling (87,210 ) — — (87,210 ) Comprehensive income attributable to DaVita Inc. $ 637,033 $ 2,000 $ 139 $ 634,894 (1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Balance Sheets	Condensed Consolidating Balance Sheets Guarantor Non- Consolidating Consolidated As of June 30, 2017 DaVita Inc. Cash and cash equivalents $ 374,973 $ 40,508 $ 296,516 $ — $ 711,997 Accounts receivable, net — 1,278,053 775,759 — 2,053,812 Other current assets 254,108 891,208 112,643 — 1,257,959 Total current assets 629,081 2,209,769 1,184,918 — 4,023,768 Property and equipment, net 345,667 1,669,583 1,232,780 — 3,248,030 Intangible assets, net 355 1,405,712 56,827 — 1,462,894 Investments in subsidiaries 10,368,953 2,375,421 — (12,744,374 ) — Intercompany receivables 3,266,741 — 1,035,735 (4,302,476 ) — Other long-term assets and investments 45,228 92,891 579,182 — 717,301 Goodwill — 7,850,917 2,038,874 — 9,889,791 Total assets $ 14,656,025 $ 15,604,293 $ 6,128,316 $ (17,046,850 ) $ 19,341,784 Current liabilities $ 399,436 $ 1,807,277 $ 566,612 $ — $ 2,773,325 Intercompany payables — 2,181,952 2,120,524 (4,302,476 ) — Long-term debt and other long-term liabilities 8,578,628 1,246,111 462,120 — 10,286,859 Noncontrolling interests subject to put provisions 593,647 — — 416,057 1,009,704 Total DaVita Inc. shareholder's equity 5,084,314 10,368,953 2,375,421 (12,744,374 ) 5,084,314 Noncontrolling interests not subject to put provisions — — 603,639 (416,057 ) 187,582 Total equity 5,084,314 10,368,953 2,979,060 (13,160,431 ) 5,271,896 Total liabilities and equity $ 14,656,025 $ 15,604,293 $ 6,128,316 $ (17,046,850 ) $ 19,341,784 Guarantor Non- Consolidating Consolidated As of December 31, 2016 DaVita Inc. Cash and cash equivalents $ 549,921 $ 59,192 $ 304,074 $ — $ 913,187 Accounts receivable, net — 1,215,232 702,070 — 1,917,302 Other current assets 277,911 736,727 135,101 — 1,149,739 Total current assets 827,832 2,011,151 1,141,245 — 3,980,228 Property and equipment, net 337,200 1,689,798 1,148,369 — 3,175,367 Intangible assets, net 487 1,491,057 36,223 — 1,527,767 Investments in subsidiaries 9,717,728 2,002,660 — (11,720,388 ) — Intercompany receivables 3,250,692 — 866,955 (4,117,647 ) — Other long-term assets and investments 39,994 86,710 523,874 — 650,578 Goodwill — 7,838,984 1,568,333 — 9,407,317 Total assets $ 14,173,933 $ 15,120,360 $ 5,284,999 $ (15,838,035 ) $ 18,741,257 Current liabilities $ 303,840 $ 1,865,193 $ 527,412 $ — $ 2,696,445 Intercompany payables — 2,322,124 1,795,523 (4,117,647 ) — Long-term debt and other long-term liabilities 8,614,445 1,215,315 392,053 — 10,221,813 Noncontrolling interests subject to put provisions 607,601 — — 365,657 973,258 Total DaVita Inc. shareholder's equity 4,648,047 9,717,728 2,002,660 (11,720,388 ) 4,648,047 Noncontrolling interests not subject to put provisions — — 567,351 (365,657 ) 201,694 Total equity 4,648,047 9,717,728 2,570,011 (12,086,045 ) 4,849,741 Total liabilities and equity $ 14,173,933 $ 15,120,360 $ 5,284,999 $ (15,838,035 ) $ 18,741,257 Condensed Consolidating Balance Sheets Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) As of June 30, 2017 Cash and cash equivalents $ 711,997 $ 107,232 $ — $ 604,765 Accounts receivable, net 2,053,812 213,804 — 1,840,008 Other current assets 1,257,959 13,679 — 1,244,280 Total current assets 4,023,768 334,715 — 3,689,053 Property and equipment, net 3,248,030 3,368 — 3,244,662 Amortizable intangibles, net 1,462,894 4,553 — 1,458,341 Other long-term assets 717,301 82,477 2,946 631,878 Goodwill 9,889,791 29,865 — 9,859,926 Total assets $ 19,341,784 $ 454,978 $ 2,946 $ 18,883,860 Current liabilities $ 2,773,325 $ 178,259 $ — $ 2,595,066 Payables to parent — 114,038 2,946 (116,984 ) Long-term debt and other long-term liabilities 10,286,859 55,870 — 10,230,989 Noncontrolling interests subject to put provisions 1,009,704 — — 1,009,704 Total DaVita Inc. shareholders’ equity 5,084,314 106,811 — 4,977,503 Noncontrolling interests not subject to put provisions 187,582 — — 187,582 Shareholders’ equity 5,271,896 106,811 — 5,165,085 Total liabilities and shareholder’s equity $ 19,341,784 $ 454,978 $ 2,946 $ 18,883,860 (1) After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Cash Flows	Condensed Consolidating Statements of Cash Flows Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2017 DaVita Inc. Cash flows from operating activities: Net income $ 574,698 $ 492,990 $ 318,521 $ (724,299 ) $ 661,910 Changes in operating assets and liabilities and non-cash items included in net income (431,980 ) 52,218 4,997 724,299 349,534 Net cash provided by operating activities 142,718 545,208 323,518 — 1,011,444 Cash flows from investing activities: Additions of property and equipment, net (50,966 ) (182,494 ) (165,480 ) — (398,940 ) Acquisitions — (538,450 ) (81,389 ) — (619,839 ) Proceeds from asset and business sales — 70,127 109 — 70,236 Proceeds (purchases) from investment sales and other items, net 49,036 (2,974 ) 50,833 — 96,895 Net cash used in investing activities (1,930 ) (653,791 ) (195,927 ) — (851,648 ) Cash flows from financing activities: Long-term debt and related financing costs, net (54,992 ) (6,893 ) (2,147 ) — (64,032 ) Intercompany (payments) borrowing (37,233 ) 98,224 (60,991 ) — — Other items (223,511 ) (1,432 ) (76,203 ) — (301,146 ) Net cash (used in) provided by financing activities (315,736 ) 89,899 (139,341 ) — (365,178 ) Effect of exchange rate changes on cash — — 4,192 — 4,192 Net decrease in cash and cash equivalents (174,948 ) (18,684 ) (7,558 ) — (201,190 ) Cash and cash equivalents at beginning of period 549,921 59,192 304,074 — 913,187 Cash and cash equivalents at end of period $ 374,973 $ 40,508 $ 296,516 $ — $ 711,997 Guarantor Non- Consolidating Consolidated For The Six Months Ended June 30, 2016 DaVita Inc. Cash flows from operating activities: Net income $ 150,816 $ 106,352 $ 290,603 $ (315,109 ) $ 232,662 Changes in operating assets and liabilities and non-cash (1,505 ) 219,697 179,676 315,109 712,977 Net cash provided by operating activities 149,311 326,049 470,279 — 945,639 Cash flows from investing activities: Additions of property and equipment, net (42,266 ) (171,164 ) (145,197 ) — (358,627 ) Acquisitions — (462,592 ) (10,722 ) — (473,314 ) Proceeds from asset and business sales — 17,393 — — 17,393 Proceeds (purchases) from investment sales and other 21,230 (10,869 ) 45,958 — 56,319 Net cash used in investing activities (21,036 ) (627,232 ) (109,961 ) — (758,229 ) Cash flows from financing activities: Long-term debt and related financing costs, net (42,493 ) (13,917 ) (4,823 ) — (61,233 ) Intercompany borrowing (payments) 11,208 247,765 (258,973 ) — — Other items (255,032 ) (6,253 ) (81,036 ) — (342,321 ) Net cash (used in) provided by financing activities (286,317 ) 227,595 (344,832 ) — (403,554 ) Effect of exchange rate changes on cash — — 444 — 444 Net (decrease) increase in cash and cash equivalents (158,042 ) (73,588 ) 15,930 — (215,700 ) Cash and cash equivalents at beginning of period 1,186,636 109,357 203,123 — 1,499,116 Cash and cash equivalents at end of period $ 1,028,594 $ 35,769 $ 219,053 $ — $ 1,283,416 Condensed Consolidating Statements of Cash Flows Consolidated Total Physician Groups Unrestricted Subsidiaries Company and Restricted Subsidiaries (1) For The Six Months Ended June 30, 2017 Cash flows from operating activities: Net income $ 661,910 $ 2,000 $ 139 $ 659,771 Changes in operating and intercompany assets and liabilities 349,534 (37,812 ) (139 ) 387,485 Net cash provided by (used in) operating activities 1,011,444 (35,812 ) — 1,047,256 Cash flows from investing activities: Additions of property and equipment (398,940 ) (5,603 ) — (393,337 ) Acquisitions and divestitures, net (619,839 ) — — (619,839 ) Proceeds from discontinued operations 70,236 — — 70,236 Investments and other items 96,895 (1,386 ) — 98,281 Net cash used in investing activities (851,648 ) (6,989 ) — (844,659 ) Cash flows from financing activities: Long-term debt (64,032 ) — — (64,032 ) Intercompany — 45,342 — (45,342 ) Other items (301,146 ) — — (301,146 ) Net cash (used in) provided by financing activities (365,178 ) 45,342 — (410,520 ) Effect of exchange rate changes on cash 4,192 — — 4,192 Net (decrease) increase in cash (201,190 ) 2,541 — (203,731 ) Cash and cash equivalents at beginning of period 913,187 104,691 — 808,496 Cash and cash equivalents at end of period $ 711,997 $ 107,232 $ — $ 604,765 (1) After elimination of the unrestricted subsidiaries and the physician groups.

Reconciliations of Numerators a

Reconciliations of Numerators and Denominators Used to Calculate Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Basic:
Net income attributable to DaVita Inc.		$ 127,001	$ 53,382	$ 574,698	$ 150,816
Weighted average shares outstanding during the period		193,282,000	206,692,000	193,923,000	206,626,000
Contingently returnable shares held in escrow for the DaVita HealthCare Partners merger (in shares)		(2,194,000)	(2,194,000)	(2,194,000)	(2,194,000)
Weighted average shares for basic earnings per share calculation (in shares)		191,088,216	204,497,970	191,728,913	204,432,315
Basic net income per share attributable to DaVita Inc. (usd per share)		$ 0.66	$ 0.26	$ 3	$ 0.74
Diluted:
Net income attributable to DaVita Inc.		$ 127,001	$ 53,382	$ 574,698	$ 150,816
Weighted average shares outstanding during the period		193,282,000	206,692,000	193,923,000	206,626,000
Assumed incremental shares from stock plans (in shares)		706,000	1,355,000	708,000	1,362,000
Weighted average shares for diluted earnings per share calculation (in shares)		193,987,983	208,047,172	194,630,936	207,987,530
Diluted net income per share attributable to DaVita Inc. (usd per share)		$ 0.65	$ 0.26	$ 2.95	$ 0.73
Anti-dilutive potential common shares excluded from calculation (in shares)	[1]	3,780,000	1,811,000	3,603,000	2,042,000
[1]	Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

Accounts Receivable - Additiona

Accounts Receivable - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Accounts Notes And Loans Receivable [Line Items]
Percentage of outstanding patient accounts receivables to be reserved as per Company's policy	100.00%
Account receivable outstanding, number of months	3 months
Decrease in allowance for doubtful accounts	$ (11,138)
Government-based Programs, Medicare and Medicaid | Accounts Receivable
Accounts Notes And Loans Receivable [Line Items]
Percentage of outstanding patient accounts receivables to be reserved as per Company's policy	80.00%
Health Care Patient | Accounts Receivable
Accounts Notes And Loans Receivable [Line Items]
Percentage of accounts receivable due	1.00%
DMG
Accounts Notes And Loans Receivable [Line Items]
Percentage of outstanding patient accounts receivables to be reserved as per Company's policy	100.00%
Account receivable outstanding, number of months	12 months

Investments (Detail)

Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Investment Holdings [Line Items]
Held to maturity	$ 210,236	$ 306,827
Available for sale	115,893	107,050
Total	326,129	413,877
Held to maturity, short-term investments	210,236	306,827
Available for sale, short-term investments	1,200	3,371
Total, short-term investments	211,436	310,198
Held to maturity, long-term investments	0	0
Available for sale, long-term investments	114,693	103,679
Total, long-term investments	114,693	103,679
Certificates of deposit, commercial paper and money market funds due within one year
Investment Holdings [Line Items]
Held to maturity	210,236	256,827
Total	210,236	256,827
Investments in mutual funds and common stock
Investment Holdings [Line Items]
Held to maturity	0	50,000
Available for sale, equity securities	53,209	47,404
Total	53,209	97,404
Cash surrender value of life insurance policies
Investment Holdings [Line Items]
Held to maturity	0	0
Available for sale, equity securities	62,684	59,646
Total	$ 62,684	$ 59,646

Investments in Debt and Equit47

Investments in Debt and Equity Securities - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Available for sale investments gross pre-tax unrealized gain (loss)	$ 6,783		$ 6,783		$ 3,701
Unrealized gains on investments	1,057	$ 638	2,614	$ 867
Proceeds from sale of mutual funds and debt securities			5,049
Pre tax reclassification of net investment realized gain (loss) into net income			(346)	(152)
Reclassification of net investment realized gain (loss) into net income, net tax			(211)	(93)
Proceeds from sale of investments available for sale				$ 1,347
HealthCare Partners (HCP)
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Required minimum cash balance	$ 56,717		56,717
Certificates of deposit, commercial paper and money market funds due within one year
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax			3,428
Unrealized gains on investments			$ 2,616

Equity investments Additional (

Equity investments Additional (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Noncontrolling Interest [Line Items]
Equity investments in nonconsolidated businesses	$ 542,468		$ 542,468		$ 502,389
Equity investment income	$ 3,614	$ (505)	$ 7,549	$ 882
Parent Company And Restricted Subsidiaries [Member]
Noncontrolling Interest [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	60.00%		60.00%
Noncontrolling Interest, Ownership Percentage by Parent	86.70%		86.70%
Deconsolidated Noncontrolling Entity [Member]
Noncontrolling Interest [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	40.00%		40.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	13.30%		13.30%

Changes in Goodwill by Reportab

Changes in Goodwill by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Jun. 30, 2017
Goodwill [Roll Forward]
Beginning balance			$ 9,407,317	$ 9,294,479	$ 9,294,479
Acquisitions			572,764		447,828
Divestitures			(32,343)		(44,759)
Goodwill impairment charges	$ (61,117)	$ (176,000)	(85,315)	(253,000)	(281,415)
Foreign currency and other adjustments			27,368		(8,816)
Ending balance	9,889,791		9,889,791		9,407,317
Goodwill						$ 10,451,199
Accumulated impairment charges						(561,408)
Goodwill, net	9,889,791		9,407,317	9,294,479	9,294,479	9,889,791
U.S. dialysis and related lab services
Goodwill [Roll Forward]
Beginning balance			5,691,587	5,629,183	5,629,183
Acquisitions			427,299		75,295
Divestitures			(32,260)		(12,891)
Ending balance	6,086,626		6,086,626		5,691,587
Goodwill						6,086,626
Accumulated impairment charges						0
Goodwill, net	6,086,626		5,691,587	5,629,183	5,629,183	6,086,626
DMG
Goodwill [Roll Forward]
Beginning balance			3,391,942	3,398,264	3,398,264
Acquisitions			31,796		248,901
Divestitures			(29)		(2,223)
Goodwill impairment charges			(50,619)		(253,000)
Ending balance	3,373,090		3,373,090		3,391,942
Goodwill						3,865,478
Accumulated impairment charges						(492,388)
Goodwill, net	3,373,090		3,391,942	3,398,264	3,398,264	3,373,090
Ancillary services and strategic initiatives
Goodwill [Roll Forward]
Beginning balance			323,788	267,032	267,032
Acquisitions			113,669		123,632
Divestitures			(54)		(29,645)
Goodwill impairment charges			(34,696)		(28,415)
Foreign currency and other adjustments			27,368		(8,816)
Ending balance	430,075		430,075		323,788
Goodwill						499,095
Accumulated impairment charges						(69,020)
Goodwill, net	$ 430,075		$ 323,788	$ 267,032	$ 267,032	$ 430,075

Goodwill Schedule of Reporting

Goodwill Schedule of Reporting Units Goodwill Balances (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
Percentage Change In Discount Rate Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment	1.00%
Percentage Change In Operating Income Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment	3.00%
Goodwill	$ 9,889,791	$ 9,407,317	$ 9,294,479
DMG
Goodwill [Line Items]
Goodwill	3,373,090	$ 3,391,942	$ 3,398,264
DMG | NEVADA
Goodwill [Line Items]
Goodwill	$ 275,914
Carrying amount coverage	17.00%
Sensitivities, operating income	(2.40%)
Sensitivities, discount rate	(3.80%)
DMG | FLORIDA
Goodwill [Line Items]
Goodwill	$ 397,127
Carrying amount coverage	0.00%
Sensitivities, operating income	(1.60%)
Sensitivities, discount rate	(2.80%)
DMG | NEW MEXICO
Goodwill [Line Items]
Goodwill	$ 70,253
Carrying amount coverage	0.00%
Sensitivities, operating income	(1.60%)
Sensitivities, discount rate	(2.40%)
DMG | WASHINGTON
Goodwill [Line Items]
Goodwill	$ 247,552
Carrying amount coverage	9.30%
Sensitivities, operating income	(1.70%)
Sensitivities, discount rate	(3.60%)

Goodwill Goodwill Narrative (De

Goodwill Goodwill Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
Goodwill, Impairment Loss	$ 61,117,000	$ 176,000,000	$ 85,315,000	$ 253,000,000	$ 281,415,000
Goodwill	9,889,791,000		9,889,791,000		9,407,317,000	$ 9,294,479,000
DMG
Goodwill [Line Items]
Goodwill, Impairment Loss			50,619,000		253,000,000
Goodwill	3,373,090,000		3,373,090,000		$ 3,391,942,000	$ 3,398,264,000
Vascular Access Clinic
Goodwill [Line Items]
Goodwill, Impairment Loss	10,498,000
Goodwill	0		0
FLORIDA | DMG
Goodwill [Line Items]
Goodwill, Impairment Loss	49,946,000	97,000,000
Goodwill	397,127,000		397,127,000
NEW MEXICO | DMG
Goodwill [Line Items]
Goodwill, Impairment Loss	673,000
Goodwill	70,253,000		70,253,000
NEVADA | DMG
Goodwill [Line Items]
Goodwill, Impairment Loss		$ 79,000,000
Goodwill	$ 275,914,000		$ 275,914,000

Components of Changes in Medica

Components of Changes in Medical Payables (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Health Care Costs Payable [Roll Forward]
Health care costs payable, beginning of the period	$ 336,381
Less: Claims paid
Health care costs payable, end of the period	390,387
Healthcare Cost
Health Care Costs Payable [Roll Forward]
Health care costs payable, beginning of the period	214,275
Add: Components of incurred health care costs
Current year	991,818
Prior years	(6,838)
Total incurred health care costs	984,980
Less: Claims paid
Current year	727,814
Prior years	186,623
Total claims paid	914,437
Health care costs payable, end of the period	$ 284,818

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Liability for unrecognized tax benefits	$ 25,926	$ 24,066
Increase in liability for unrecognized tax benefits	(1,860)
Accrued interest and penalties related to unrecognized tax benefits, net of federal tax benefits	$ 3,891	$ 2,595

Long-term Debt (Detail)

Long-term Debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Senior notes	$ 4,500,000	$ 4,500,000
Acquisition obligations and other notes payable	139,371	117,547
Capital lease obligations	305,643	299,682
Total debt principal outstanding	9,165,014	9,192,229
Discount and deferred financing costs	(71,877)	(79,861)
Carrying Amount of Long-Term Debt, Net of Unamortized Discount or Premium, Current and Noncurrent, Total	9,093,137	9,112,368
Less current portion	(182,323)	(165,041)
Long-term debt	8,910,814	8,947,327
Term Loan A
Debt Instrument [Line Items]
Senior Secured Credit Facilities	825,000	862,500
Term Loan B
Debt Instrument [Line Items]
Senior Secured Credit Facilities	$ 3,395,000	$ 3,412,500

Scheduled Maturities of Long-te

Scheduled Maturities of Long-term Debt (Detail) $ in Thousands	Jun. 30, 2017USD ($)
Debt Disclosure [Abstract]
2017 (remainder of the year)	$ 96,454
2,018	172,318
2,019	746,464
2,020	71,432
2,021	3,303,146
2,022	1,280,031
Thereafter	$ 3,495,169

Long-term Debt - Additional Inf

Long-term Debt - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Unrealized losses on interest rate cap and swap agreements	$ (1,815)	$ (2,616)	$ (5,002)	$ (8,085)
Weighted average effective interest rate at quarter end	4.76%		4.76%
Weighted average effective interest rate during quarter	4.69%
Fixed interest rate	53.31%		53.31%
DMG
Debt Instrument [Line Items]
Letters of credit outstanding	$ 1,286		$ 1,286
Revolving Credit Facility
Debt Instrument [Line Items]
Undrawn revolving credit facilities	1,000,000		1,000,000
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding	94,623		94,623
Interest Rate Cap Agreements Effective September 30, 2016
Debt Instrument [Line Items]
Interest rate agreements, notional amount	3,500,000		$ 3,500,000
Derivative, effective date			Sep. 30, 2016
Derivative, expiration date			Jun. 30, 2018
Fair value of assets	1		$ 1
Debt expense recognized			4,139
Unrealized losses on interest rate cap and swap agreements			115
Interest Rate Cap Agreements Effective June 29, 2018
Debt Instrument [Line Items]
Interest rate agreements, notional amount	3,500,000		$ 3,500,000
Derivative, effective date			Jun. 29, 2018
Derivative, expiration date			Jun. 30, 2020
Fair value of assets	$ 1,742		$ 1,742
Unrealized losses on interest rate cap and swap agreements			$ 8,071
London Interbank Offered Rate (LIBOR) | Interest Rate Cap Agreements Effective September 30, 2016
Debt Instrument [Line Items]
LIBOR cap rate	3.50%		3.50%
London Interbank Offered Rate (LIBOR) | Interest Rate Cap Agreements Effective June 29, 2018
Debt Instrument [Line Items]
LIBOR cap rate	3.50%		3.50%
Term Loan A
Debt Instrument [Line Items]
Debt instrument, annual principal payment	$ 37,500		$ 37,500
Senior Secured Credit Facilities	825,000		$ 825,000		$ 862,500
Term Loan A | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, variable interest rate margin			2.00%
Term Loan B
Debt Instrument [Line Items]
Debt instrument, annual principal payment	17,500		$ 17,500
Senior Secured Credit Facilities	3,395,000		$ 3,395,000		$ 3,412,500
Term Loan B | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, variable interest rate margin			2.75%
Term Loan B | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Debt instrument, variable interest rate margin			3.50%
Term Loan A subject to interest rate caps
Debt Instrument [Line Items]
Senior Secured Credit Facilities	105,000		$ 105,000
Term Loan A subject to uncapped portion of variability of LIBOR
Debt Instrument [Line Items]
Senior Secured Credit Facilities	$ 720,000		$ 720,000
Senior Secured Credit Facilities
Debt Instrument [Line Items]
Weighted average effective interest rate at quarter end	4.20%		4.20%

Derivative Instruments (Detail)

Derivative Instruments (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Designated as Hedging Instrument | Interest rate cap agreements | Other long-term assets
Derivative [Line Items]
Derivative assets, Fair value	$ 1,743	$ 9,929

Effects of Interest Rate Swap a

Effects of Interest Rate Swap and Cap Agreements (Detail) - Cash Flow Hedging - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Derivative Instruments Gain Loss [Line Items]
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	$ (1,815)	$ (2,616)	$ (5,002)	$ (8,085)
Amount of losses reclassified from accumulated OCI into income	1,265	448	2,529	913
Tax benefit
Derivative Instruments Gain Loss [Line Items]
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	1,154	1,667	3,184	5,149
Amount of losses reclassified from accumulated OCI into income	(805)	(285)	(1,610)	(581)
Interest rate swap agreements | Debt Expense (Including Refinancing Charges)
Derivative Instruments Gain Loss [Line Items]
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	0	(168)	0	(860)
Amount of losses reclassified from accumulated OCI into income	0	123	0	274
Interest rate cap agreements | Debt Expense (Including Refinancing Charges)
Derivative Instruments Gain Loss [Line Items]
Amount of gains (losses) recognized in OCI on interest rate swap and cap agreements	(2,969)	(4,115)	(8,186)	(12,374)
Amount of losses reclassified from accumulated OCI into income	$ 2,070	$ 610	$ 4,139	$ 1,220

Contingencies - Additional Info

Contingencies - Additional Information (Detail) $ in Thousands	1 Months Ended		3 Months Ended			6 Months Ended
	Jun. 30, 2015USD ($)	Dec. 31, 2012Clinic	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Other Commitments [Line Items]
Loss contingency liability			$ 62,000			$ 62,000		$ 69,000
Gain on litigation settlement			$ 0		$ 0	$ 526,827	$ 0
Dialysis and other businesses
Other Commitments [Line Items]
Number of businesses acquired | Clinic		2
Vainer Private Civil Suit
Other Commitments [Line Items]
Litigation settlement amount	$ (450,000)
Legal fees	$ 45,000
US Department Of Veterans Affairs Suit
Other Commitments [Line Items]
Litigation settlement amount				$ 538,000
Gain on litigation settlement				527,000
Noncontrolling Interest | US Department Of Veterans Affairs Suit
Other Commitments [Line Items]
Gain on litigation settlement				9,000
Operating Income (Loss) | US Department Of Veterans Affairs Suit
Other Commitments [Line Items]
Gain on litigation settlement				530,000
Equity Method Investments | Noncontrolling Interest | US Department Of Veterans Affairs Suit
Other Commitments [Line Items]
Gain on litigation settlement				$ 3,000

Noncontrolling Interests Subj60

Noncontrolling Interests Subject to Put Provisions and Other Commitments - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Minimum
Other Commitments [Line Items]
Scheduled dissolution term of joint ventures	10 years
Maximum
Other Commitments [Line Items]
Scheduled dissolution term of joint ventures	50 years
Commitments to provide operating capital
Other Commitments [Line Items]
Other potential commitments to provide operating capital to several dialysis centers	$ 5,892

Long-term Incentive Compensat61

Long-term Incentive Compensation - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Long-term incentive program (LTIP) expense	$ 30,946	$ 50,647
Stock-based compensation expense	17,504	23,717
Estimated tax benefits recorded for stock-based compensation	5,912	8,160
Unrecognized compensation cost related to outstanding LTIP awards	149,543
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under equity compensation and stock purchase plans	$ 84,475
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under performance-based cash component of LTIP costs, weighted average remaining period (in years)	1 year 2 months 12 days
Unrecognized compensation cost related to nonvested stock-based compensation arrangements under stock-based component of LTIP costs, weighted average remaining period (in years)	1 year 6 months
Tax benefits from stock award exercises	$ 5,693	$ 23,658
Stock Appreciation Rights
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock granted (in shares)	1,426
Aggregate grant-date fair value	$ 20,865
Weighted-average expected life (in years)	4 years 2 months 12 days
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock granted (in shares)	387
Aggregate grant-date fair value	$ 25,517
Weighted-average expected life (in years)	3 years 4 months 24 days
Cash Settled Stock Based Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock granted (in shares)	15
Aggregate grant-date fair value	$ 204
Weighted-average expected life (in years)	4 years 3 months 18 days

Share Repurchases Statement

Share Repurchases Statement - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jul. 13, 2017
Equity, Class of Treasury Stock [Line Items]
Treasury Stock, Shares, Acquired	3,575
Treasury Stock, Value, Acquired, Cost Method	$ (231,674)
Treasury Stock Acquired, Average Cost Per Share	$ 64.81
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 445,430
Subsequent Event [Member]
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Authorized Amount		$ 1,240,748
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 259,252

Comprehensive Income (Detail)

Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance			$ 4,849,741
Ending balance	$ 5,271,896		5,271,896
Interest rate swaps and cap agreements
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(13,952)	$ (15,929)	(12,029)	$ (10,925)
Unrealized (losses) gains	(2,969)	(4,283)	(8,186)	(13,234)
Related income tax benefit (expense)	1,154	1,667	3,184	5,149
Unrealized (losses) gains net	(1,815)	(2,616)	(5,002)	(8,085)
Reclassification from accumulated other comprehensive income into net income	2,070	733	4,139	1,494
Related income tax (expense) benefit	(805)	(285)	(1,610)	(581)
Reclassification from accumulated other comprehensive income into net income net of tax	1,265	448	2,529	913
Ending balance	(14,502)	(18,097)	(14,502)	(18,097)
Investment securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	3,594	1,497	2,175	1,361
Unrealized (losses) gains	1,446	782	3,428	1,124
Related income tax benefit (expense)	(389)	(293)	(812)	(406)
Unrealized (losses) gains net	1,057	489	2,616	718
Reclassification from accumulated other comprehensive income into net income	(117)	0	(346)	(152)
Related income tax (expense) benefit	46	0	135	59
Reclassification from accumulated other comprehensive income into net income net of tax	(71)	0	(211)	(93)
Ending balance	4,580	1,986	4,580	1,986
Foreign currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(66,528)	(39,081)	(79,789)	(50,262)
Unrealized (losses) gains	49,142	(4,844)	62,403	6,337
Unrealized (losses) gains net	49,142	(4,844)	62,403	6,337
Reclassification from accumulated other comprehensive income into net income	0	0	0	0
Reclassification from accumulated other comprehensive income into net income net of tax	0	0	0	0
Ending balance	(17,386)	(43,925)	(17,386)	(43,925)
Accumulated other comprehensive (loss) income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(76,886)	(53,513)	(89,643)	(59,826)
Unrealized (losses) gains	47,619	(8,345)	57,645	(5,773)
Related income tax benefit (expense)	765	1,374	2,372	4,743
Unrealized (losses) gains net	48,384	(6,971)	60,017	(1,030)
Reclassification from accumulated other comprehensive income into net income	1,953	733	3,793	1,342
Related income tax (expense) benefit	(759)	(285)	(1,475)	(522)
Reclassification from accumulated other comprehensive income into net income net of tax	1,194	448	2,318	820
Ending balance	$ (27,308)	$ (60,036)	$ (27,308)	$ (60,036)

Acquisitions and divestitures -

Acquisitions and divestitures - Additional Information (Detail) $ in Thousands	May 01, 2017USD ($)ClinicPerson	Dec. 31, 2012Clinic	Jun. 30, 2017USD ($)	Jun. 30, 2017USD ($)Clinic	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Business Acquisition [Line Items]
Cash paid to acquire businesses				$ 619,839	$ 473,314
Contingent earn-out obligations associated with acquisitions				$ 16,684
Amortizable intangible assets acquired, weighted-average estimated useful lives				5 years
Business Combination, Contingent Consideration, Liability			$ 11,674	$ 11,674		$ 9,977
Other Accrued Liabilities
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability			4,666	4,666
Other long-term liabilities
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability			7,008	7,008
Other companies
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability			11,674	$ 11,674
Minimum | Other companies | EBITDA or Operating Income Performance Targets or Quality Margins
Business Acquisition [Line Items]
Earn-out consideration payment period				1 year
Maximum | Other companies | EBITDA or Operating Income Performance Targets or Quality Margins
Business Acquisition [Line Items]
Earn-out consideration payment period				6 years
Dialysis and other businesses
Business Acquisition [Line Items]
Number of businesses acquired | Clinic		2
Cash paid to acquire businesses				$ 258,276
Deferred purchase price obligations				3,823
Contingent earn-out obligations associated with acquisitions				8,787
Goodwill deductible for tax purposes associated with acquisitions			207,080	207,080
Renal Ventures
Business Acquisition [Line Items]
Business Acquisition, Effective Date of Acquisition	May 1, 2017
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Number Of Dialysis Patients | Person	2,600
Number of States in which Entity Operates	6
Proceeds from Divestiture of Businesses	$ 21,219
Business Acquisition, Transaction Costs			4,600	4,600
Cash paid to acquire businesses	$ 361,563
Goodwill deductible for tax purposes associated with acquisitions			$ 296,582	$ 296,582
Noncompete Agreements
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives				5 years
Noncompete Agreements | Renal Ventures
Business Acquisition [Line Items]
Amortizable intangible assets acquired, weighted-average estimated useful lives			5 years
U.S. dialysis and related lab services | Dialysis and other businesses
Business Acquisition [Line Items]
Number of businesses acquired | Clinic				20
Foreign Dialysis Centers | Dialysis and other businesses
Business Acquisition [Line Items]
Number of businesses acquired | Clinic				55
Other Medical Businesses | Dialysis and other businesses
Business Acquisition [Line Items]
Number of businesses acquired | Clinic				5
Operating Dialysis Center [Member] | Dialysis and other businesses
Business Acquisition [Line Items]
Number of Businesses Divested | Clinic	3
Operating Dialysis Center [Member] | Renal Ventures
Business Acquisition [Line Items]
Number of businesses acquired | Clinic	36
Number of Businesses Divested | Clinic	3
New Center Under Construction [Member] | Dialysis and other businesses
Business Acquisition [Line Items]
Number of Businesses Divested | Clinic	1
New Center Under Construction [Member] | Renal Ventures
Business Acquisition [Line Items]
Number of businesses acquired | Clinic	1
Home Dialysis Clinic [Member] | Renal Ventures
Business Acquisition [Line Items]
Number of businesses acquired | Clinic	1

Aggregate Purchase Cost Allocat

Aggregate Purchase Cost Allocations for Acquisitions (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	May 01, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 9,889,791		$ 9,407,317	$ 9,294,479
Renal Ventures
Business Acquisition [Line Items]
Current assets		$ 24,529
Property and equipment		36,295
Amortizable intangible and other long-term assets		11,547
Goodwill		296,582
Current liabilities		(6,912)
Long-term liabilities		(478)
Aggregate purchase price		$ 361,563
Dialysis and other businesses
Business Acquisition [Line Items]
Current assets	7,439
Property and equipment	13,278
Amortizable intangible and other long-term assets	14,180
Non-amortizable intangibles	4,833
Goodwill	276,182
Current liabilities	(6,467)
Long-term liabilities	(2,484)
Noncontrolling interests	(36,075)
Aggregate purchase price	$ 270,886

Reconciliation of Changes in Co

Reconciliation of Changes in Contingent Earn-Out Obligations (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Contingent Earn-Out Obligations [Roll Forward]
Beginning balance, January 1, 2017	$ 9,977
Contingent earn-out obligations associated with acquisitions	3,849
Remeasurement of fair value for contingent earn-out obligations	415
Payments on contingent earn-out obligations	(2,567)
Ending balance	$ 11,674

Acquisitions and divestitures P

Acquisitions and divestitures Pro Forma Summary of Results of Opeation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Business Acquisition, Pro Forma Revenue	$ 3,900,750	$ 3,820,558	$ 7,678,519	$ 7,576,206
Business Acquisition, Pro Forma Net Income (Loss)	$ 128,654	$ 58,996	$ 579,906	$ 160,709
Business Acquisition, Pro Forma Earnings Per Share, Basic	$ 0.67	$ 0.29	$ 3.02	$ 0.79
Business Acquisition, Pro Forma Earnings Per Share, Diluted	$ 0.66	$ 0.28	$ 2.98	$ 0.77

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Detail) $ in Thousands	Jun. 30, 2017USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Asset	$ 765,663
Liabilities	$ 402,425

Assets, Liabilities and Tempora

Assets, Liabilities and Temporary Equity Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Assets
Investments in mutual funds and common stock	$ 115,893	$ 107,050
Liabilities
Contingent earn-out obligations	11,674	$ 9,977
Fair Value, Measurements, Recurring
Assets
Investments in mutual funds and common stock	53,209
Cash surrender value of life insurance policies	62,684
Funds on deposit with third parties	75,671
Liabilities
Contingent earn-out obligations	11,674
Temporary equity
Noncontrolling interests subject to put provisions	1,009,704
Fair Value, Measurements, Recurring | Interest rate cap agreements
Assets
Interest rate cap agreements	1,743
Fair Value, Measurements, Recurring | Level 1
Assets
Investments in mutual funds and common stock	53,209
Cash surrender value of life insurance policies	0
Funds on deposit with third parties	75,671
Liabilities
Contingent earn-out obligations	0
Temporary equity
Noncontrolling interests subject to put provisions	0
Fair Value, Measurements, Recurring | Level 1 | Interest rate cap agreements
Assets
Interest rate cap agreements	0
Fair Value, Measurements, Recurring | Level 2
Assets
Investments in mutual funds and common stock	0
Cash surrender value of life insurance policies	62,684
Funds on deposit with third parties	0
Liabilities
Contingent earn-out obligations	0
Temporary equity
Noncontrolling interests subject to put provisions	0
Fair Value, Measurements, Recurring | Level 2 | Interest rate cap agreements
Assets
Interest rate cap agreements	1,743
Fair Value, Measurements, Recurring | Level 3
Assets
Investments in mutual funds and common stock	0
Cash surrender value of life insurance policies	0
Funds on deposit with third parties	0
Liabilities
Contingent earn-out obligations	11,674
Temporary equity
Noncontrolling interests subject to put provisions	1,009,704
Fair Value, Measurements, Recurring | Level 3 | Interest rate cap agreements
Assets
Interest rate cap agreements	$ 0

Fair Value of Financial Instr70

Fair Value of Financial Instruments - Additional Information (Detail) $ in Thousands	Jun. 30, 2017USD ($)
Estimate of Fair Value Measurement | Senior Secured Credit Facilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term debt, fair value	$ 4,240,812
Estimate of Fair Value Measurement | Senior Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term debt, fair value	4,565,875
Reported Value Measurement | Senior Secured Credit Facilities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term debt, fair value	4,148,123
Reported Value Measurement | Senior Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term debt, fair value	$ 4,500,000

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2017Segment
Segment Reporting [Abstract]
Number of operating segments	2

Summary of Segment Net Revenues

Summary of Segment Net Revenues, Segment Operating Income (Loss) and Reconciliation of Segment Income to Consolidated Income Before Income Taxes (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Patient service revenues		$ 2,682,467	$ 2,583,514	$ 5,283,845	$ 5,065,448
Less: Provision for uncollectible accounts		(115,485)	(111,428)	(228,468)	(220,633)
Net dialysis and related lab services patient service revenues		2,566,982	2,472,086	5,055,377	4,844,815
Other revenues		288,417	345,580	579,269	665,979
Total net operating revenues		3,877,477	3,717,651	7,574,760	7,298,787
Capitated revenues		1,022,078	899,985	1,940,114	1,787,993
Operating income (loss)		378,316	329,070	1,266,552	693,959
Corporate administrative support		(11,031)	(5,417)	(21,622)	(12,337)
Debt expense		(107,962)	(102,894)	(212,391)	(205,778)
Other income, net		5,253	3,215	9,496	6,191
Consolidated income before income taxes		275,607	229,391	1,063,657	494,372
Operating Segments
Segment Reporting Information [Line Items]
Total net operating revenues		3,914,873	3,746,885	7,651,277	7,354,227
Operating income (loss)		389,347	334,487	1,288,174	706,296
Operating Segments | U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Patient service revenues		2,429,658	2,367,044	4,802,319	4,695,015
Less: Provision for uncollectible accounts		(109,335)	(106,515)	(216,105)	(211,266)
Net dialysis and related lab services patient service revenues		2,320,323	2,260,529	4,586,214	4,483,749
Other revenues	[1]	4,891	4,250	10,194	8,223
Total net operating revenues		2,325,214	2,264,779	4,596,408	4,491,972
Operating income (loss)	[2]	450,472	449,190	1,395,212	889,245
Operating Segments | U.S. dialysis and related lab services | External Sources
Segment Reporting Information [Line Items]
Patient service revenues		2,403,222	2,352,574	4,752,123	4,666,236
Operating Segments | U.S. dialysis and related lab services | Intersubsegment Eliminations
Segment Reporting Information [Line Items]
Patient service revenues		26,436	14,470	50,196	28,779
Operating Segments | DMG
Segment Reporting Information [Line Items]
Net dialysis and related lab services patient service revenues		189,529	169,167	368,501	281,601
Other revenues	[3]	19,070	16,235	37,339	26,569
Total net operating revenues		1,196,066	1,059,565	2,283,050	2,048,423
Capitated revenues		987,420	874,119	1,877,105	1,740,138
Operating income (loss)		(12,880)	(102,059)	(572)	(159,204)
Operating Segments | DMG | Intersubsegment Eliminations
Segment Reporting Information [Line Items]
Other revenues		47	44	105	115
Operating Segments | Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Net dialysis and related lab services patient service revenues		83,566	56,860	150,858	108,244
Other revenues		264,456	325,095	531,736	631,187
Total net operating revenues		393,593	422,541	771,819	813,832
Capitated revenues		34,658	25,866	63,009	47,855
Operating income (loss)		(48,245)	(12,644)	(106,466)	(23,745)
Operating Segments | Ancillary services and strategic initiatives | Intersubsegment Eliminations
Segment Reporting Information [Line Items]
Total net operating revenues		10,913	14,720	26,216	26,546
Intersegment Elimination
Segment Reporting Information [Line Items]
Total net operating revenues		$ (37,396)	$ (29,234)	$ (76,517)	$ (55,440)
[1]	{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjNkYTY3ZThkYWYzYjQyNmY5Y2Q2Zjg3ODA5NDczYzUyfFRleHRTZWxlY3Rpb246NEFFMDJDRjcyRDc0NTc3Mjg2QUU3ODM3RURGMDBCRjEM}
[2]	{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjNkYTY3ZThkYWYzYjQyNmY5Y2Q2Zjg3ODA5NDczYzUyfFRleHRTZWxlY3Rpb246NzMwMzJFRkEwRDM4NTAwNUIyNjlEQjlFRjQxQzg0MjgM}
[3]	{F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjNkYTY3ZThkYWYzYjQyNmY5Y2Q2Zjg3ODA5NDczYzUyfFRleHRTZWxlY3Rpb246QThEN0Y2MDhDRDUzNTMzMzkzRUE1ODNCNjc1MzdGMDYM}

Summary of Depreciation and Amo

Summary of Depreciation and Amortization Expense by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 200,038	$ 180,381	$ 390,244	$ 349,736
U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Depreciation and amortization	130,002	119,350	255,030	235,887
DMG
Segment Reporting Information [Line Items]
Depreciation and amortization	60,011	54,211	117,334	100,473
Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 10,025	$ 6,820	$ 17,880	$ 13,376

Summary of Assets by Segment (D

Summary of Assets by Segment (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Feb. 25, 2017	Dec. 31, 2016
ASSETS
Total assets	$ 19,341,784		$ 18,741,257
U.S. dialysis and related lab services
ASSETS
Total assets	11,500,974	$ 338,963	11,099,137
DMG
ASSETS
Total assets	6,282,819		6,213,091
Ancillary services and strategic initiatives
ASSETS
Total assets	$ 1,557,991		$ 1,429,029

Summary of Assets by Segment (P

Summary of Assets by Segment (Phantom) (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Equity method and other investments	$ 542,468	$ 502,389
U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Equity method and other investments	83,102	66,924
DMG
Segment Reporting Information [Line Items]
Equity method and other investments	13,169	10,350
Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Equity method and other investments	$ 446,197	$ 425,115

Summary of Expenditures for Pro

Summary of Expenditures for Property and Equipment by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Expenditures for property and equipment	$ 184,405	$ 185,440	$ 398,940	$ 358,627
U.S. dialysis and related lab services
Segment Reporting Information [Line Items]
Expenditures for property and equipment	152,233	150,932	325,761	284,380
DMG
Segment Reporting Information [Line Items]
Expenditures for property and equipment	20,883	18,098	48,671	38,243
Ancillary services and strategic initiatives
Segment Reporting Information [Line Items]
Expenditures for property and equipment	$ 11,289	$ 16,410	$ 24,508	$ 36,004

Effects of Changes in DaVita In

Effects of Changes in DaVita Inc's Ownership Interest on Company's Equity (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net income attributable to DaVita Inc.	$ 127,001	$ 53,382	$ 574,698	$ 150,816
Net transfers to noncontrolling interests	618	(2,078)	195	(4,530)
Net income attributable to DaVita Inc., net of transfers to noncontrolling interests	127,619	51,304	574,893	146,286
Additional paid-in capital
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Sales of noncontrolling interests	0	(885)	0	0
Purchases of noncontrolling interests	$ 618	$ (1,193)	$ 195	$ (4,530)

Condensed Consolidating Stateme

Condensed Consolidating Statements of Income (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Condensed Income Statements Captions [Line Items]
Patient service revenues	$ 2,682,467	$ 2,583,514	$ 5,283,845	$ 5,065,448
Less: Provision for uncollectible accounts	(115,485)	(111,428)	(228,468)	(220,633)
Net patient service operating revenues	2,566,982	2,472,086	5,055,377	4,844,815
Capitated revenues	1,022,078	899,985	1,940,114	1,787,993
Other revenues	288,417	345,580	579,269	665,979
Total net operating revenues	3,877,477	3,717,651	7,574,760	7,298,787
Operating expenses and charges	3,499,161	3,388,581	6,308,208	6,604,828
Operating income	378,316	329,070	1,266,552	693,959
Interest and Debt Expense	(107,962)	(102,894)	(212,391)	(205,778)
Other income, net	5,253	3,215	9,496	6,191
Income tax expense	113,982	134,888	401,747	261,710
Equity (loss) earnings in subsidiaries	0	0	0	0
Net income	161,625	94,503	661,910	232,662
Less: Net income attributable to noncontrolling interests	(34,624)	(41,121)	(87,212)	(81,846)
Net income attributable to DaVita Inc.	127,001	53,382	574,698	150,816
Consolidating adjustments
Condensed Income Statements Captions [Line Items]
Patient service revenues	(54,579)	(40,793)	(105,309)	(80,209)
Less: Provision for uncollectible accounts	0	0	0	0
Net patient service operating revenues	(54,579)	(40,793)	(105,309)	(80,209)
Capitated revenues	(1,721)	(84)	(2,266)	(211)
Other revenues	(441,286)	(404,144)	(885,132)	(782,595)
Total net operating revenues	(497,586)	(445,021)	(992,707)	(863,015)
Operating expenses and charges	(497,586)	(445,021)	(992,707)	(863,015)
Operating income	0	0	0	0
Interest and Debt Expense	105,486	103,464	208,838	205,368
Other income, net	(105,486)	(103,464)	(208,838)	(205,368)
Income tax expense	0	0	0	0
Equity (loss) earnings in subsidiaries	(177,954)	(182,366)	(724,299)	(315,109)
Net income	(177,954)	(182,366)	(724,299)	(315,109)
Less: Net income attributable to noncontrolling interests	(34,624)	(41,121)	(87,212)	(81,846)
Net income attributable to DaVita Inc.	(212,578)	(223,487)	(811,511)	(396,955)
DaVita Inc. | Reportable Legal Entities
Condensed Income Statements Captions [Line Items]
Patient service revenues	0	0	0	0
Less: Provision for uncollectible accounts	0	0	0	0
Net patient service operating revenues	0	0	0	0
Capitated revenues	0	0	0	0
Other revenues	193,585	196,910	414,971	383,885
Total net operating revenues	193,585	196,910	414,971	383,885
Operating expenses and charges	138,104	134,072	270,014	256,345
Operating income	55,481	62,838	144,957	127,540
Interest and Debt Expense	(106,159)	(102,101)	(208,823)	(203,202)
Other income, net	102,299	98,654	202,636	197,214
Income tax expense	22,969	41,942	57,062	77,088
Equity (loss) earnings in subsidiaries	98,349	35,933	492,990	106,352
Net income	127,001	53,382	574,698	150,816
Less: Net income attributable to noncontrolling interests	0	0	0	0
Net income attributable to DaVita Inc.	127,001	53,382	574,698	150,816
Guarantor subsidiaries | Reportable Legal Entities
Condensed Income Statements Captions [Line Items]
Patient service revenues	1,681,249	1,664,361	3,234,605	3,317,673
Less: Provision for uncollectible accounts	(74,413)	(74,498)	(136,694)	(133,311)
Net patient service operating revenues	1,606,836	1,589,863	3,097,911	3,184,362
Capitated revenues	467,852	463,732	931,479	931,694
Other revenues	501,861	521,065	979,536	1,005,420
Total net operating revenues	2,576,549	2,574,660	5,008,926	5,121,476
Operating expenses and charges	2,396,723	2,510,119	4,276,878	4,887,749
Operating income	179,826	64,541	732,048	233,727
Interest and Debt Expense	(92,346)	(91,259)	(183,747)	(183,432)
Other income, net	2,191	5,421	5,728	9,757
Income tax expense	70,927	89,203	292,348	162,457
Equity (loss) earnings in subsidiaries	79,605	146,433	231,309	208,757
Net income	98,349	35,933	492,990	106,352
Less: Net income attributable to noncontrolling interests	0	0	0	0
Net income attributable to DaVita Inc.	98,349	35,933	492,990	106,352
Non- Guarantor subsidiaries | Reportable Legal Entities
Condensed Income Statements Captions [Line Items]
Patient service revenues	1,055,797	959,946	2,154,549	1,827,984
Less: Provision for uncollectible accounts	(41,072)	(36,930)	(91,774)	(87,322)
Net patient service operating revenues	1,014,725	923,016	2,062,775	1,740,662
Capitated revenues	555,947	436,337	1,010,901	856,510
Other revenues	34,257	31,749	69,894	59,269
Total net operating revenues	1,604,929	1,391,102	3,143,570	2,656,441
Operating expenses and charges	1,461,920	1,189,411	2,754,023	2,323,749
Operating income	143,009	201,691	389,547	332,692
Interest and Debt Expense	(14,943)	(12,998)	(28,659)	(24,512)
Other income, net	6,249	2,604	9,970	4,588
Income tax expense	20,086	3,743	52,337	22,165
Equity (loss) earnings in subsidiaries	0	0	0	0
Net income	114,229	187,554	318,521	290,603
Less: Net income attributable to noncontrolling interests	0	0	0	0
Net income attributable to DaVita Inc.	$ 114,229	$ 187,554	$ 318,521	$ 290,603

Condensed Consolidating State79

Condensed Consolidating Statements of Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Condensed Financial Statements Captions [Line Items]
Net income	$ 161,625	$ 94,503	$ 661,910	$ 232,662
Other comprehensive income	49,578	(6,374)	62,333	(61)
Total comprehensive income	211,203	88,129	724,243	232,601
Less: Comprehensive income attributable to the noncontrolling interests	(34,624)	(41,270)	(87,210)	(81,995)
Comprehensive income attributable to DaVita Inc.	176,579	46,859	637,033	150,606
Consolidating adjustments
Condensed Financial Statements Captions [Line Items]
Net income	(177,954)	(182,366)	(724,299)	(315,109)
Other comprehensive income	0	0	0	0
Total comprehensive income	(177,954)	(182,366)	(724,299)	(315,109)
Less: Comprehensive income attributable to the noncontrolling interests	(34,624)	(41,270)	(87,210)	(81,995)
Comprehensive income attributable to DaVita Inc.	(212,578)	(223,636)	(811,509)	(397,104)
DaVita Inc. | Reportable Legal Entities
Condensed Financial Statements Captions [Line Items]
Net income	127,001	53,382	574,698	150,816
Other comprehensive income	436	(1,530)	(70)	(6,398)
Total comprehensive income	127,437	51,852	574,628	144,418
Less: Comprehensive income attributable to the noncontrolling interests	0	0	0	0
Comprehensive income attributable to DaVita Inc.	127,437	51,852	574,628	144,418
Guarantor subsidiaries | Reportable Legal Entities
Condensed Financial Statements Captions [Line Items]
Net income	98,349	35,933	492,990	106,352
Other comprehensive income	0	0	0	0
Total comprehensive income	98,349	35,933	492,990	106,352
Less: Comprehensive income attributable to the noncontrolling interests	0	0	0	0
Comprehensive income attributable to DaVita Inc.	98,349	35,933	492,990	106,352
Non- Guarantor subsidiaries | Reportable Legal Entities
Condensed Financial Statements Captions [Line Items]
Net income	114,229	187,554	318,521	290,603
Other comprehensive income	49,142	(4,844)	62,403	6,337
Total comprehensive income	163,371	182,710	380,924	296,940
Less: Comprehensive income attributable to the noncontrolling interests	0	0	0	0
Comprehensive income attributable to DaVita Inc.	$ 163,371	$ 182,710	$ 380,924	$ 296,940

Condensed Consolidating Balance

Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	$ 711,997	$ 913,187	$ 1,283,416	$ 1,499,116
Accounts receivable, net	2,053,812	1,917,302
Other current assets	1,257,959	1,149,739
Total current assets	4,023,768	3,980,228
Property and equipment, net	3,248,030	3,175,367
Amortizable intangibles, net	1,462,894	1,527,767
Investments in subsidiaries	0	0
Intercompany receivables	0	0
Other long-term assets and investments	717,301	650,578
Goodwill	9,889,791	9,407,317		9,294,479
Total assets	19,341,784	18,741,257
Current liabilities	2,773,325	2,696,445
Intercompany payables	0	0
Long-term debt and other long-term liabilities	10,286,859	10,221,813
Noncontrolling interests subject to put provisions	1,009,704	973,258
Total DaVita Inc. shareholder's equity	5,084,314	4,648,047
Noncontrolling interests not subject to put provisions	187,582	201,694
Shareholders’ equity	5,271,896	4,849,741
Total liabilities and equity	19,341,784	18,741,257
Consolidating adjustments
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0
Other current assets	0	0
Total current assets	0	0
Property and equipment, net	0	0
Amortizable intangibles, net	0	0
Investments in subsidiaries	(12,744,374)	(11,720,388)
Intercompany receivables	(4,302,476)	(4,117,647)
Other long-term assets and investments	0	0
Goodwill	0	0
Total assets	(17,046,850)	(15,838,035)
Current liabilities	0	0
Intercompany payables	(4,302,476)	(4,117,647)
Long-term debt and other long-term liabilities	0	0
Noncontrolling interests subject to put provisions	416,057	365,657
Total DaVita Inc. shareholder's equity	(12,744,374)	(11,720,388)
Noncontrolling interests not subject to put provisions	(416,057)	(365,657)
Shareholders’ equity	(13,160,431)	(12,086,045)
Total liabilities and equity	(17,046,850)	(15,838,035)
DaVita Inc. | Reportable Legal Entities
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	374,973	549,921	1,028,594	1,186,636
Accounts receivable, net	0	0
Other current assets	254,108	277,911
Total current assets	629,081	827,832
Property and equipment, net	345,667	337,200
Amortizable intangibles, net	355	487
Investments in subsidiaries	10,368,953	9,717,728
Intercompany receivables	3,266,741	3,250,692
Other long-term assets and investments	45,228	39,994
Goodwill	0	0
Total assets	14,656,025	14,173,933
Current liabilities	399,436	303,840
Intercompany payables	0	0
Long-term debt and other long-term liabilities	8,578,628	8,614,445
Noncontrolling interests subject to put provisions	593,647	607,601
Total DaVita Inc. shareholder's equity	5,084,314	4,648,047
Noncontrolling interests not subject to put provisions	0	0
Shareholders’ equity	5,084,314	4,648,047
Total liabilities and equity	14,656,025	14,173,933
Guarantor subsidiaries | Reportable Legal Entities
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	40,508	59,192	35,769	109,357
Accounts receivable, net	1,278,053	1,215,232
Other current assets	891,208	736,727
Total current assets	2,209,769	2,011,151
Property and equipment, net	1,669,583	1,689,798
Amortizable intangibles, net	1,405,712	1,491,057
Investments in subsidiaries	2,375,421	2,002,660
Intercompany receivables	0	0
Other long-term assets and investments	92,891	86,710
Goodwill	7,850,917	7,838,984
Total assets	15,604,293	15,120,360
Current liabilities	1,807,277	1,865,193
Intercompany payables	2,181,952	2,322,124
Long-term debt and other long-term liabilities	1,246,111	1,215,315
Noncontrolling interests subject to put provisions	0	0
Total DaVita Inc. shareholder's equity	10,368,953	9,717,728
Noncontrolling interests not subject to put provisions	0	0
Shareholders’ equity	10,368,953	9,717,728
Total liabilities and equity	15,604,293	15,120,360
Non- Guarantor subsidiaries | Reportable Legal Entities
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	296,516	304,074	$ 219,053	$ 203,123
Accounts receivable, net	775,759	702,070
Other current assets	112,643	135,101
Total current assets	1,184,918	1,141,245
Property and equipment, net	1,232,780	1,148,369
Amortizable intangibles, net	56,827	36,223
Investments in subsidiaries	0	0
Intercompany receivables	1,035,735	866,955
Other long-term assets and investments	579,182	523,874
Goodwill	2,038,874	1,568,333
Total assets	6,128,316	5,284,999
Current liabilities	566,612	527,412
Intercompany payables	2,120,524	1,795,523
Long-term debt and other long-term liabilities	462,120	392,053
Noncontrolling interests subject to put provisions	0	0
Total DaVita Inc. shareholder's equity	2,375,421	2,002,660
Noncontrolling interests not subject to put provisions	603,639	567,351
Shareholders’ equity	2,979,060	2,570,011
Total liabilities and equity	$ 6,128,316	$ 5,284,999

Condensed Consolidating State81

Condensed Consolidating Statements of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income	$ 161,625	$ 94,503	$ 661,910	$ 232,662
Changes in operating assets and liabilities and non-cash items included in net income			349,534	712,977
Net cash provided by (used in) operating activities			1,011,444	945,639
Cash flows from investing activities:
Additions of property and equipment	(184,405)	(185,440)	(398,940)	(358,627)
Acquisitions			(619,839)	(473,314)
Proceeds from asset and business sales			70,236	17,393
Proceeds (purchases) from investment sales and other items, net			96,895	56,319
Net cash used in investing activities			(851,648)	(758,229)
Cash flows from financing activities:
Long-term debt and related financing costs, net			(64,032)	(61,233)
Intercompany (payments) borrowing			0	0
Payments For Other Financing Activities			(301,146)	(342,321)
Net cash (used in) provided by financing activities			(365,178)	(403,554)
Effect of exchange rate changes on cash			4,192	444
Net (decrease) increase in cash			(201,190)	(215,700)
Cash and cash equivalents at beginning of period			913,187	1,499,116
Cash and cash equivalents at end of period	711,997	1,283,416	711,997	1,283,416
Consolidating adjustments
Cash flows from operating activities:
Net income	(177,954)	(182,366)	(724,299)	(315,109)
Changes in operating assets and liabilities and non-cash items included in net income			724,299	315,109
Net cash provided by (used in) operating activities			0	0
Cash flows from investing activities:
Additions of property and equipment			0	0
Acquisitions			0	0
Proceeds from asset and business sales			0	0
Proceeds (purchases) from investment sales and other items, net			0	0
Net cash used in investing activities			0	0
Cash flows from financing activities:
Long-term debt and related financing costs, net			0	0
Intercompany (payments) borrowing			0	0
Payments For Other Financing Activities			0	0
Net cash (used in) provided by financing activities			0	0
Effect of exchange rate changes on cash			0	0
Net (decrease) increase in cash			0	0
Cash and cash equivalents at beginning of period			0	0
Cash and cash equivalents at end of period	0	0	0	0
DaVita Inc. | Reportable Legal Entities
Cash flows from operating activities:
Net income	127,001	53,382	574,698	150,816
Changes in operating assets and liabilities and non-cash items included in net income			(431,980)	(1,505)
Net cash provided by (used in) operating activities			142,718	149,311
Cash flows from investing activities:
Additions of property and equipment			(50,966)	(42,266)
Acquisitions			0
Proceeds from asset and business sales			0	0
Proceeds (purchases) from investment sales and other items, net			49,036	21,230
Net cash used in investing activities			(1,930)	(21,036)
Cash flows from financing activities:
Long-term debt and related financing costs, net			(54,992)	(42,493)
Intercompany (payments) borrowing			(37,233)	11,208
Payments For Other Financing Activities			(223,511)	(255,032)
Net cash (used in) provided by financing activities			(315,736)	(286,317)
Effect of exchange rate changes on cash			0	0
Net (decrease) increase in cash			(174,948)	(158,042)
Cash and cash equivalents at beginning of period			549,921	1,186,636
Cash and cash equivalents at end of period	374,973	1,028,594	374,973	1,028,594
Guarantor subsidiaries | Reportable Legal Entities
Cash flows from operating activities:
Net income	98,349	35,933	492,990	106,352
Changes in operating assets and liabilities and non-cash items included in net income			52,218	219,697
Net cash provided by (used in) operating activities			545,208	326,049
Cash flows from investing activities:
Additions of property and equipment			(182,494)	(171,164)
Acquisitions			(538,450)	(462,592)
Proceeds from asset and business sales			70,127	17,393
Proceeds (purchases) from investment sales and other items, net			(2,974)	(10,869)
Net cash used in investing activities			(653,791)	(627,232)
Cash flows from financing activities:
Long-term debt and related financing costs, net			(6,893)	(13,917)
Intercompany (payments) borrowing			98,224	247,765
Payments For Other Financing Activities			(1,432)	(6,253)
Net cash (used in) provided by financing activities			89,899	227,595
Effect of exchange rate changes on cash			0	0
Net (decrease) increase in cash			(18,684)	(73,588)
Cash and cash equivalents at beginning of period			59,192	109,357
Cash and cash equivalents at end of period	40,508	35,769	40,508	35,769
Non- Guarantor subsidiaries | Reportable Legal Entities
Cash flows from operating activities:
Net income	114,229	187,554	318,521	290,603
Changes in operating assets and liabilities and non-cash items included in net income			4,997	179,676
Net cash provided by (used in) operating activities			323,518	470,279
Cash flows from investing activities:
Additions of property and equipment			(165,480)	(145,197)
Acquisitions			(81,389)	(10,722)
Proceeds from asset and business sales			109	0
Proceeds (purchases) from investment sales and other items, net			50,833	45,958
Net cash used in investing activities			(195,927)	(109,961)
Cash flows from financing activities:
Long-term debt and related financing costs, net			(2,147)	(4,823)
Intercompany (payments) borrowing			(60,991)	(258,973)
Payments For Other Financing Activities			(76,203)	(81,036)
Net cash (used in) provided by financing activities			(139,341)	(344,832)
Effect of exchange rate changes on cash			4,192	444
Net (decrease) increase in cash			(7,558)	15,930
Cash and cash equivalents at beginning of period			304,074	203,123
Cash and cash equivalents at end of period	$ 296,516	$ 219,053	$ 296,516	$ 219,053

Supplemental Data - Condensed C

Supplemental Data - Condensed Consolidating Statements of Income (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Condensed Income Statements Captions [Line Items]
Patient service operating revenues		$ 2,682,467	$ 2,583,514	$ 5,283,845	$ 5,065,448
Less: Provision for uncollectible accounts		(115,485)	(111,428)	(228,468)	(220,633)
Net patient service operating revenues		2,566,982	2,472,086	5,055,377	4,844,815
Capitated revenues		1,022,078	899,985	1,940,114	1,787,993
Other revenues		288,417	345,580	579,269	665,979
Total net operating revenues		3,877,477	3,717,651	7,574,760	7,298,787
Operating expenses		3,499,161	3,388,581	6,308,208	6,604,828
Operating income		378,316	329,070	1,266,552	693,959
Debt expense, including refinancing charges				(212,391)
Other income		5,253	3,215	9,496	6,191
Income tax expense		113,982	134,888	401,747	261,710
Net income		161,625	94,503	661,910	232,662
Less: Net income attributable to noncontrolling interests		(34,624)	(41,121)	(87,212)	(81,846)
Net income attributable to DaVita Inc.		$ 127,001	$ 53,382	574,698	$ 150,816
Physician Groups
Condensed Income Statements Captions [Line Items]
Patient service operating revenues				273,017
Less: Provision for uncollectible accounts				(7,351)
Net patient service operating revenues				265,666
Capitated revenues				785,139
Other revenues				19,596
Total net operating revenues				1,070,401
Operating expenses				1,032,529
Operating income				37,872
Debt expense, including refinancing charges				(3,323)
Other income				151
Income tax expense				32,700
Net income				2,000
Net income attributable to DaVita Inc.				2,000
Unrestricted Subsidiaries
Condensed Income Statements Captions [Line Items]
Operating expenses				(232)
Operating income				232
Income tax expense				93
Net income				139
Net income attributable to DaVita Inc.				139
Company and Restricted Subsidiaries(1)
Condensed Income Statements Captions [Line Items]
Patient service operating revenues	[1]			5,010,828
Less: Provision for uncollectible accounts	[1]			(221,117)
Net patient service operating revenues	[1]			4,789,711
Capitated revenues	[1]			1,154,975
Other revenues	[1]			559,673
Total net operating revenues	[1]			6,504,359
Operating expenses	[1]			5,275,911
Operating income	[1]			1,228,448
Debt expense, including refinancing charges	[1]			(209,068)
Other income	[1]			9,345
Income tax expense	[1]			368,954
Net income	[1]			659,771
Less: Net income attributable to noncontrolling interests	[1]			(87,212)
Net income attributable to DaVita Inc.	[1]			$ 572,559
[1]	After elimination of the unrestricted subsidiaries and the physician groups.

Supplemental Data - Condensed83

Supplemental Data - Condensed Consolidating Statements of Comprehensive Income (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Condensed Financial Statements Captions [Line Items]
Net income		$ 161,625	$ 94,503	$ 661,910	$ 232,662
Other comprehensive income		49,578	(6,374)	62,333	(61)
Total comprehensive income		211,203	88,129	724,243	232,601
Less: Comprehensive income attributable to the noncontrolling interests		(34,624)	(41,270)	(87,210)	(81,995)
Comprehensive income attributable to DaVita Inc.		$ 176,579	$ 46,859	637,033	$ 150,606
Physician Groups
Condensed Financial Statements Captions [Line Items]
Net income				2,000
Total comprehensive income				2,000
Comprehensive income attributable to DaVita Inc.				2,000
Unrestricted Subsidiaries
Condensed Financial Statements Captions [Line Items]
Net income				139
Total comprehensive income				139
Comprehensive income attributable to DaVita Inc.				139
Company and Restricted Subsidiaries(1)
Condensed Financial Statements Captions [Line Items]
Net income	[1]			659,771
Other comprehensive income	[1]			62,333
Total comprehensive income	[1]			722,104
Less: Comprehensive income attributable to the noncontrolling interests	[1]			(87,210)
Comprehensive income attributable to DaVita Inc.	[1]			$ 634,894
[1]	After elimination of the unrestricted subsidiaries and the physician groups.

Supplemental Data - Condensed84

Supplemental Data - Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands		Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents		$ 711,997	$ 913,187	$ 1,283,416	$ 1,499,116
Accounts receivable, net		2,053,812	1,917,302
Other current assets		1,257,959	1,149,739
Total current assets		4,023,768	3,980,228
Property and equipment, net		3,248,030	3,175,367
Amortizable intangibles, net		1,462,894	1,527,767
Other long-term assets		717,301	650,578
Goodwill		9,889,791	9,407,317		$ 9,294,479
Total assets		19,341,784	18,741,257
Current liabilities		2,773,325	2,696,445
Long-term debt and other long-term liabilities		10,286,859	10,221,813
Noncontrolling interests subject to put provisions		1,009,704	973,258
Total DaVita Inc. shareholders’ equity		5,084,314	4,648,047
Noncontrolling interests not subject to put provisions		187,582	201,694
Shareholders’ equity		5,271,896	4,849,741
Total liabilities and shareholder’s equity		19,341,784	18,741,257
Physician Groups
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents		107,232	104,691
Accounts receivable, net		213,804
Other current assets		13,679
Total current assets		334,715
Property and equipment, net		3,368
Amortizable intangibles, net		4,553
Other long-term assets		82,477
Goodwill		29,865
Total assets		454,978
Current liabilities		178,259
Payables to parent		114,038
Long-term debt and other long-term liabilities		55,870
Total DaVita Inc. shareholders’ equity		106,811
Shareholders’ equity		106,811
Total liabilities and shareholder’s equity		454,978
Unrestricted Subsidiaries
Condensed Balance Sheet Statements Captions [Line Items]
Other long-term assets		2,946
Total assets		2,946
Payables to parent		2,946
Total liabilities and shareholder’s equity		2,946
Company and Restricted Subsidiaries(1)
Condensed Balance Sheet Statements Captions [Line Items]
Cash and cash equivalents	[1]	604,765	$ 808,496
Accounts receivable, net	[1]	1,840,008
Other current assets	[1]	1,244,280
Total current assets	[1]	3,689,053
Property and equipment, net	[1]	3,244,662
Amortizable intangibles, net	[1]	1,458,341
Other long-term assets	[1]	631,878
Goodwill	[1]	9,859,926
Total assets	[1]	18,883,860
Current liabilities	[1]	2,595,066
Payables to parent	[1]	(116,984)
Long-term debt and other long-term liabilities	[1]	10,230,989
Noncontrolling interests subject to put provisions	[1]	1,009,704
Total DaVita Inc. shareholders’ equity	[1]	4,977,503
Noncontrolling interests not subject to put provisions	[1]	187,582
Shareholders’ equity	[1]	5,165,085
Total liabilities and shareholder’s equity	[1]	$ 18,883,860
[1]	After elimination of the unrestricted subsidiaries and the physician groups.

Supplemental Data - Condensed85

Supplemental Data - Condensed Consolidating Statements of Cash Flows (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net income		$ 161,625	$ 94,503	$ 661,910	$ 232,662
Changes in operating and intercompany assets and liabilities and non-cash items included in net income				349,534	712,977
Net cash provided by (used in) operating activities				1,011,444	945,639
Cash flows from investing activities:
Additions of property and equipment		(184,405)	(185,440)	(398,940)	(358,627)
Acquisitions and divestitures, net				(619,839)
Proceeds from discontinued operations				70,236	17,393
Investments and other items				96,895	56,319
Net cash used in investing activities				(851,648)	(758,229)
Cash flows from financing activities:
Long-term debt				(64,032)	(61,233)
Intercompany				0	0
Payments For Other Financing Activities				(301,146)	(342,321)
Net cash (used in) provided by financing activities				(365,178)	(403,554)
Effect of exchange rate changes on cash				4,192	444
Net (decrease) increase in cash				(201,190)	(215,700)
Cash and cash equivalents at beginning of period				913,187	1,499,116
Cash and cash equivalents at end of period		711,997	$ 1,283,416	711,997	$ 1,283,416
Physician Groups
Cash flows from operating activities:
Net income				2,000
Changes in operating and intercompany assets and liabilities and non-cash items included in net income				(37,812)
Net cash provided by (used in) operating activities				(35,812)
Cash flows from investing activities:
Additions of property and equipment				(5,603)
Investments and other items				(1,386)
Net cash used in investing activities				(6,989)
Cash flows from financing activities:
Long-term debt				0
Intercompany				45,342
Net cash (used in) provided by financing activities				45,342
Net (decrease) increase in cash				2,541
Cash and cash equivalents at beginning of period				104,691
Cash and cash equivalents at end of period		107,232		107,232
Unrestricted Subsidiaries
Cash flows from operating activities:
Net income				139
Changes in operating and intercompany assets and liabilities and non-cash items included in net income				(139)
Company and Restricted Subsidiaries(1)
Cash flows from operating activities:
Net income	[1]			659,771
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	[1]			387,485
Net cash provided by (used in) operating activities	[1]			1,047,256
Cash flows from investing activities:
Additions of property and equipment	[1]			(393,337)
Acquisitions and divestitures, net	[1]			(619,839)
Proceeds from discontinued operations	[1]			70,236
Investments and other items	[1]			98,281
Net cash used in investing activities	[1]			(844,659)
Cash flows from financing activities:
Long-term debt	[1]			(64,032)
Intercompany	[1]			(45,342)
Payments For Other Financing Activities	[1]			(301,146)
Net cash (used in) provided by financing activities	[1]			(410,520)
Effect of exchange rate changes on cash	[1]			4,192
Net (decrease) increase in cash	[1]			(203,731)
Cash and cash equivalents at beginning of period	[1]			808,496
Cash and cash equivalents at end of period	[1]	$ 604,765		$ 604,765
[1]	After elimination of the unrestricted subsidiaries and the physician groups.